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 This Ph.D. project was directed at evaluation of the anticancer and 
chemopreventive properties of isothiocyanates (ITCs). The anticancer potential of 
ITCs was evaluated by studying their growth inhibitory and cytotoxic efficacies 
against human-derived colorectal carcinoma HCT 116 and lung carcinoma A549 
cells.  The aromatic ITCs, which include naturally-occurring benzyl isothiocyanate 
(BITC), phenethyl isothiocyanate (PEITC) and their synthetic analogs, displayed 
stronger cytotoxic efficacies as compared to aliphatic ITCs, which include 
naturally-occurring sulforaphane (SF) and its synthetic analogs. At growth 
inhibitory concentrations, aromatic ITCs caused cell cycle arrest at the M phase 
and induced apoptosis following disruption of microtubule network and tubulin 
aggregation in HCT 116 cells. In addition to these cellular effects, inhibition of 
redox regulating enzymes thioredoxin reductase (TrxR) and glutathione reductase 
(GR) was demonstrated as a likely mechanism underlying the anticancer activities 
of aromatic ITCs. Structural features that enhanced or attenuated the anticancer 
potential of aromatic ITCs were revealed. 
 The aliphatic ITC analogs were evaluated for their chemopreventive 
potential by studying their anti-inflammatory and cytoprotective activities.  Their 
effects on LPS-induced inflammatory response were investigated in mouse 
macrophage-like RAW 264.7 cells and human CD14
+
 monocytes isolated from 
blood of healthy donors. At non-toxic concentrations, dose-dependent inhibition of 
NO and PGE2 release through inhibition of expression of inducible nitric oxide 
synthase (iNOS) and cyclooxygenase-2 (COX-2) was observed in RAW 264.7 
cells. Similar inhibitory effects on matrix metalloproteinase-9 (MMP-9) 
expression, extracellular secretion and gelatinolytic activity were observed in 
mouse macrophage-like RAW 264.7 cells and human monocytes.  Expression and 
release of pro-inflammatory cytokines IL-6, TNF-α and IL-1β were also inhibited 
by aliphatic ITCs. In addition, they attenuated antibody-independent phagocytic 
abilities and chemotaxis of human monocytes. Among the aliphatic ITCs, while the 
anti-inflammatory potency remained unaffected upon replacement of the sulfoxide 
group in SF with a ketone group, it was decreased with a decrease in the alkyl 
xiv 
  
chain length connecting the S=O/C=O and ITC functional group. Molecular 
investigation revealed that the aliphatic ITCs suppressed activation of PI3K, AKT, 
MAPK and NF-κB pathways. Interaction of aliphatic ITCs with cysteine residues 
in IKK-β isolated from ITC-treated HEK-293 cells had exposed IKK-β as a 
molecular target.  
 Investigation of cytoprotective properties of aliphatic ITCs revealed their 
ability to induce ARE-dependent transcriptional activity in HEK-293 cells. In 
mouse embryonic fibroblasts (MEFs), they exhibited Keap1-dependent induction 
of protein levels of Nrf2 and phase II enzymes. Keap1 was established as a target 
based on the interaction of aliphatic ITCs with its cysteine residues. The 
observations demonstrated modulation of Nrf2-Keap1 pathway as a mechanism 
underlying the cytoprotective properties of aliphatic ITCs. The orders of anti-
inflammatory and cytoprotective potencies of aliphatic ITCs were found to be well 
correlated.  
  In conclusion, the ITC analogs possessed immense potential to be 
developed into clinical candidates for the treatment of cancer and prevention of 
inflammation and carcinogenesis. The findings of this Ph.D. study have provided 
insights into understanding the antitumor and chemopreventive properties of ITCs 
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Chapter 1  
Introduction 
1.1 Phytochemicals  
 Mankind has resorted to the use of plants as medicine since ancient times. 
Over the millennia, plant-derived chemical compounds have been widely explored 
for their biological activities and grouped to be known as phytochemicals. 
Phytochemicals are secondary metabolites that are responsible for organoleptic 
properties; they are usually synthesized in plants for appropriate cellular signaling 
in response to environmental stimuli.  In the plant kingdom, structures of these 
chemicals have been screened and those well suited for binding to biological 
macromolecules  and display compatibility with the intracellular environment have 
been naturally selected as constituents in the plants (Clardy & Walsh, 2004; 
Paterson & Anderson, 2005). Phytochemicals therefore serve as a prolific source of 
lead molecules for drug discovery (Cragg et al., 2009). Interestingly, accumulating 
evidence from population and laboratory studies has demonstrated the inverse 
relationship between consumption of fruits and vegetables and incidence of 
occurrence of cancer and several other chronic disorders (Steinmetz & Potter, 
1991a; 1991b). The beneficial effects of fruits and vegetables on human health 
have been attributed to the dietary phytochemicals. In the evolutionary journey, 
interaction between the animal and plant ecosystems through the ingestion of plants 
has triggered the development of complex molecular systems adapted to eliminate 
xenobiotics. This system involves biotransformation enzymes, redox systems, as 
well as redox-sensitive transcription factors regulating their transactivation. It is 
thus only natural that these phytochemicals are able to generate oxidative or 
electrophilic stress that initiates an intracellular “electrophile counter-attack 
response” that includes upregulation of antioxidant and detoxifying enzymes 
(Prestera et al., 1993). While a mild, yet sufficient amount of electrophilic stress 
tends to stimulate cytoprotective systems aimed to eliminate xenobiotics for cell 
survival, an intensely excessive amount of oxidative/electrophilic insult can be 
cytotoxic. Therefore, dietary phytochemicals, derived from fruits and vegetables, 
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are currently being extensively investigated by the scientific community. While 
phytochemicals are available to mankind through freshly harvested foods, 
processed and cooked food are poor sources of phytochemicals due to their loss in 
considerable amounts during processing or cooking. In addition, several natural 
compounds are not sufficiently potent, poorly selective for molecular targets and 
lack desirable pharmacokinetic profiles albeit their biological activities in vitro. 
Nevertheless, natural compounds can serve as potential lead scaffolds where 
chemical modifications can be applied to yield derivatives of superior therapeutic 
properties coupled with desired pharmacokinetic profiles (Beghyn et al., 2008; 
Molinari, 2009). 
1.2 Isothiocyanates (ITCs)   
 Isothiocyanates are class of phytochemicals derived from cruciferous 
vegetables such as broccoli, cabbage, cauliflower, watercress and Brussels sprouts.  
ITCs have been reported to exhibit a diverse range of biological activities in vivo 
and in vitro since a few decades. They include antibacterial (Kim & Lee, 2009; 
Jang et al., 2010), antifungal (Manici et al., 1997; Kurt et al., 2011) and antitumor 
activities, and blockade of chemical carcinogenesis (IARC, 2004).  
1.2.1 Source, bioavailability and metabolism of ITCs 
 Cruciferous plants of order the Brassicales accumulate huge quantities of 
sulphur- and nitrogen-containing organic secondary metabolites called 
glucosinolates. Myrosinase, a class of enzyme that is physically separated from 
glucosinolates in intact plants, interacts with glucosinolates when cruciferous 
vegetables are chopped or chewed. The enzyme catalyzes the hydrolysis of 
glucosinolates and biologically active ITCs are released as end products of the 
reaction (Fig.1.1) (Fenwick G. R., 1983). 
 
 
Figure 1.1General scheme of hydrolysis of glucosinolates to ITCs 




 A variety of glucosinolates are found in different cruciferous vegetables, 
each of which can rearrange to form a different ITC upon hydrolysis. Examples of 
a few known and well studied ITCs are sulforaphane (SF) derived from broccoli, 
benzyl ITC (BITC) and phenethyl ITC (PEITC) derived from Chinese cabbage and 
water cress respectively. Considerable amounts of ITCs are formed and absorbed 
upon consumption of raw cruciferous vegetables with thorough chewing. Even 
when the cruciferous vegetables are cooked and myrosinase is inactivated by the 
generated heat, myrosinases present in the human intestinal microbial flora allow 
for some (Getahun & Chung, 1999), but substantially lesser extent of 
glucosinolates-to-ITC conversion. (Shapiro et al., 1998; Conaway et al., 2000). 
ITCs are ultimately metabolized to mercapturic acids through conjugation to 
glutathione (GSH) by family of enzymes called glutathione-S-transferases (GSTs) 
(Shapiro et al., 1998). 
1.2.2 Chemistry of ITCs 
 The chemical asset of ITCs is the isothiocyanato –N=C=S functional group. 
Due to the electronegativity of the N and S atoms, the central carbon atom is highly 
electrophilic and reactive. The biological activities of ITCs have been suggested to 
be primarily mediated through the reaction of this central carbon atom with 
nucleophilic amino acids in intracellular proteins. Conjugation of ITCs with 
cellular thiols followed by the mercapturic acid pathway is the major route of their 
metabolism. The side chains in ITCs determine their physico-chemical properties 
such as lipophilicity and also contribute to their biological activities possibly by 
affecting the electrophilicity of the –N=C=S functional group. 
Investigators have postulated a possible tautomerization of the 
methylene ITC moiety to a structure resembling α, β-unsaturated thioketone, which 
is similar to an α, β- unsaturated carbonyl (also called a Michael acceptor) moiety 
(Fig 1.2). A Michael acceptor moiety is a common chemical scaffold present in 
numerous phytochemicals found to possess the ability to induce chemoprotective 




1.2.3 Potential of ITCs as drugs against cancer 
 Since three decades ago, epidemiological studies have revealed that 
consumption of cruciferous vegetables are associated with decreased risks for 
cancer (IARC, 2004). The ITCs derived upon consumption of cruciferous 
vegetables have been suggested to contribute to the biological effects of cruciferous 
vegetables. This has since triggered immense interest in the potential of ITCs as 
drugs against cancer. ITCs have therefore been explored widely for their potential 
to prevent the occurrence of cancer. Additionally, they have also been explored for 
their potential in the treatment of cancer (Singh & Singh, 2012).  
1.2.3.1 Chemopreventive potential of ITCs 
 A few epidemiological studies have revealed the inverse association 
between higher intake of cruciferous vegetables and the risk of lung, breast, 
colorectal and colon cancer (Keum et al., 2004). In these studies, investigators have 
quantified dietary ITC intake by food-frequency questionnaire or measurement of 
ITC levels in urine. Among these studies, a few have also shown that the inverse 
association between ITC intake and cancer risk is stronger among GSTT1-null 
phenotype individuals who have been found to excrete less  ITCs as compared to 
GSTT1 positive phenotype individuals (Zhang, 2004). From the time of discovery 
of natural ITCs until recent times, accumulating in vitro and in vivo evidence has 
demonstrated the anticarcinogenic potential of ITCs. The natural ITCs such as allyl 
ITC (AITC), BITC, PEITC and SF, as well as a number of synthetic ITC analogs 
have been shown to inhibit chemical carcinogenesis in one or more organ sites of 
rodents, including bladder, colon, oesophagus, mammary glands, pancreas and 
stomach (IARC, 2004; Zhang, 2004). ITCs are thus highly promising to be 
investigated as potential chemopreventive agents.   
≈ 
Isothiocyanate structure resembling  
α, β- unsaturated thioketone 
α,β- unsaturated ketone  
(Michael acceptor moiety ) 
 
Figure 1.2 Scheme of postulated tautomerization of ITC to a structure resembling α, β-
unsaturated thioketone which is similar to α, β-unsaturated ketone (Michael acceptor moiety) 
(Talalay et al., 1988). 
Figure 1.2 Scheme of postulated tautomerization of ITC to a structure resembling α, β-unsaturated 




1.2.3.2 Anticancer potential of ITCs 
 While most studies have focussed on the inhibitory effects of ITCs on the 
initiation of carcinogenesis, a few in vivo studies and several in vitro studies have 
demonstrated their anti-cancer effects post-initiation on cancer cell xenografts in 
rodents suggesting the potential of ITCs to eliminate established cancer cells (Pham 
et al., 2004; Singh et al., 2004; Xiao et al., 2006; Yin et al., 2009). Interestingly, 
ITCs have been shown to enhance chemotherapy against cancer cells 
overexpressing MRP-1 and Pgp-1, the efflux proteins responsible for drug 
resistance in several types of cancers (Tseng et al., 2002). Some studies have also 
revealed that ITCs appear to be more toxic to transformed or malignant cells than 
to normal cells, although the reason remains unclear (Gamet-Payrastre et al., 2000; 
Trachootham et al., 2006). More in-depth investigation of the molecular 
mechanisms is necessary to allow better understanding of selective toxicities of 
ITCs.  
1.2.3.3 Structure-dependent variations in chemopreventive and anti-cancer 
activities of ITCs 
 Interestingly, a number of studies as listed in Table 1.1 have revealed that 
the extent of various biological activities of ITCs varies depending on the side 
chain. 
 
Author, Year Inference of study 
(Morse et al., 
1989) 
Increase in the alkyl chain length in a series of arylalkyl 
ITCs had led to corresponding increase in inhibition of 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) -
induced lung neoplasia.  
(Zhang et al., 
1992) 
Analogs containing an alkyl bridge of four or five carbons 
between the sulfinyl and isothiocyanato functional group 
had been found to possess stronger activity in inducing 
nicotinamide adenine dinucleotide phosphate (NAD(P)H): 
quinone oxidoreductase 1 (NQO1) enzyme activity than an 
analog bearing a 3-carbon alkyl bridge. 




Author, Year Inference of study 
(Posner et al., 
1994) 
Replacement of the sulfinyl group in SF to a carbonyl 
group had not affected the potency in inducing NQO1 
enzyme activity. 
(Lui et al., 2003) PEITC had not exhibited significant anti-proliferative 
activity as BITC, which underscored the effect of structural 
changes such as lack of carbon spacer on anti-proliferative 
activity. 
(Tseng et al., 2004) The anti-proliferative potency of BITC and PEITC had 
been found to higher than that of SF.  
(Prawan et al., 
2009) 
Examination of NF-κB inhibitory activity of aliphatic and 
aromatic ITC analogs had revealed that aromatic ring is not 
essential for inhibiting NF-κB activity.  
Table 1.1 Review of studies reporting the influence of side chains on biological activities of ITCs. 
Based on findings of studies reported thus far, the ITC group serves to 
be a promising scaffold for the development of novel chemotherapeutic and 
chemopreventive agents.  
1.2.3.4 Mechanistic complexity of chemopreventive and anti-cancer activities 
of ITCs 
Natural ITCs have been shown not only to eliminate cancer cells but 
also to inhibit the steps involved in transformation and development of cancer cells. 
They have been reported to exhibit such dual properties through several biological 
mechanisms (Zhang, 2004). Molecular investigations have revealed multiple 
biological pathways being altered by ITCs (Cheung & Kong, 2010).  Interestingly, 
the mechanisms underlying the biological effects of structurally different ITCs 
have been reported to differ. For instance while PEITC has been shown to induce 
transcription factor Nuclear factor erythroid 2- related factor 2 (Nrf2) induction 
through the Mitogen-activated protein kinases (MAPK) pathway (Keum et al., 
2003; Xu et al., 2006), SF has been shown to bind to Kelch-like ECH-associated 
protein 1 (Keap1) that in turn leads to stabilization of Nrf2 levels (Dinkova-
Kostova, 2002). In addition, PEITC and SF have been shown to inhibit toll-like 
receptor 3 (TLR-3) signaling through different mechanisms (Zhu et al., 2013). The 
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diversity of intracellular responses upon treatment with structurally different ITCs 
remains to be entirely understood. Based on literature thus far, the anti-cancer 
mechanisms of ITCs have been suggested to include induction of apoptosis, cell 
cycle arrest and microtubule polymerization, the chemopreventive mechanisms of 
ITCs reported earlier include inhibition of phase I enzymes, induction of phase II 
enzymes and anti-inflammatory activities (IARC, 2004; Zhang, 2004).   
Based on findings of studies reported thus far, the ITC group serves to 
be a promising scaffold for the development of novel chemotherapeutic, anti-
inflammatory and chemopreventive agents. A library of ITC analogs bearing 
chemical modifications of naturally-occurring BITC, PEITC and SF had been 
synthesized previously in the laboratory. The broad objective of this PhD study was 
to investigate the antitumor potential, anti-inflammatory potential, 
chemopreventive potential and mechanisms of actions of structurally different ITC 
analogs of the library. The project predominantly involved mechanistic 
investigations of the anti-cancer, anti-inflammatory and chemopreventive 
properties of synthetic ITC analogs. Therefore, a review on the cancer disease and 
its characteristics, inflammation and its relevance to cancer and chemoprevention is 
presented in the following sections to provide sufficient background for the specific 
aims (revealed in Section 1.6) and the experimental facets of this PhD project. In 
addition, the biological pathways targeted by the ITCs in exhibiting their antitumor, 
anti-inflammatory and chemopreventive effects that are of relevance to the 
mechanistic investigations in this PhD study are detailed in the following sections. 
1.3 Cancer 
Cancer is a leading cause of death worldwide. In 2008, it was estimated 
by World Health Organization that 7.6 million people died of cancer. According to 
WHO’s statistical forecast, 84 million people will die in the next 10 years if no 
action is taken (WHO, 2011). Hence there is a pressing need to reduce the burden 
of cancer on the human society.  
There are several factors that contribute to carcinogenesis. They 
include cigarette smoke, alcohol, UV radiation, pollution, unhealthy diet, lack of 
exercise, occupational exposure to carcinogens, stress and genetics (Waalkes, 
1994; Baba AI, 2007). Since not all of these factors are preventable, treatment 
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strategies are warranted. The existing treatment strategies include chemotherapy, 
radiotherapy, or surgical intervention. The problem of anticancer drug resistance is 
a major hindrance to chemotherapy, which necessitates the development of novel 
chemotherapeutic agents. 
1.3.1Hallmarks of cancer  
 Accumulating evidence gathered from global cancer research efforts has 
attributed the loss of control over several biological processes that are otherwise 
tightly regulated in normal cells, as the cause of carcinogenesis and tumor 
progression. As reviewed by Hanahan and Weinberg in 2000, the six hallmarks of 
cancer were highlighted as: (1) ability of cancer signals to stimulate their own 
growth, (2) ability to evade anti-growth signals, (3) ability to evade programmed 
cell death (apoptosis), (4) unlimited replicative potential, (5) pro-angiogenic 
characteristics and (6) invasive and metastatic potential. In 2011, the authors gave 
an updated review, where four new hallmarks that underpin the pathogenesis of 
cancer were added (Hanahan & Weinberg, 2011). The new hallmarks are: (1) 
dysregulated metabolic pathways, (2) evasion of immunosurveillance, (3) 
abnormalities in chromosome and instability of DNA and (4) inflammation in the 
surrounding environment. With the better understanding of the molecular 
complexities underlying the process of multistage carcinogenesis, strategies to treat 
cancer are being focussed on targeting the dysregulated molecular events in cancer 
cells. 
1.3.2 Cell cycle 
 Cancer cells are mainly characterized by their unregulated growth and 
proliferation. While normal cells are triggered into cell cycle progression only 
during necessary times of growth or repair of damaged tissue, cancer cells are 
rapidly dividing through undergoing cell division in vicious cycles. 
 Cell cycle is the sequence of events leading to self replication and 
multiplication of cells. It comprises of distinct phases, namely the gap phase or 
checkpoint 1 (G1) phase, synthesis phase (S), gap or checkpoint 2 (G2) phase and 
mitosis phase (M). A persistent growth signal nudges cells towards entering the cell 
cycle. During the G1 phase, a favourable environment ensuring availability of 
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nutrients for protein synthesis triggers transcription of necessary cyclins (cell cycle 
proteins) and chromosomes are prepared for replication. In general, commitment 
for cell division is decided during this phase. In the S phase, DNA is replicated. In 
the G2 phase, possible damage to DNA is repaired following which the nuclear 
envelope is broken, transcription of all genes is stalled and condensation of 
chromosomes begins pushing the cells towards mitosis. During mitosis, organized 
division into daughter cells occurs. The spindle assembly checkpoint (Metaphase 
checkpoint or M checkpoint) in the middle of mitosis is a critical event for division 
to proceed. The mitotic microtubule spindle is pertinent for even segregation of 
chromosomes into daughter cells and the M checkpoint ensures attachment and 
alignment of each chromosome to the spindle apparatus, as well as proper 
microtubule structure before segregation and mitotic exit.  The progression through 
these four phases is tightly regulated by cyclins and cyclin dependent kinases 
(Lodish et al., 2008).  
 The cells are steered into a G0 resting phase upon sufficient growth or if the 
necessary requirements for cell cycle are not achieved at the G1 checkpoint. At the 
G2 checkpoint, if DNA repair is unsuccessful, cells enter senescence or undergo 
apoptosis. Spindle assembly defects occurring at the M checkpoint can either lead 
to death of cells or mitotic slippage (exit of cell cycle with uneven chromosomal 
segregation) producing abnormal daughter cells with highly defective DNA that are 
arrested in the next cell cycle and eventually killed (Blagosklonny, 2007; Orth et 
al., 2012)  
 Given that prolonged sustenance at the various checkpoints in cell cycle 
progression ultimately drives cancer cells into apoptosis, anticancer strategies 
exploiting these checkpoints as molecular targets are therefore rational and 
promising (Malumbres, 2006). Such strategies selectively target cells that are 
actively proliferating. Clinically used anticancer agents that cause cell cycle arrest 
include etoposide (causes G2 phase arrest), bleomycin (causes S phase arrest), 
vinca alkaloids and taxols (causes M phase arrest). It is noteworthy that most of the 




1.3.3 Tubulin and microtubules 
 Tubulin belongs to a family of globular proteins expressed ubiquitously in 
the cells. The α- and β- tubulin subunits each of molecular weight 55 kDa, are the 
most common members of the tubulin family. Heterodimers of α- and β- tubulin 
polymerize end to end with the α-sub unit of one dimer connecting to the β-sub unit 
of the next and protafilaments are formed. The protafilaments associate parallel to 
each other forming long tubular polymers known as microtubules (Fig 1.3).  One 
end of the microtubules with the exposed α-units is termed the (-) end whereas the 
other end with exposed β-units is termed the (+) end (Lodish et al., 2008). 
Microtubules are important components of the cytoskeleton and necessary for 
maintenance of cell shape, cell motility, intracellular transport of cellular 





Figure 1.3 Microtubule formation. Heterodimers of soluble α- and β- tubulin polymerize to 
form a microtubule nucleus which grows into a dynamic microtubule by further addition of 
heterodimers. Figure adapted from Dumontet & Jordan (2010). 
Figure 1.3 Microtubule formation 
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1.3.3.1 Microtubules dynamics in cell cycle  
 Microtubules exist in a state of dynamic instability with simultaneous 
assembly and disassembly of their structure (Mitchison & Kirschner, 1984; Horio 
& Hotani, 1986). Microtubule polymerization dynamics, as well as their formation, 
shortening and lengthening contribute towards regulating their cellular functions of 
microtubules (Williams et al., 1986). During cell cycle progression, microtubules 
undergo rapid changes and their turnover increases further upon onset of mitosis 
when the cellular microtubule network disassembles to form mitotic spindles (Zhai 
et al., 1996). The organelle called centrosome is a centre for nucleation of 
microtubules (McGill & Brinkley, 1975; Bergen & Borisy, 1980). After 
progressing through S phase of the cell cycle, the centrosome duplicates and the 
daughter centrosomes separate to two distant poles. In doing so, the mitotic spindle 
is formed. While the (-) end of the microtubules are adhered to the poles, the (+) 
end undergoes rapid elongation and shrinkage so as to search for kinetochores, the 
anchoring points on chromosomes  (Huitorel & Kirschner, 1988). Microtubules 
also play critical roles of pushing the spindle poles apart and securing the poles to 
the cell membrane. The M checkpoint is activated by kinetochores unattached to 
microtubules (Musacchio & Salmon, 2007).  Once sister kinetochores (one on each 
sister chromatid) get attached to the microtubules from both poles, chromosomes 
get bi-oriented and dynein protein is released to inactivate the M checkpoint. 
Synchronous and sustained lengthening at the (+) ends and shrinking at the (-) ends 
of the microtubules attached to the sister kinetochores aligns all the chromosomes 
in the central region of division and keeps the chromosomes bridged to the 
centrosome (Mitchison, 1989). Eventually the protein that associates the sister 
chromatids is cleaved and each of the chromatids are pulled towards the opposite 
poles by shortening of microtubules (Mitchison et al., 1986; Koshland et al., 1988; 
Bruce Alberts, 2002) (Fig 1.4). However, if the microtubule dynamics is disrupted, 
kinetochores unattached or defectively attached to microtubules will delay the 
activation of the M checkpoint and dynein protein will not be released. This shall 




1.3.3.2 Tubulin as therapeutic target in cancer 
 Tubulin-binding agents have long been employed against cancer. While 
some of them such as the vinca alkaloids and colchicine analogs inhibit 
polymerization of microtubules, others such as the taxanes and epitholines enhance 
microtubule formation. Both inhibition and increase in polymerization of tubulin 
disrupt the balance in microtubule dynamics and thus hinder the normal 
progression of cell cycle, especially at the mitosis phase. However, the tubulin 
binding agents are not successful for use in all cancers due to the problem of drug 
resistance development. Tumors with increased expression of multidrug resistance- 
associated proteins are able to pump anticancer agents such as the taxanes and 
vinca alkaloids out of the intracellular milieu (Fojo & Menefee, 2007). With an 
increasing number of reported resistances of cancers against tubulin binding agents, 
there is certainly an urgent need to develop novel agents as alternatives. 
Figure 1.4 Morphological changes in microtubule structure during progression of mitosis. 
A bipolar spindle is formed at the onset of mitosis. Chromosomes are attached to spindle 
and aligned along the metaphase plate and spindle check point is activated. Upon release of 
dynein, chromosomes are pulled towards two poles by microtubule dynamics. Figure 
adapted from Jackson et al., (2007).  
Figure 1.4 Morphological changes in microtubule structure during progression of mitosis 
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1.3.4 Thioredoxin reductase (TrxR)  
 Mammalian TrxR is an enzyme that belongs to the class of pyridine 
nucleotide disulfide oxidoreductases. It is a member of the thioredoxin (Trx) 
system involved in maintaining oxidative balance of cells and regulation of redox 
signaling. Evolutionarily, the Trx system is suggested to participate in cellular 
defense against damage due to oxygen metabolism. At least two isoforms of TrxR 
exist in mammalian cells: the cytosolic TrxR1 (Gasdaska et al., 1995), the 
mitochondrial TrxR2 (Miranda-Vizuete et al., 1999). TrxR exists as homodimers of 
which each monomer consists of a flavin adenine dinucleotide (FAD) prosthetic 
group and a NADPH binding site. Within the N-terminal FAD-binding domain, it 
has a conserved –Cys-Val-Asn-Val-Gly-Cys- catalytic redox-active dithiol site 
(Mustacich & Powis, 2000). It has a second redox-active –Gly-Cys-SeCys-Gly- 
(SeCys is Selenocysteine) active site at the C-terminus. It acts by catalyzing 
reduction of Trx and other substrates. Its mechanism of action involves electron 
transfer from NADPH through the FAD binding domain to the dithiol site of one 
subunit, which then reduces the selenosulfide at the C-terminus on the other 
subunit. The reduced selenothiol finally transfers electron to Trx such that the 
disulfide at the active site gets reduced to dithiols. The reduced Trx then carries out 
its functions as a disulfide reductase to reduce protein disulfides (Fig 1.5).  
 
 
Figure 1.5 Schematic of the thioredoxin system mediated reduction of proteins 
 
 
 The cellular functions of TrxR are mainly mediated through the biological 
activities of the effector protein Trx. Certain chief functions of Trx include 
Figure 1.5 Schematic of the thioredoxin system mediated reduction of proteins. Figure adapted 
from Holmgren & Lu, (2010) 
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regulation of redox signaling through redox control of redox-sensitive kinases and 
transcription factors, promoting cell growth through donation of electrons to 
ribonucleotide reductase (RNR), the enzyme is involved in DNA replication and 
repair, as well as combat oxidative stress through the H2O2 scavenging activities 
of peroxiredoxins.  
1.3.4.1 Thioredoxin reductase in cancer  
 While the Trx system in normal cells has pro-survival functions such as 
initiation of DNA repair, anti-apoptotic activity and promotion of cell growth, 
cancer cells have evolved to exploit the system for their aggressive growth and 
survival. Cancer cells exhibit elevated expression of components of the Trx system. 
For instance, TrxR is found to be overexpressed in tumors of the liver, prostate, 
breast and thyroid, as well as in several human cancer cell lines that include Jurkat 
and A549 cells (Lincoln et al., 2003; Lincoln et al., 2010).  
 1.3.4.2 Inhibition of TrxR in cancer 
 Targeted removal of TrxR has been shown to reverse phenotype, 
tumorigenecity, self-sufficient growth and DNA replication in cancer cells (Yoo et 
al., 2006; Yoo et al., 2007). Interestingly, selenium deficiency is found to decrease 
tumor formation in transgenic mice (Novoselov et al., 2005). Chemical inhibitors 
of TrxR1 have been reported to inhibit cancer cell proliferation (Wipf et al., 2001; 
Chew et al., 2010). Cells overexpressing TrxR1 have shown constitutive increase 
in DNA binding activity of AP-1 and NF-κB, both of which are involved in pro-
survival signaling suggesting inhibition of TrxR1 could prevent activation of pro-
survival signaling pathways (Smart et al., 2004). Although TrxR1 inhibitors have 
been suggested for combination therapy to overcome resistance to certain anti-
cancer agents such as cisplatin, it should be noted that the problem of resistance to 
use of TrxR inhibitors cannot be overlooked. Indeed, (Du et al., 2012) had recently 
demonstrated that the glutathione and glutaredoxin system had a backup role to 
keep Trx reduced in cells suffering from loss of TrxR1 activity. This warrants the 
development of therapeutic agents that can holistically perturb the oxidative 





 Inflammation classically is described as an adaptive response invoked by 
infection or injury. The cardinal signs of an inflammatory response include 
swelling, redness, pain, fever, and loss of function, traditionally known as tumor, 
rubor, dolor, calor and functio laesa respectively. All these signs usually appear in 
an inflammatory response that occurs on the host’s body surface, whereas not all 
are developed when inflammation occurs in internal organs. Although an acute 
inflammatory response, is crucial for the removal of inflammatory trigger and the 
healing process, sustained/chronic inflammation is detrimental when dysregulated 
and uncontrolled. Chronic inflammation can lead to excessive tissue injury 
following continuous attempts to tissue repair, and therefore possesses the potential 
to cause sepsis, neoplastic transformation and chronic diseases. 
 Traditionally, infection and tissue injury are considered as inducers of 
inflammation. Scientific exploration has revealed other endogenous states that can 
induce inflammation. These include tissue stress, tissue malfunction, loss of tissue 
homeostasis and metabolic surplus. Researchers have suggested referring to such 
inflammatory states as para- or meta-inflammation. These subtypes of 
inflammation can have systemic consequences and are increasingly being explored 
as pathological states underlying several chronic disorders (Hotamisligil, 2006).  
 Several diseases, whether or not their pathologies are fully unravelled, have 
been associated with chronic inflammation. Chronic inflammation perturbs the 
homeostatic balance, making the human body more vulnerable to several diseases 
and ageing. As revealed in a review by Nathan (2002) diseases known to be 
associated with chronic inflammation have been highlighted (Table 1.2). Given the 
wide spectrum of medical conditions that can be addressed through controlling 
inflammation, anti-inflammatory therapeutic strategies are of utmost necessity and 







Disorders in which an important pathogenetic role is assigned to inflammation 
Alzheimer’s disease  Osteoarthritis  
Anaphylaxis  Pemphigus  
Ankylosing spondylitis  Periodic fever syndromes  
Asthma  Psoriasis  
Atherosclerosis  Rheumatoid arthritis  
Atopic dermatitis  Sarcoidosis  
Chronic obstructive pulmonary disease  Systemic lupus erythematosus  
Crohn’s disease (regional enteritis)  Type I diabetes mellitus  
Gout  Ulcerative colitis  
Hashimoto’s thyroiditis  Xenograft rejection  
lschaemia- reperfusion injury (occlusive and embolic 
stroke and  myocardial infarction)  
Vasculitides (Wegener’s syndrome, Goodpasture’s 
syndrome, giant cell arteritis, polyarteritis nodosa) 
Multiple sclerosis  
Diseases of infectious origin in which inflammation may contribute as much to pathology as does 
microbial toxicity 
Bacterial dysentery  Influenza virus pneumonia  
Chagas disease (Trypanosoma cruzi)  Leprosy (tuberculoid form)  
Cystic fibrosis pneumonitis  Neisserial or pneumococcal meningitis  
Filariasis  Post-streptococcal glomerulonephritis  
Heicobactor pylori gastritis  Sepsis syndrome  
Hepatitis C Tuberculosis 
Diseases of diverse origin in which post-inflammatory fibrosis is a principal cause of pathology 
Bleomycin-induced pulmonary fibrosis  Hepatic cirrhosis (post-viral or alcoholic)  
Chronic allograft rejection Radiation-induced pulmonary fibrosis  
Idiopathic pulmonary fibrosis  Schistosomiasis  
Table 1.2 List of diseases associated with inflammation. 
   
1.4.1 Inflammation and cancer 
 The first association of inflammation with cancer was reported by Rudolf 
Virchow in 1858; based on the observation that infiltrating leukocytes were 
detected within the neoplastic tissues, he suggested that cancer neoplasms 
originated at the site of chronic inflammation (Virchow & Chance, 1859). Since 
then, several preclinical and clinical studies have demonstrated the progression of 
dysregulated persistent inflammation to cancer development. A list of 
inflammation-associated neoplasmic states is summarized in Table 1.3. In general, 
chemical-induced inflammation, as well as chronic inflammation caused by 
infectious (bacteria and viruses) and non-infectious agents (cigarette smoke, 
asbestos, silica and others) have been reported to increase the risk of developing 
cancer. Factors mediating the process of carcinogenesis include through generation 
of pro-oxidants, pro-inflammatory mediators, growth factors, angiogenic factors 
and matrix degrading proteases (Coussens & Werb, 2002). Suppression of 
inflammation is therefore being viewed and explored as a chemopreventive and 




cancer therapeutic strategy. Interestingly, it has been suggested inflammatory cells 
are unlikely to become drug resistant, as they retain a normal and stable genome 
unlike cancer cells (Karin, 2008).  
 
Chronic inflammatory conditions associated with neoplasms 
Pathologic condition   Associated neoplasm(s)   Aetiologic agent  
Asbestosis, silicosis          Mesothelioma, lung carcinoma       Asbestos fibres, silica particles 
Bronchitis Lung carcinoma  
 Silica, asbestos, smoking 
(nitrosamines, peroxides)  
Cystitis, bladder Inflammation Bladder carcinoma 
 Chronic indwelling, urinary 
catheters  
Gingivitis lichen planus  Oral squamous cell carcinoma  
Inflammatory bowel disease, 
Crohn’s disease, chronic 
ulcerative colitis  
Colorectal carcinoma   
Lichen sclerosus  Vulvar squamous cell carcinoma   
Chronic pancreatitis, hereditary 
pancreatitis 
 Pancreatic carcinoma 
 Alcoholism, mutation in 
trypsinogen gene on Ch. 7 
 Reflux oesophagitis, Barrett’s 
oesophagus 
Oesophageal carcinoma   Gastric acids  
Sialadenitis  Salivary gland carcinoma   
Sjogren syndrome, Hashimoto’s 
thyroiditis  
 MALT lymphoma   
Skin inflammation  Melanoma  Ultraviolet light 
Cancers associated with infectious agents 
Opisthorchis, Cholangitis  
Cholangiosarcoma, colon 
carcinoma 
Liver flukes (Opisthorchis 
viverrini), bile acids 
Chronic cholecystitis  Gall bladder cancer Bacteria, gall bladder stones  
Gastritis/ulcers  Gastric adenocarcinoma, MALT  HeIicobactor  pylori 
Hepatitis Hepatocellular carcinoma Hepatitis B and/or C virus  
Mononucleosis  
B-cell non - Hodgkin’s lymphoma, 
Burkitts lymphoma 
 Epstein - Barr Virus  
AIDS 
Non-Hodgkin’s-lymphoma, 
squamous cell carcinomas, 
Kaposi’s sarcoma 
Human immunodeficiency virus, 
human herpesvirus type 8  
Osteomyelitis  Skin carcinoma in draining sinuses Bacterial infection  
Pelvic inflammatory disease, 
chronic cervicitis 
Ovarian carcinoma, cervical/anal 
carcinoma 
 Gonnorrhoea, chlamydia human 
papillomavirus  
Chronic cystitis  
Bladder, liver, rectal Carcinoma, 
follicular lymphoma of the spleen 
Schistosomiasis  
Table 1.3 Chronic inflammatory conditions associated with neoplasms. 
1.4.2 The inflammatory response  
 Inflammation is a stereotyped biological response that involves inducers, 
sensors, mediators and effectors. An inflammatory inducer is initially detected by 
receptors present on surface of leukocytes resident at the site of stimulus. The 
activated resident leukocytes then release inflammatory mediators that include 
cytokines and chemokines that respectively activate and attract leukocytes from the 
bloodstream to the site of inflammation. The inflammatory response is thus 
amplified. In acute inflammation, neutrophils arrive first and combat the source of 





inflammation. Subsequently, circulating precursor leukocytes such as monocytes 
migrate by chemotaxis to the site of inflammation. They secrete monokines, 
phagocytose inflammation-inducing elements and differentiate into effector 
immune cells such as macrophages. Macrophages also release several 
proinflammatory enzymes, reactive oxygen species (Ross et al.) and proteases for 
the purpose of eliminating any remaining inflammatory debris. However, in the 
process of doing so, the surrounding tissue may also be destroyed. Once the source 
is eliminated, resolution and healing should begin. Failure of complete resolution 
of the triggered response results in a vicious cycle characterized by chronic 
inflammation (Medzhitov, 2008).  
1.4.3 Mediators and effectors of inflammation 
 The inflammatory response is executed by secretion of biochemical 
mediators that orchestrate the recruitment of leukocytes and diverse functions of 
leukocytes.  
1.4.3.1 Nitric oxide (NO) and inducible nitric oxide synthase (iNOS) 
 NO is produced by NOS isoforms through the enzymatic conversion of L-
arginine to citrulline. Two isoforms, endothelial NOS (eNOS) and neuronal NOS 
(nNOS), are constitutively expressed (Stuehr, 1999) and their production of NO at 
low concentrations is required for regulated vasodilation and neurotransmission. 
The third isoform, inducible NOS (iNOS), is produced through signaling activated 
in response to cell-cell adhesion, cytokine stimulation, ROS, alterations in 
environmental pH and stimulation by microbial products such as lipopolysacharide 
(LPS) (Bogdan, 2001). Increased expression of iNOS generates high concentrations 
of NO, especially in leukocytes, which is involved in adhesion of leukocytes to the 
endothelium, inhibition of growth of microbes and elimination of tumor cells. 
Prolonged production of high concentrations of NO coupled with an increase in its 
highly reactive derivative (peroxynitrite, ONOO
-
), has been found to promote 
inflammation-related carcinogenesis through DNA damage, inhibition of DNA 
repair enzymes, promotion of cell proliferation and promotion of angiogenesis and 
metastatsis (Chen et al., 2007). Dysregulated expression of iNOS has also been 
19 
  
implicated in conditions such as contractile dysfunction and cardiomyocyte loss 
(Dessy & Feron, 2004).  
1.4.3.2 Prostaglandins (PG) and Cyclooxygenase-2 (COX-2) 
 PGs are biochemical lipid compounds derived from fatty acids by 
enzymatic actions of cyclooxygenases. Their physiological functions include 
modulation of immune responses, protection of gastrointestinal mucosa, 
maintenance of renal homeostasis and regulation of blood clotting. In pathological 
conditions, PGs are known to promote inflammation, swelling, pain and fever 
(Funk, 2001). COX-1 is constitutively expressed in a wide range of tissues 
including the kidney, lung, stomach, small intestine and colon and is responsible 
for producing basal levels of PGs required for tissue homeostasis. COX-2 is an 
inducible enzyme found to be expressed during inflammation and tumorigenesis; it 
produces elevated levels of PGs with implications on the pathogenesis of chronic 
disorders. The COX-2/PGE2 pathway has been deregulated in cancers (Greenhough 
et al., 2009). It has been shown to affect tumorigenesis via several mechanisms and 
is suggested to have a possible role in tumor initiation. Of note, mice 
overexpressing COX-2 are more prone to malignant tumors and mice deficient in 
COX-2 are less susceptible to develop intestinal, breast or skin cancers (Muller-
Decker et al., 2002).  
1.4.3.3 Matrix metalloproteinases (MMPs) 
 MMPs are zinc-dependent endopeptidases which are either bound to plasma 
membrane or secreted. Activated immune cells can either release activated MMPs 
or latent pro-MMP precursors. An important function of MMPs is induction of 
extracellular matrix (ECM) and basement membrane remodelling (Stamenkovic, 
2003). ECM sequesters several biological factors and ECM signaling is associated 
with apoptosis, neoplastic transformation and immunity (Werb, 1997). The family 
of MMPs can cleave almost the entire diverse set of structural proteins in ECM and 
disintegrate the ECM thereby releasing the biological factors sequestered in ECM 
and activate ECM signaling (Birkedal-Hansen, 1995). MMPs can also cleave and 
activate cellular receptors such as transforming growth factor-β (TGF-β) (Yu & 
Stamenkovic, 2000) and chemokines such as interleukin-8 (IL-8) (Schonbeck et al., 
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1998). They are required for chemotaxis of leukocytes to sites of inflammation and 
modulate the migratory capacity of immune cells (Gong et al., 2008) (Van Lint & 
Libert, 2007). They have also been found to be involved in several cellular 
processes that include proliferation, differentiation, angiogenesis, apoptosis and 
host defense (McCawley & Matrisian, 2001). Therefore, MMPs are important 
players in regulation of diverse aspects of inflammation and carcinogenesis (Parks 
et al., 2004; Gialeli et al., 2011). Among the more than 20 types of MMPs 
discovered to date, MMP-9 is a key effector found to be strongly associated with 
inflammatory conditions and carcinogenesis (Xu et al., 2010; Yu et al., 2012). For 
instance, carcinogenesis in MMP-9-deficient mice was significantly lesser than in 
MMP-9-proficient mice (Coussens et al., 1999; Coussens et al., 2000). 
1.4.3.4 Cytokines 
 Cytokines are soluble biochemicals that stimulate cellular signaling through 
activation of specific receptors on cell surface for up-regulation or down-regulation 
of genes and transcription factors. This leads to corresponding modulation in 
expression of other cytokines and surface receptors. Cytokines can regulate their 
own effects through feedback inhibition. Their functions mainly involve, but are 
not limited to, immunomodulation. They are involved in communication between 
cells through autocrine, paracrine or endocrine signaling. Their effects depend on 
their extracellular abundance and the abundance of their receptors. Downstream 
signals upon cytokine stimulation also vary depending on their host cell type. In an 
inflammatory response, among the various types of stimulated cells, leukocytes 
produce higher quantities of cytokines. Thus, activated immune cells are viewed as 
the main cell types responsible for perpetuating the inflammatory response. 
 Tumor necrosis factor alpha (TNF-α) is an endogenous cytokine chiefly 
produced by activated macrophages and is involved in systemic inflammation 
(Hehlgans & Pfeffer, 2005). The default response of TNF-α is induction of genes 
involved in inflammation and cell survival. On the contrary, as its name implies, 
TNF-α is also capable of inducing apoptotic cell death, however only as a late 
response when NF-κB activation is not successful (Varfolomeev & Ashkenazi, 
2004). The mechanisms underlying the paradoxical growth stimulatory and growth 
inhibitory effects of TNF-α are yet to be discovered and understood. However, 
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increasing number of studies have demonstrated the pathogenesis of chronic 
diseases such as Alzheimer’s and inflammatory bowel disease, Helicobacter pyroli 
infection and cancer to be associated with dysregulation of TNF-α production 
(Leek et al.,1998; Neylor et al., 1993). In addition, increased expression of TNF-α 
in tumor environment have been reported to augment promotion and metastasis of 
cancers (Balkwill, 2002; 2009). Of note, TNF-α deficient mice are less susceptible 
to development of skin cancer (Moore et al., 1999). 
 Interleukin-6 (IL-6) and Interleukin-1β (IL-1β) are cytokines of the 
interleukin family that are also produced in high quantities by activated leukocytes 
during an inflammatory response. They are known to activate production of other 
cytokines. Along with other cytokines, they have been reported to be associated 
with several chronic disease states such as atherosclerosis, rheumatoid arthritis, 
Alzheimer’s disease and cancers (Feldmann et al., 1996; Ait-Oufella et al., 2011; 
Rubio-Perez & Morillas-Ruiz, 2012). IL-6-deficient-mice are more resistant to 
development of melanoma and inhibition of IL-1β in mice decreased metastasis of 
tumor cells (Vidal-Vanaclocha et al., 2000; von Felbert et al., 2005).  
1.4.4 Toll-like receptor (TLR) signaling pathway 
 TLRs are proteins that belong to the family of pattern recognition receptors, 
and recognize foreign material with pathogen-associated molecular patterns. Their 
classic function is to provoke an inflammatory reaction by the innate immunity in 
response to noxious microbial stimuli. To date, there are 10 different TLRs, each of 
which recognizes different bacterial components, dsRNA or ssRNA (Creagh & 
O'Neill, 2006; Kawai & Akira, 2006). The widely used inflammatory inducer for 
scientific experimentation is lipopolysaccharide (LPS), which is recognized by 
TLR-4. Stimulated TLRs activate cell signalling pathways that lead to up-
regulation and production of pro-inflammatory cytokines. The common 
downstream signalling components of the TLR signalling cascade include inhibitor 
of NF-κB kinase (IKK) complex, IKK-related kinases and mitogen-activated 
protein kinases (MAPKs) (Mäkelä et al., 2009). Activated kinases then activate 




1.4.4.1 Nuclear factor-kappaB (NF-κB) pathway 
 NF-κB is a transcription factor activated by all TLR signaling pathways. It 
controls transcription of inflammatory mediators during the innate and adaptive 
immune response and is involved in cell survival. A diverse set of endogenous and 
exogenous stimuli has been reported to trigger its activation. The classical and 
alternative pathways are two distinct NF-κB activation pathways, each of which is 
involved in switching on different sets of genes and thus mediates different 
immune functions (Gilmore, 2006). Most of the existing knowledge relates the 
classical pathway to its pro-carcinogenic functions where it mediates tumor 
initiation and development through stimulating expression of pro-inflammatory 
factors (Karin & Greten, 2005).  
In the absence of a stimulus, NK-κB p50 and p65 subunits are 
sequestered in the cytosol through association with inhibitor of κB (IĸB) proteins. 
Inflammatory stimuli such as bacterial/viral infections and pro-inflammatory 
mediators initiate activation of the classical pathway. In this pathway, the stimuli 
trigger an upstream kinase complex called inhibitor of IκB kinase complex (IKK). 
This complex is composed of two identical catalytic subunits IKK-α and IKK-β 
and a regulatory subunit IKK-γ; the IKK-α/β subunits get phosphorylated upon 
activation. The phosphorylated IKK-β of the activated complex in turn rapidly 
phosphorylates IκB and targets them for proteasomal degradation, thereby 
liberating NF-κB dimers. The liberated NF-ĸB dimers composed of p65 (RELA), 
cREL and p50 subunits, which translocate into the nucleus. p65 is phosphorylated 
at Serine 536 and together with p50, bind to the NF-κB promoter sequence at the 5’ 
end of NF-κB target genes, leading to the promotion of gene transcription (Ghosh 
& Karin, 2002; Hayden & Ghosh, 2004; Karin et al., 2004). A schematic summary 




Figure 1.6 The NF-κB signalling cascade and its activation 
 
 The NF-κB pathway has been found to be chronically active in several 
inflammatory diseases such as gastritis, asthma, atherosclerosis, arthritis, sepsis and 
inflammatory bowel disease (Yamamoto & Gaynor, 2001; Roman-Blas & Jimenez, 
2006). Dysregulation of the NF-κB pathway has been associated with inflammatory 
and autoimmune diseases, viral infections and septic shock. It has also been found 
to augment carcinogenesis by enhancing cell proliferation, inhibiting apoptosis and 
promoting angiogenesis, invasiveness and metastasis through increased expression 
of associated inflammatory mediators (Mantovani et al., 2008) . In particular, the 
IKK-β and IKK-α proteins have been shown to contribute to tumor promotion and 
metastatogenesis respectively (Karin, 2008).The NF-kB pathway therefore serves 
as a valid target for therapeutic strategies aimed to treat chronic inflammatory 
disorders and cancer. 
Figure 1.6 The NF-κB signaling cascade and its activation. Pro-inflammatory stimulus such as 
LPS triggers the classical pathway of NF-ĸB activation. This leads to phosphorylation of IKK-
α and IKK-β, which in turn phosphorylate IκBs. Phosphorylated IκB is targeted for 
proteasomal degradation. This liberates NF-ĸB dimers that translocate into the nucleus and 




1.4.4.2 MAPK signalling 
 The MAPKs are primary components of intracellular signalling pathways 
that regulate the activity of several transcription factors that include NF-κB and 
AP-1. They integrate and process several extracellular signals and regulate cellular 
process such as growth, proliferation, differentiation and apoptosis. They consist of 
a series of three protein kinases: a MAPK that is activated through phosphorylation 
by an upstream MAP kinase kinase (MAPKK), which in turn is activated through 
phosphorylation by a further upstream MAP kinase kinase kinase (MAPKKK). At 
least three different MAPK pathways are known to exist: the extracellular signal 
regulated kinases (ERK1/2), the stress-activated protein kinases/c-Jun N-terminal 
kinases (SAPK/JNK) and the p38α MAPK.  They are activated through dual 
phosphorylation of the threonine and tyrosine residues in their structure. The 
effector functions that correspond to the specific activation signal are then executed 
through MAPK-dependent activation of transcription factors and nuclear proteins 
or regulation of other signalling cascades through activating other protein kinases. 
A schematic summary of the activation of the MAPK signalling pathways is 




Figure 1.7 The MAPK signaling pathways and their activation. 
  
 In general, the ERKs are activated by mitogenic and proliferative stimuli 
and the JNKs and p38 MAPKs are stimulated by stressors and inflammatory 
cytokines. Despite the differences between the types of stimuli, studies have 
demonstrated that all three MAPKs can be activated by inflammation-associated 
TLR signalling, leading to expression of inflammatory mediators (Schumann et al., 
1998; Anderson, 2000). A few lines of experimental evidence have indeed 
demonstrated the involvement of these MAPKs in an inflammatory response. For 
Figure 1.7 The MAPK signaling pathways and their activation. Stimulation of multiple 
receptors such as chemoattractant receptors, toll-like receptors and cytokine receptors trigger 
signaling cascade that activate the MAPKs through phosphorylation of threonine and tyrosine 
residues within a conserved “TXY” motif in their kinase domains. Activated MAPKs 
phosphorylate intracellular proteins including transcription factors and mediate transcription 
of genes for cellular responses such as cytokine production, apoptosis and migration.  
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instance, inhibition of ERK has been reported to affect the production of TNF-α 
(Dumitru et al., 2000), while JNK1-deficient mice have been found to be less 
susceptible to inflammation, tissue injury, as well as obesity induced-insulin 
resistance resulting from low grade inflammation (Han et al., 2001) (Hirosumi et 
al., 2002). Moreover, inhibition of p38 MAPK has also been shown to suppress 
synthesis of pro-inflammatory mediators (Kumar et al., 2003; Kaminska, 2005). 
Therefore, it can be concluded that interference of MAPK signalling serves as a 
promising strategy to combat inflammation and inflammation associated cancer.   
1.4.4.3 PI3K-PDK1-Akt signalling 
 PI3Ks are a family of enzymes that consist of a p85 regulatory and a 
catalytic p110 subunit. PI3Ks are activated through phosphorylation of the p85 
subunit by stimulated cell surface receptors. They catalyze the phosphorylation of 
lipid substrates to generate phosphoinositides (PI), PI(3,4)P2 and PI(3,4,5)P3. These 
products of PI3Ks in turn recruit Akt and PDK-1 into a complex on the plasma 
membrane, and mediate the phosphorylation of Akt by PDK-1 (Vanhaesebroeck & 
Alessi, 2000). Phosphorylated Akt transduces the signal to other kinases, resulting 
in the regulation of several cellular functions that include immune responses. While 
some reports have demonstrated positive regulation of TLR signalling by the PI3K 
pathway, some others have demonstrated a negative regulatory effect (Fukao & 
Koyasu, 2003). The effect of the PI3K pathway on TLR signalling seems to vary 
depending on cell type and stimulus. Nonetheless, in mouse macrophages, the 
PI3K-Akt pathway has been shown to positively regulate TLR-4 signalling, 
suggesting that inhibition of the PI3K pathway does bring about anti-inflammatory 
effects (Ojaniemi et al., 2003). A schematic summary of the activation of the PI3K-






1.5 Cancer Chemoprevention 
  The problem of cancer only seems to get harder given its nature of 
rapid evolution with increasing resistance to chemotherapeutic agents. In addition, 
it has been predicted that the number of cancer cases would rise to 20 million by 
2030 (Ferlay et al., 2008). A long term solution to address this problem is to go by 
the adage “prevention is better than cure”. Cancer is a complex group of diseases 
caused due to a diverse set of factors of which not all are preventable. Therefore, a 
feasible preventive strategy that the scientific community is exploring is to enhance 
the host defense systems. 
 Oxidative stress is an important phenomenon during carcinogenesis. Cells 
have inherent defense systems developed to combat oxidative and electrophilic 
stress. The concept of chemoprevention relies on strengthening the inherent 
antioxidant and detoxification systems of the cell. Inhibition of carcinogenesis by 
pre-exposure to chemical agents had been observed almost a century ago 
Figure 1.8 The PI3k-PDK1-Akt signaling pathway. The PI3Ks are activated upon stimulation of 
receptors containing a protein kinase cytosolic domain. Activated PI3Ks mediate formation of PI 
from the membrane inositols. The PI recruits PDK1 and Akt to inner surface of cell membrane 
leading to phosphorylation of Akt by PDK1. Phosphorylated Akt propagates the signal 
intracellularly by activation of cellular targets such as the NF-κB pathway.   
Figure 1.8 The PI3k-PDK1-Akt signaling pathway 
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(Berenblum, 1941). Years later in 1976, Michael B. Sporn coined the word 
“chemoprevention”. It is referred to prevention of initiation, promotion and 
progression of carcinogenesis by the use of natural or synthetic agents. Since then, 
the chemoprotective induction response has been widely studied with strong 
enthusiasm in the scientific community. The response involves induction of phase I 
(oxidation) and phase II (detoxification) enzyme. These are enzymes that 
metabolize and detoxify carcinogens respectively. The chemical agents that induce 
chemoprotective response are generally electrophiles. They are classified as 
monofunctional inducers, which bring about induction of phase II enzymes, or 
bifunctional inducers, which induce both, phase I and phase II enzymes.  The 
induction occurs at the transcriptional level. Transcriptional induction of phase I 
and phase II genes is mediated through activation of the arylhydrocarbon receptor 
(Ah-receptor) and dioxin response element (DRE). An additional receptor 
mediating transcriptional induction of phase II genes by monofunctional inducers 
and a subset of bifunctional inducers is the xenobiotics-activated receptor with a 
cis-acting DNA regulatory sequence identified as the antioxidant response element 
The ARE consists of the consensus sequence 5’-TGACnnnGC-3’ (Nioi et al., 
2003). 
1.5.1 NF-E2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 
(Keap1) signaling pathway  
1.5.1.1 Negative regulation of Nrf2 by Keap1 
 Transcriptional induction through the ARE is effected by redox 
sensor complex comprising of Nrf2 and Keap1 (Motohashi, 2004; Dinkova-
Kostova et al., 2005). The structure of Nrf2 consists of six highly conserved 
functional domains: Nrf2-ECH homology 1-6 (Neh1-6). The structure of Keap1 
contains five domains, namely the N-terminal region (NTR), broad complex tram-
track and bric-a-brac (BTB) domain, intervening region (IVR), the Kelch domain 
containing six Kelch repeats (DGR) and the C-terminal region (CTR). The domains 
present in the structure of Nrf2 and Keap1 are summarized in Fig 1.9. The Neh2 
domain in Nrf2 interacts with the Kelch repeats in the DGR domain of Keap1 (Itoh 
et al., 1999). Under unstimulated and basal conditions, Nrf2 is sequestered in the 
cytosol as an inactive complex by its cytosolic repressor Keap1 that is anchored to 
29 
  
cytoskeletal protein actin. The BTB domain in Keap1 interacts with the ubiquitin 
E3 ligase cullin 3 (Cul3) (Zipper & Mulcahy, 2002). Keap1 is a substrate adaptor 
for the Cul3 ubiquitin E3 ligase complex. It negatively regulates levels of Nrf2 
through directing it for Cul3-dependent ubiquitinylation of the lysine residues in 
Nrf2’s domain, followed by proteasomal degradation of the ubiquitinylated Nrf2 
(Cullinan et al., 2004; Kobayashi et al., 2004a; Zhang et al., 2004; Furukawa & 






1.5.1.2 The Nrf2-ARE response 
Upon oxidative or electrophilic stress, Keap1 withdraws its repressive 
effect on Nrf2. Nrf2 thus escapes degradation and is free to translocate into the 
nucleus where it forms heterodimers with small Maf proteins and binds to the ARE 
motif in the promoter regions of its target genes (Prestera et al., 1995; Itoh et al., 
1997). A summary of the sequence of events is presented in Fig 1.10. The target 
Figure 1.9 Domains present in the structures of Nrf2 and Keap1. (A)  The N-terminal region 
of Nrf2 is designated as the Neh2 domain, which contains two motifs (DLG and ETGE) that 
are responsible for the interaction with Keap1.  Neh4, Neh5, and Neh3 domains are important 
for the transactivational activity of Nrf2. The Neh1 domain is a basic-region leucine zipper 
motif for DNA binding and dimerization with Maf. (B) Keap1 structure is divided into five 
domains; NTR, BTB, IVR, DGR and CTR. The N-terminal BTB region mediates 
homodimerization and association with Cul3, and the C-terminal DGR region mediates 
binding with Nrf2. The IVR region contains highly reactive cysteines that act as redox 
sensors. Figure adapted from Mitsuishi (2012) 
A 
B 
Figure 1.9 Domains present in the structures of Nrf2 and Keap1 
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genes of Nrf2 include those encoding for enzymes such as NAD(P)H:quinone 
oxidoreductase 1(NQO1), glutathione-S-transferase (GST), TrxR, heme oxygenase 
1 (HO-1), γ-glutamyl cysteine ligase (γGCL) and UDP glucuronosyltransferase, 
each of which can eliminate endogenous and exogenous stressors (Thimmulappa et 





1.5.1.3 Cysteines in Keap1 serve as sensors of the cellular redox state 
 Keap1 is a redox-sensitive protein; it consists of a high number of cysteine 
residues that is almost twice the average number of cysteine residues present in 
other proteins. Human Keap1 (full-length 624 amino acids) has 27 cysteines, of 
which many are in proximity to basic residues and have low pKa values. Three 
cysteines at amino acid position 151, 273 and 288 have been shown to be critical 
for Keap1’s function. While mutation of Cys151 has been found to abolish the 
ability of Keap1 to sense oxidative stress and therefore the lack of Nrf2 repressor 
activity, mutation of Cys273 and Cys288 has resulted in abolishment of Keap1’s 
ability to direct Nrf2 for ubiquitination (Zhang & Hannink, 2003; Kobayashi et al., 
Figure 1.10 Nrf2 regulation by Keap1. At basal conditions, Nrf2 is sequestered by Keap1 in 
the cytosol and directed for proteasomal degradation. On exposure to electrophiles or 
oxidative stress, Nrf2 escapes from Keap1, translocates to the nucleus, heterodimerizes with 
small Maf proteins and binds to ARE to induce transactivation of genes encoding phase II 
antioxidant and detoxifying enzymes. Figure based on Itoh et al., (2010) 
Figure 1.10 Nrf2 regulation by Keap1. 
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2004b; Wakabayashi et al., 2004).Structurally diversified electrophiles have been 
shown to interact with cysteine residues of Keap1 and it is suggested that each 
group of electrophile follows a “cysteine code” (distinct pattern of cysteine 
residues modified) to induce Nrf2. To date, the mechanisms underlying 
stabilization of Nrf2 based on modification on the cysteine residues in Keap1 
remain to be fully elucidated. 
1.5.1.4 Current proposed mechanisms of Nrf2 stabilization 
 Different mechanisms pertaining to stabilization of Nrf2 levels upon 
application of an electrophilic stimulus have been hypothesized and investigated by 
researchers. They are as follow: 
 1. It has been hypothesized that interaction of electrophiles with Keap1 
would disrupt the interaction between Keap1 and Nrf2. However, this hypothesis 
has not been supported and experimental observations showed that Keap1-Nrf2 
interaction was not disrupted in the presence of electrophiles. The more plausible 
hypothesis, which is supported by experimental observations, is a resulting 
reduction in Keap1-Cul3 ligase activity in the presence of electrophiles. Nrf2 
ubiquitination is therefore suppressed, and accumulated Nrf2 translocates into the 
nucleus to induce the ARE response (Zhang, 2006). 
 2. Keap1 exists as a homodimer where each monomer interacts with the 
low-affinity DLG and high-affinity ETGE motif in Nrf2 (Lo et al., 2006; 
McMahon et al., 2006; Tong et al., 2006; Ogura et al., 2010). Under normal 
physiological conditions, interaction exists at both motifs. Upon application of an 
electrophilic stimulus, binding at the low-affinity DLG motif is disrupted. This 
results in suppression of ubiquitination of Nrf2, thereby stabilizing Keap1-Nrf2 
complexes that lead to enhancement in ARE-dependent transactivation (Tong et 
al., 2007). 
 3. Another hypothesis proposes a switch in ubiquitination from Nrf2 to 
Keap1 mediated through disruption of Keap1-Nrf2-Cul3 binding. As a result, 




1.5.2 Cross talk between the Keap1-Nrf2 and NF-κB signaling pathways 
 The majority of phytochemicals possessing chemopreventive potential 
mediated at least in part through inducing the Nrf2/Keap1 pathway are also 
observed to possess anti-inflammatory properties mediated at least partly through 
their action on the NF-κB pathway. It is noteworthy that Talalay and co-workers 
had previously demonstrated the existence of correlation between NQO1 inductive 
capacities and NO inhibitory potential of different classes of phytochemicals (Liu 
et al., 2008b). Apparently, there is increasing enthusiasm among researchers to 
explore possibilities of cross-talk between the Nrf2-Keap1 and NF-κB signaling 
pathway.  
 At present, there are contradicting reports on the anti-inflammatory role of 
Nrf2. In a study by Yamamoto and co-workers (2004) using a mouse model of 
acute inflammation, Nrf2 deficiency was found to lead to prolonged neutrophil 
recruitment and delayed recruitment of macrophages in model of acute 
inflammation in mice. In other studies, Nrf2-deficient mice have been found to be 
more susceptible to colorectal cancer associated with a decreased expression of 
antioxidant/phase II enzymes along with upregulation of pro-inflammatory 
cytokines and dextran sulphate sodium-induced inflammation (Khor et al., 2006). 
In addition, Nrf2 is reported to suppress TNF-α-induced and IL-1β-induced 
monocyte chemoattractant protein 1 (MCP-1) and inhibit monocyte adhesion to 
endothelial cells (Chen et al., 2006). Although these studies have suggested an anti-
inflammatory role for Nrf2, the NO inhibitory or anti-inflammatory activities of the 
phase II inducers have been observed to be similar in both wild-type and Nrf2
−/−
 
peritoneal macrophages (Liu et al., 2008b). As such, a possible anti-inflammatory 
role for Nrf2 and the underlying mechanism remains to be fully understood.  
 Keap1 is also a potential molecular link between the Nrf2-Keap1 and NF-
κB signaling pathways. Although the precise role of Keap1 in mediating the 
inflammatory response through the NF-κB pathway remains to be fully elucidated, 
findings from studies to-date have indicated that there is indeed cross-talk between 
the two signalling pathways. For instance, the p65 subunit has been found to bind 
to Keap1, which leads to a decrease in Nrf2 activity mediated through increased 
ubiquitination and degradation of Nrf2 and diminished Nrf2 binding to DNA  (Liu 
et al., 2008a) (Yu et al., 2011). On the other hand, Keap1 has been found to bind to 
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the kinase domain of IKK-β, which leads to IKK degradation (Lee et al., 2009; 
Kim et al., 2010).  
 Having reviewed the biology relevant to mechanistic investigations aimed 
in this PhD project, the hypothesis, specific aims and scope of the PhD project are 
detailed in following the section. 
1.6 Hypothesis and objectives of the PhD project 
1.6.1 General Objective 
 Natural and a few synthetic ITCs have been shown to possess anti-
tumor and chemopreventive properties through pre-clinical investigations 
(reviewed in Section 1.2.3). These studies suggest that the ITCs possess potential to 
be developed into clinical candidates for prevention and treatment of cancer. 
Structurally different ITCs have been reported to exhibit varying biological effects 
and mechanisms of action (reviewed in Section 1.2.3). This inspired us to 
investigate the structure dependent variations in the anti-cancer effects, 
chemopreventive effects and underlying mechanisms of action of ITCs for 
development of ITC analogs with superior biological potencies and therapeutic 
potential. To pursue such an investigation, a library of synthetic ITC analogs was 
generated previously in the laboratory through structural modifications of 
naturally-occurring ITCs. The synthesis had been carried out by Mr.Lee Neng Cun 
Baxter (National university of Singapore) and Dr.Yang Hong (National university 
of Singapore).  
1.6.2 Rationale of structural modifications in the library of ITC analogs 
The biological effects of ITCs are attributed to their reaction with intra-
cellular nucleophilic elements such as glutathione and nucleophilic amino acids of 
proteins (see Section 1.2.2). Therefore, the biological effects of an ITC are 
determined to a great extent by the reactivity of the ITC group. The reactivity of an 
ITC analog depends on the side chain present in the analog as it affects the 
electrophilicity of the ITC functional group. Therefore, structural modifications of 
the side chains in the naturally occurring BITC, PEITC and SF had been carried out 
to generate a library of ITC analogs (Fig 1. 11). The library consisted of 
structurally different synthetic ITC analogs that can be broadly classified into two 
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major groups, the aromatic ITCs and the aliphatic ITCs. The aromatic ITC analogs 





Figure 1.12 Chemical structure of NMPEA used as negative control in investigations. 
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Figure 1.11 Chemical structures of novel ITC analogs synthesized and under investigation in the 
laboratory 
Aliphatic ITC analogs Aromatic ITC analogs 
SF PEITC BITC 




Figure 1.12 Chemical structure of NMPEA used as negative control in investigations 





electron donating methoxy groups at the ortho and para positions as well as the 
electron withdrawing fluorine group at the meta positions were carried out to 
generate analogs B2, B9, B10, B14 and B15. The aliphatic ITC analogs were 
derived from SF. The sulfinyl group was replaced with a carboxyl group to get B7. 
The chain length between the carbonyl group and ITC functional group in B7 was 
decreased to get B8. Of note, the earlier studies reporting the structure activity 
relationship of aromatic ITCs (reviewed in Section 1.2.3) had not explored the 
effects of methoxy and fluorine substitutions on the benzene ring of aromatic ITCs. 
In the case of aliphatic ITCs, studies were limited to investigating the effect of 
replacement of sulfinyl to carbonyl on induction of activity of NQO1. The effect of 
alkyl chain length on the potencies of carbonyl containing ITCs remain unexplored. 
1.6.3 Hypothesis and specific aims 
 It was hypothesized that the synthetic ITC analogs of the library may 
exhibit improved biological efficacies than their parent ITCs. The synthetic ITC 
analogs were therefore investigated for their antitumor and chemopreventive 
potencies in comparison with their parent ITCs. Further investigations were 
pursued to understand the biological mechanisms of actions of the ITC analogs. N-
methylphenethylamine (NMPEA), which is devoid of the ITC functional group, 
was used as negative control.   
The specific aims set out for this project were: 
 To screen the ITC analogs for their anti-proliferative efficacies and identify 
compounds with superior bioactivities as potential chemotherapeutic 
agents.  
 To elucidate the cellular events and mechanisms underlying the anti-tumor 
properties of ITC analogs. 
 To evaluate ITC analogs with weaker anti-proliferative properties for their 
anti-inflammatory properties and elucidate the mechanisms underlying their 
anti-inflammatory properties. 
 To evaluate ITC analogs with weaker anti-proliferative properties for their 




Given these aims, the project encompasses the in-vitro evaluation of 
antitumor efficacies, chemopreventive efficacies and mechanistic investigations of 
the synthetic ITC analogs in comparison to their parent ITCs. The methods 
employed for pursuing the aims of the project are detailed in Chapter 2. The 
investigations addressing the specific aims and the results obtained are described in 
Chapters 3, 4, 5 and 6. The general conclusions of this PhD study are summarized 
and followed by future directions in Chapter 7. 
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Chapter 2  
Materials and Methods 
2.1 Materials 
Chemicals, antibodies, plasmids and instruments with their suppliers/source are 
enlisted in Table 2.1.  
Table 2.1 List of materials 
Material Supplier 
Chemicals 
1,4-Piperazinediethanesulfonic acid (PIPES) Sigma Aldrich (St. Louis, MO, USA) 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma Aldrich (St. Louis, MO, USA) 
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) Sigma Aldrich (St. Louis, MO, USA) 
Acrylamide/bis-acrylamide 40% solution 37.1:1 Bio-Rad Laboratories (Hercules, CA, USA) 
Agarose Invitrogen (Carlsbad, CA, USA) 
Ammonium persulfate (APS) Sigma Aldrich (St. Louis, MO, USA) 
Ampicillin Sigma Aldrich (St. Louis, MO, USA) 
β-mercaptoethanol Bio-Rad Laboratories (Hercules, CA, USA) 
Bacto
TM
 agar BD (Franklin Lakes, NJ, USA) 
Bacto
TM 
tryptone BD (Franklin Lakes, NJ, USA) 
Bacto
TM 
yeast extract BD (Franklin Lakes, NJ, USA) 
Bicinchoninic acid protein assay kit Thermo Scientific (Rockford, IL, USA) 
Biotinylated  iodoacetamide (BIAM) Sigma Aldrich (St. Louis, MO, USA) 
Bovine serum albumin (BSA) Thermo Scientific (Rockford, IL, USA) 
Bradford Dye Reagent Concentrate Bio-Rad Laboratories (Hercules, CA, USA) 
Calcium chloride Sigma Aldrich (St. Louis, MO, USA) 
Cinnamic acid (CAC) Sigma Aldrich (St. Louis, MO, USA) 
Chloroquine diphosphate salt Sigma Aldrich (St. Louis, MO, USA) 
CL-Xposure® X-ray films Thermo Scientific (Rockford, IL, USA) 
Commassie Brilliant blue R-250 Bio-Rad Laboratories (Hercules, CA, USA) 
Dimethylsulfoxide (DMSO) Fisher Scientific (Loughborough, UK) 
Sigma Aldrich (St. Louis, MO, USA) 
DMEM medium (high glucose) Sigma Aldrich (St. Louis, MO, USA) 
Doxorubicin hydrochloride Sigma Aldrich (St. Louis, MO, USA) 
Ethylenediamine tetracetic acid (EDTA) Merck (Darmstadt, Germany) 
Ethylene glycol-bis(β-aminoethylether)-
N,N,N’,N’-tetraacetic acid (EGTA) 
MP Biomedicals (Solon, OH, USA) 
Fetal Bovine Serum (FBS) HyClone Laboratories (Logan, UT, USA) 
FluoSpheres® Polystyrene Microspheres, 1.0 
μM, Yellow green fluorescent (505/515) 
Molecular Probes (Eugene, OR, USA) 
GeneJuice® transfection reagent Novagen (Gibbstown, NJ, USA) 
Glutathione disulfide (GSSG) Sigma Aldrich (St. Louis, MO, USA) 
Glutathione (GSH) Sigma Aldrich (St. Louis, MO, USA) 
Glycerol Fluka Biochemika (Buchs, Switzerland) 
Glycine 1
st
 Base (Singapore) 
Griess reagent Fluka Biochemika (Buchs, Switzerland) 
Guanosine triphosphate (GTP) Sigma Aldrich (St. Louis, MO, USA) 






• Sulforaphane, Phenethyl-ITC, Benzyl-ITC 
 
• B2, B4, B5, B7, B8, B9, B10, B14 & B15 
(purity > 95%) 
 
 
Sigma Aldrich (St. Louis, MO, USA) 
 
Synthesized by Dr.Yang Hong & Mr. Lee 
Neng Cun Baxter 
L-glutamine HyClone Laboratories (Logan, UT, USA) 
Laemmili sample buffer (2x) Bio-Rad Laboratories (Hercules, CA, USA) 
Lipopolysaccharide (LPS) from E.coli Sigma Aldrich (St. Louis, MO, USA) 
Low melting agarose Pronadisa (Madrid, Spain) 
Magnesium Chloride Sigma Aldrich (St. Louis, MO, USA) 
Methanol Fisher Scientific (Loughborough, UK) 
N,N,N’,N’-tetramethylene ethyldiamine 
(TEMED) 
Calbiochem (Gibbstown, NJ, USA) 
Nitrocellulose membrane Bio-Rad Laboratories (Hercules, CA, USA) 
Nicotinamide adenine dinucleotide phosphate 
reduced form (NADPH) 
Sigma Aldrich (St. Louis, MO, USA) 
Paclitaxel Sigma Aldrich (St. Louis, MO, USA) 
Pageruler
XM
 prestained protein ladder Fermentas (Glen Burnie, MD USA) 
Paraformaldehyde Sigma Aldrich (St. Louis, MO, USA) 
Penicillin-Streptomycin PAN Biotech GmbH (Aidenbach, Germany) 
Phosphate buffered saline (PBS) 1
st
 Base (Singapore) 
Poly-L-lysine 1%w/v solution Sigma Aldrich (St. Louis, MO, USA) 
Porcine tubulin Cytoskeleton (Denver, CO, USA) 
Primers 1
st
 Base (Singapore) 
Propidium iodide Sigma Aldrich (St. Louis, MO, USA) 
Protease inhibitor cocktail tablets Roche Diagnostics (Manheim, Germany) 
Protein G Sepharose
TM
 beads Amersham Biosciences (Uppsala, Sweden) 
Qiaprep miniprep spin kit Qiagen GmbH (Hilden, Germany) 
Ribonuclease A (RNAse A) Sigma Aldrich (St. Louis, MO, USA) 
RPMI 1640 medium GIBCO (Grand Island, NY, USA) 
Sodium β-glycerophosphate Sigma Aldrich (St. Louis, MO, USA) 
Sodium bicarbonate MP Biomedicals (Solon, OH, USA) 
Sodium citrate BDH Chemicals (Poole, UK) 
Sodium chloride 1
st
 Base (Singapore) 
Sodium dodecyl sulphate (SDS) 1
st
 Base (Singapore) 
Sodium hydroxide Kanto Kagaku (Singapore) 
Sodium fluoride Sigma Aldrich (St. Louis, MO, USA) 
Sodium orthovanadate MP Biomedicals (Solon, OH, USA) 
Sodium pyrophosphate Sigma Aldrich (St. Louis, MO, USA) 
Sodium pyruvate GIBCO (Grand Island, NY, USA) 
Streptavidin Agarose Resin Thermo Scientific (Rockford, IL, USA) 
Streptavidin-horseradish peroxidise 
(Streptavidin-HRP) 
Biosource International (Camarillo, TX, USA) 
Sucrose Sigma Aldrich (St. Louis, MO, USA) 
Trans-cinnamaldehyde Sigma Aldrich (St. Louis, MO, USA) 
Tris 1
st
 Base (Singapore) 
Triton X-100 USB (Cleveland, OH, USA) 
Trypsin/EDTA (1x) GIBCO (Grand Island, NY, USA) 
Tween 20 Sinopharm Chemical Reagent Co.Ltd 
(Shanghai, China) 
X-ray developer Konica Minolta Holdings (Tokyo, Japan) 
X-ray fixer Konica Minolta Holdings (Tokyo, Japan) 
Recombinant proteins 
Stromal Cell-Derived Factor-1alpha protein 
(SDF-1α) 
Immuno Tools (Friessoythe, Germany) 
rat and human thioredoxin reductase Dr. Elias Arner’s laboratory (Division of 





human thioredoxin IMCO Corp Ltd (Stockholm, Sweden) 
Tubulin Cytoskeleton Inc (Danver, CO, USA) 
Antibodies 
anti-β-actin Santa Cruz biotechnology (Santa cruz, CA, 
USA) 
anti-Akt Cell Signaling technology (Danvers, MA, 
USA) 
anti-β-tubulin Sigma Aldrich (St. Loius, MO, USA) 
anti-caspase 3 Cell Signaling technology (Danvers, MA, 
USA) 
anti-cleaved caspase 3 Cell Signaling technology (Danvers, MA, 
USA) 
anti-COX-2 Santa Cruz biotechnology (Santa cruz, CA, 
USA) 
anti-FLAG Sigma Aldrich (St. Louis, MO, USA) 
 
anti-γ-GCL Santa Cruz biotechnology (Santa cruz, CA, 
USA) 
anti-GSTA1 Obtained from Dr.John D.Hayes’ laboratory 
(Ninewell Hospital and Medical School, 
University of Dundee, Dundee, UK) 
anti-HO-1 Stressgen (San Deigo, CA, USA) 
anti-Ikbα Cell Signaling technology (Danvers, MA, 
USA) 
anti-IKKα Cell Signaling technology (Danvers, MA, 
USA) 
anti-IKKβ Cell Signaling technology (Danvers, MA, 
USA) 
anti-iNOS Cell Signaling technology (Danvers, MA, 
USA) 
anti-MMP-9 Cell Signaling technology (Danvers, MA, 
USA) 
anti-NQO1 Obtained from Dr.John D.Hayes’ laboratory 
(Ninewell Hospital and Medical School, 
University of Dundee, Dundee, UK 
anti-Nrf2 Obtained from Dr.John D.Hayes’ laboratory 
(Ninewell Hospital and Medical School, 
University of Dundee, Dundee, UK 
anti-p38 MAPK Cell Signaling technology (Danvers, MA, 
USA) 
anti-p44/42 MAPK Erk(1/2) Cell Signaling technology (Danvers, MA, 
USA) 
anti-p65 Cell Signaling technology (Danvers, MA, 
USA) 
anti-PARP Cell Signaling technology (Danvers, MA, 
USA) 
anti-phospho-Akt Cell Signaling technology (Danvers, MA, 
USA) 
anti-phospho-histone H2AX Cell Signaling technology (Danvers, MA, 
USA) 
anti-phospho-histone H3 Cell Signaling technology (Danvers, MA, 
USA) 
anti-phospho-Iκbα Cell Signaling technology (Danvers, MA, 
USA) 
anti-phospho- IKKα/β Cell Signaling technology (Danvers, MA, 
USA) 






anti-phospho-p44/42 MAPK Erk(1/2) Cell Signaling technology (Danvers, MA, 
USA) 
anti-phospho-p65 Cell Signaling technology (Danvers, MA, 
USA) 
anti-phospho-SAPK/JNK Cell Signaling technology (Danvers, MA, 
USA) 
anti-Trx IMCO Corp Ltd (Stockholm, Sweden) 
anti- TrxR Santa Cruz biotechnology (Santa cruz, CA, 
USA) 
anti-TNF-α Calbiochem (Gibbstown, NJ, USA) 
anti-V5 ABD Serotec Inc (Kidlington, Oxford, UK) 
Reagent or Assay kits  
RNeasy Mini Kit  Qiagen (Hilden, Germany) 
RevertAid™ First strand cDNA synthesis Kit Fermentas (Vilnius, Lithuania and  CA) 
PGE2 EIA Kit Cayman Chemical Company 
Dual Luciferase® Reporter assay system Promega (Madison, WI, USA) 
DuoSet ELISA Development kit R&D systems (Minneapolis, MN ,USA) 
Enhanced Chemiluminescence western blotting 
kit 
Perkin Elmer  (Waltham, MA, USA) 
Thermo Scientific (Rockford, IL, USA) 
Plasmids  
pcDNA3.1/ZeoV5-KEAP1 Cloned by Dr. Chew Eng Hui (National 
University of Singapore) 
pcDNA3.1 FLAG-IKK-β Cloned by Mr.Shelar Sandeep Balu (National 
University of Singapore) 
pGL3-ARE firefly luciferase reporter  Dr. Alan Porter’s laboratory (Institute of 
Molecular and Cell biology, Singapore) 
pRL-CMV reporter  Stratagene (La Jolla, CA) 
Instruments 
Ultraspec 2000 pro UV/Vis spectrophotometer Amersham Biosciences, Inc (Amersham, UK) 
SRX101A radiofilm processor Konica Minolta Holdings (Tokyo, Japan) 
FC 500 MCL Flow cytometry System with MXP 
software 
Beckman Coulter, Inc (Brea, CA, USA) 
Mastercycler ® Eppendorf (Hamburg, Germany) 
VERSAmax microplate reader Molecular Devices, LLC (Sunnyvale, USA) 
Eclipse Ti-S epifluorescence microscope with 
DS-RiL Camera 
Nikon, Tokyo, Japan 
ChemiDoc™ imaging system Bio-Rad (Hercules, CA, USA) 
Agilent 1100 Series isocratic HPLC System Agilent Technologies (Santa Clara, CA, USA) 











2.2.1 Preparation of drug stocks 
 All compounds were accurately weighed and dissolved in DMSO to obtain 
50 mM solutions. Aliquots of stock solution were stored protected from light at -
20˚C for up to 1 year.   
2.2.2 Stability analysis using HPLC 
 Stock solutions of all ITCs were freshly diluted to final concentration of 
1mM in PBS and incubated at 37˚C. 10 μl aliquots drawn from the incubated 
samples at several time points (0, 3, 6, 12, 24, 36, 48, 72 h) were immediately 
separated using Eclipse XDB-C18 reverse phase column and detected by UV 
absorption at 240nm on an Agilent 1100Series HPLC system. The mobile phase 
composition used for each of the ITC analog is listed in Appendix I. The column 
was maintained at 30˚C and flow rate was set to 1ml/min. Drug free DMSO blank 
samples were also analyzed to eliminate any possible unknown peaks not attributed 
to the presence of the drug. 
2.2.3 General cell culture 
 All cell culture procedures were performed in class II biological safety 
cabinet. The cell lines, media, cell cultureware and cell detachment method 
employed during sub-culturing are enlisted in Table 2.5.  
 







HCT 116 Frozen stock 
in laboratory 
RPMI-1640 T-75 flask Trypsinisation 1 : 10 
A549 Frozen stock 
in laboratory 
Ham’s F12  T-75 flask Trypsinisation 1 : 8 
RAW 264.7 Frozen stock 
in laboratory 
DMEM  100 mm dish Scraping 1 : 3 




with 100 mg/L 
sodium pyruvate) 






Dr. John D. 
Hayes’ 
laboratory **  
IMDM 100 mm dish 
(pre-coated with 
1% w/v gelatin 
solution for 4 h) 
Trypsinisation 1 : 4  and 1 : 8 
respectively 
Table 2.2 Cell lines and requirements for culture methods 
*  Supplemented with 1 μg/ml streptomycin, 100units/ml penicillin and 10% w/v FBS (heat-inactivated at   
56˚C for 1 h) 
** Ninewells Hospital and Medical School, University of Dundee, Dundee, UK 





 Frozen stocks of cells were revived by rapid thawing at 37˚C following 
suspension in 5 ml fresh medium and centrifugation at 1200 rpm for 5min to pellet 
cells. Pelleted cells were cultured in T25 flask containing 7 ml medium and were 
eventually transferred to appropriate cell cultureware. All cells were cultured in 5% 
CO2 incubator at 37˚C. Cells in T75 flask/ 100 mm dish were subcultured upon 
reaching 80-90 % confluency. For subculturing, spent cell culture medium was 
aspirated and the cell monolayer was rinsed with PBS. Cells were detached by 
either trypinization or scraping. For trypinization, 0.8 ml of trypsin/EDTA solution 
was added to the cultureware and gently spread on the cell monolayer following 
incubation of cell cultureware at 37˚C for up to 5 min until the cells had detached 
completely. For scrapping, cells were dislodged gently using a cell scraper. 
Detached cells were uniformly suspended in fresh medium; part of the suspension 
was transferred to new cell cultureware with 10 ml fresh medium and the rest was 
utilized to plate cells for experiments. Cells were stored in vials for long term by 
freezing in 90% culture medium and 10% DMSO. Vials were frozen gradually in 
freezing container (1C cooling per min), stored at -80˚C for two days and 
transferred to a liquid nitrogen tank.  
2.2.4 MTT cell viability assay 
 Cells suspension in fresh medium obtained during sub-culturing were 
passed through 23G needle to obtain a uniform suspension of single cells. 
Following counting using a haemocytometer, the suspension was diluted according 
to required cell densities (HCT 116: 3000 cells/well, HEK-293: 15000 cells/well, 
RAW 264.7: 15000 cells/well) and inoculated to 96-well plates (180 μl/well). An 
extra plate (two rows) was also inoculated for use as T0 plate. After 24 h, DMSO 
stock solutions of the ITCs were diluted using cell culture medium. 20 μl of the 
diluted ITC solutions were added to the wells containing 180 μl of medium to 
obtain required final ITC concentrations and 20 μl of medium were added to 
control wells and wells of the T0 plate. The T0 plate was terminated then to obtain 
a measure of number of cells at the time of ITC addition. The ITC-treated plates 
were incubated for 24 h or 72 h and then terminated. For termination, 50 μl of MTT 
solution (2 mg/ml, final concentration in well 0.4 mg/ml) was added to each well 
and the plates were incubated for 4 h at 37˚C to allow for formation of purple 





wells were aspirated and the crystals were dissolved in 150 μl of DMSO: glycine 
buffer (4:1, pH 10.5) by gentle shaking for 15 min. Upon complete solubilization, 
optical densities of the wells were measured at 550 nm and the absorbance values 
were used to estimate GI50 and LC50 values of the ITCs using the following 
equations. 
  
501 GI 1 2
50 1
1 2









501 LC 1 2
50 1
1 2



























1OD , 2OD Absorbance values such that 1OD >OD  at 50GI and 2OD at 50 2LC >OD , 
respectively. 
ControlOD      Absorbance value of untreated cells after 72 h 
0t
OD             Absorbance value of untreated cells at the time of drug addition. 
1 2x ,x           Concentrations that elicit the absorbance responses 1OD and 2OD , respectively. 
2.2.5 Cell cycle analysis 
 HCT 116 cells were seeded in 6-well plates at a density of 1 × 10
6
 cells/well 
in 2 ml culture medium and incubated overnight at 37˚C for cell attachment. 
Adhered cells were treated with ITCs or DMSO for 14 h. After ITC treatment, 
medium containing detached cells was collected and the attached cells were 
trypsinized. The floating and attached cells were pooled and pelleted by 
centrifugation at 1200 rpm, 4˚C for 5 min. The cell pellet was then washed with 
ice-cold PBS and resuspended in 0.5 ml of hypotonic fluorochrome solution (0.1% 
sodium citrate, 0.1% Triton-X-100, 50 μg/ml propidium iodide (PI) and 0.1 mg/ml 





in the dark at 4˚C. The cell suspension was then syringed through 23G needle to 
disintegrate any clumps and analyzed by flow cytometry using cytometer. The 
fluorescent signals of PI-stained nuclei were analyzed by MXP software.   
2.2.6 DTNB assay for analysis of sulfhydryl groups in tubulin 
 The DTNB assay was used to assess the interaction of ITC analogs with 
sulfhydryl groups in tubulin protein. A stock solution of 10 mg/ml purified porcine 
tubulin in of PIPES-MgCl2 buffer (0.1 M PIPES, 0.5 mM MgCl2, pH 7.5) was 
prepared and diluted with PIPES-MgCl2 buffer to obtain required working 
concentrations. 100 μl of 4 μM tubulin solution was incubated with ITC analogs for 
30 min at 37˚C in a 96-well plate. 50 μl PIPES-MgCl2 buffer containing 1.5 mM 
DTNB and 5 mM Guanidine HCl was added to each sample. The plate was then 
incubated for an additional 5 min and absorbance at 412 nm was measured using 
spectrophotometer. Number of sulfhydryl groups per tubulin dimer was calculated 
based on the assumption that 20 sulfhydryl groups (present in the 20 cysteine 
residues per tubulin dimer) contributed to the absorbance response of untreated 
sample. 
2.2.7 Colorimetric assays for Trx/TrxR activity  
  Method of Kunkel et al. (1997) was modified and following assays were 
performed.  
2.2.7.1 TrxR-mediated DTNB reduction assay  
 This assay was based on TrxR’s ability to directly reduce 5, 5’-dithiobis (2-
nitrobenzoic acid) (DTNB). The assay was carried out in 96-well plate. In a volume 
of 100 μl of 50 mM Tris-HCl pH 7.5 and 2 mM EDTA buffer (TE buffer) per well, 
ITCs (final concentration range 1-100 μM) were incubated with 100 nM 
recombinant rat TrxR and 200 μM reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) at room temperature for 30 and 60 min. Following incubation, 
100 μl of 10 mM DTNB and 200 μM NADPH solutions in TE buffer was added to 
each well and linear increase in absorbance at 412 nm for 2 min was measured 
using plate reader. The percentage of TrxR activity of ITC-treated sample over than 
of DMSO control was estimated and the concentration to inhibit TrxR activity by 






2.2.7.2 Insulin reduction assay 
HCT 116 cells were seeded in 6-well plates at a density of 1 × 10
6
 cells/well in 2 
ml culture medium and incubated overnight at 37˚C for cell attachment. Adhered 
cells were treated with ITCs or DMSO for 14 h. Following treatment with ITCs, 
medium containing detached cells was collected and the attached cells were 
trypsinized. The floating and attached cells were pooled and pelleted by 
centrifugation at 1200 rpm, 4˚C for 5 min. The cell pellet was then washed with 
ice-cold PBS and dissolved in 180 μl Triton-X-100 lysis buffer (25 mM Tris-HCl 
pH 7.5, 100 mM NaCl, 2.5 mM EGTA, 2.5 mM EDTA, 20 mM NaF, 1 mM 
Na3VO4, 10 mM sodium pyrophosphate, 20 mM sodium β-glycerophosphate, 0.5% 
Triton X-100 with freshly added protease inhibitor cocktail). Collected lysates were 
pre-cleared by centrifugation at 13000 rpm, 4˚C for 10 min and used freshly for the 
following assays. To measure TrxR activity, lysate containing 25 μg of protein was 
incubated in TE buffer with 33 μl of insulin master mix (85 mM HEPES buffer 
pH7.6, 0.3 mM insulin, 2.5 mM EDTA and 660 μM NADPH) and 10 μM human 
Trx in a final volume of 50 μl in a 96-well plate for 40 min at 37˚C. Controls 
consisting of lysates and all reaction reagents except Trx were included. Following 
incubation, 200 μl of 1mM DTNB in 6 M guanidine-HCl and 200 mM Tris-HCl 
pH 8.0 was added to each sample and the absorbance at 412 nm generated from 
insulin reduction was measured using microplate reader. Trx activity was measured 
by similar procedure except that cell lysates were incubated only for 20 min with 
600 nM recombinant rat TrxR instead of human Trx. TrxR and Trx activities were 
calculated based on absorbance at 412 subtracted from that of corresponding blank 
and percentage activity of each sample over DMSO control was estimated.   
2.2.8 Glutathione reduction assay 
HCT 116 cells were seeded in 6-well plates at a density of 1 × 10
6
 cells/well in 2 
ml culture medium and incubated overnight at 37˚C for cell attachment. Adhered 
cells were treated with ITCs or DMSO for 14 h. Following treatment with ITCs, 
attached and floating cells were pooled and pelleted by centrifugation at 1200 rpm, 
4˚C for 5 min. The cell pellet was then washed with ice-cold PBS and resuspended 
in 180 μl Triton-X-100 lysis buffer. Collected lysates were pre-cleared by 
centrifugation at 13000 rpm, 4˚C for 10 min and used freshly for the assay. Lysate 





μM NADPH in phosphate buffer saline (PBS) pH 7.5. Absorbance of the mixture 
was measured at 340 nM, and 37˚C for 10 min. GR activity was measured based on 




 min and percentage of GR 
activity of ITC-treated sample over DMSO control was estimated.   
2.2.9 Isolation of CD14+ human monocytes  
25 ml of blood from healthy donors was added gently on top of 20 ml of Ficoll-
Hypaque reagent and subjected to density gradient centrifugation at 3000 rpm for 
20 min to obtain distinct layers of plasma on the top, buffy interphase containing 
peripheral blood mononuclear cells (PBMCs) above the Ficoll-Hypaque reagent 
and granulocytes and erythrocytes at the bottom. The top layer of plasma is 
aspirated and the buffy layer of PBMCs is carefully transferred to another tube and 
washed with PBS-E (PBS with 2mM EDTA). Monocytes were isolated from 
PBMCs by positive selection using human CD14 Micro beads (Miltenyi Biotec) 
and MACS columns as per manufacturer’s protocol.  The purity of isolated 
monocytes was assessed by cytometry and was consistently >95%. Fresh human 
monocytes were suspended in RPMI medium and immediately used for all 
experiments. 
2.2.10 Trypan blue cell viability assay 
Human monocytes were seeded in a 12-well plate at a density of 6105cells/ well 
and treated with ITCs for 24 h. Following treatment, cells were trypsinized and 
collected by centrifugation at 300g for 5 min. Collected cells were resuspended in 
200 μl medium. 10 μl of cell suspension was gently mixed with 2 μl of Trypan blue 
solution. Number of viable cells (cells that had not been stained) were counted 
using haemocytometer. 
2.2.11 Nitrite assay 
RAW 264.7 cells (5105cells/ well) were cultured in 6-well plates until 70% 
confluent and conditioned in serum free medium before treatment with ITCs and 
LPS (500 ng/ml). 20 h following treatment with LPS, the spent cell culture media 
were collected and centrifuged at 1200 rpm to pellet floating cells. The 
supernatants from different samples were immediately used to analyze for amounts 
of nitrite (NO2
-
) by the Griess reaction (Nims et al., 1996). Briefly, equal volumes 





well plate and incubated in dark at room temperature. After 15 min, absorbance of 
the media reagent mix was read at 540nm. The amounts of nitrite in samples were 
calculated from a sodium nitrite standard curve (0-100 µM) prepared in fresh cell 
culture media. A dose response curve was obtained by absorbance at 540 nm vs. 
Log10 of drug concentration (µM) and the Inhibitory concentration 50 (IC50) was 
calculated using the following equation: 
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2.2.12 Enzyme-linked immuno-sorbant assays 
2.2.12.1 PGE2 assay 
RAW 264.7 cells (5105cells/ well) were cultured in 12-well plates until 70% 
confluent and were maintained in serum-free medium for 12 h before ITC 
introduction and induction with LPS (500 ng/ml). 20 h following induction with 
LPS, the spent cell culture media were centrifuged and fresh supernatants were 
immediately analyzed for PGE2 concentrations using the PGE2 EIA kit according to 
the manufacturer’s instructions. A dose response curve was obtained by absorbance 
at 412 nm vs. Log10 of ITC concentration (µM) and the Inhibitory concentration 50 
(IC50) was calculated using equation stated under “Nitrite assay”.  
2.2.12.2 Cytokine assay 
Human CD14
+
 monocytes (2106 cells/well) in complete medium were seeded in 
12-well plates and subjected to pre-treatment with ITCs for 1 h and induction with 
LPS (100 ng/ml). Freshly collected supernatants of drug-treated and LPS-induced 
cells were cleared by centrifugation and analyzed for IL-1β, IL-6 and TNF-α 
concentrations using DuoSet ELISA Development kit (R&D systems (Minneapolis, 





2.2.13 RNA isolation and Reverse transcription polymerase chain reaction 
(RT-PCR) 
RAW 264.7 cells (5105 cells/well) were cultured in 6-well plates until 80% 
confluent and were maintained in serum-free medium for 12 h before treatment. 
Cells pre-treated with ITCs or DMSO for 1 hr was induced with LPS. For analysis 
of iNOS, COX-2 and IL-6 mRNA, the cells were harvested at 5 h after treatment 
with LPS. For analysis of TNF- mRNA, the cells were harvested at 1.5 h after 
treatment with LPS. Total RNA from harvested cells was isolated using RNeasy 
Mini Kit according to manufacturer’s instructions. Single strand cDNA was 
synthesized from 4 µg of RNA using RevertAid™ First strand cDNA synthesis Kit. 
Fragments specific to examined genes were amplified in reaction solution (20 µL) 
containing 2 µL generated cDNA, 2µL deoxyribonucleotide triphosphate (2 mM), 
0.2 µL Taq DNA Polymerase and 1µL of each specific sense and anti-sense 
primers (5 mM). PCR was run for 30 cycles of 94˚C for 15 s (denaturation), 58˚C 
for 15 s (annealing) 72˚C for 30 s (extension). The primer sequences used are listed 
in Table 2.6. The PCR products were electrophoresed in 1.2% agarose gels 
containing ethidium bromide and images were captured under UV light using 
ChemiDoc imaging system (Bio-Rad). 
 
Gene Primer sequence 
Forward primer Reverse primer 
GAPDH 5’-GGT GCT GAG TAT GTC GTG 
GA -3’ 
5’-GAC ACA TTG GGG GTA GGA 
AC -3’ 
i-NOS 5’-GTG TTC CAC CAG GAG ATG 
TTG-3’ 
5’-CTC CTG CCC ACT GAG TTC 
GTC-3’ 
COX-2 5’-GGA GAG ACT ATC AAG ATA 
GTG ATC-3’ 
5’- ATG GTC AGT AGA CTT TTA 
CAG CTC -3’ 
IL-6 5’- GTA CTC CAG GGA ACC AGA 
GG -3’ 
5’-TGC TGG TGA CAA CCA CGG 
CC -3’ 
TNF-α 5’-TTG ACC TCA GCG CTG AGT 
TG  -3’ 
5’- CCT GTA GCC CAC GTC GTA 
GC -3’ 
IL-1β 5’- CAG GAT GAG GAC ATG AGC 
ACC -3’ 
5’-CTCTGC AGA CTC AAA CTC 
CAC -3’ 
Table 2.3 Primer sequences of genes 





2.2.14 Gelatin zymography 
RAW 264.7 cells (5105cells/ well) were cultured in 6-well plates until 70% 
confluent and were maintained in serum-free medium for 12 h before ITC 
treatment and induction with LPS. Human CD14
+
 monocytes were suspended in 
medium containing 1 % FBS, plated in 12-well plates at a density of 2×10
6
 cells/ 
well, treated with ITCs and induced with LPS. 20 h following induction with LPS, 
the spent cell culture media were centrifuged and supernatants were stored at -80˚C 
until analysis. For analysis, equal volumes of media of each sample were resolved 
by SDS-PAGE in gels (10-12%) containing gelatin (1 mg/ml). 1 ml of freshly 
prepared 10 mg/ml gelatin stock solution was incorporated into 10 ml of resolving 
gel solution to obtain gelatin gel. 10 mg/ml gelatin (in water) stock solution was 
prepared by heating at 60˚C for 10 min to completely solubilise gelatin and cooled 
to room temperature before addition to resolving gel solution.  Resolved gelatin 
gels were washed twice by gentle agitation for 30 min each in Zymography 
renaturing buffer (2.5 % Triton-X-100 solution (v/v) in water) to remove SDS. The 
gels were then washed and equilibrated with Zymography developing buffer (50 
mM Tris-HCl, 10mM CaCl2, 0.15M NaCl pH 7.5) for 30 min each. The 
equilibrated gel was then incubated overnight in fresh developing buffer for 16-48 
h, washed with distilled water and subjected to analysis by Coomasie staining for 
zone of clearance bands corresponding to MMP-9.  
2.2.15 Immunocytochemistry  
RAW 264.7 cells (5105cells/ well)  were cultured on sterile coverslips pre-
coated with 0.01% w/v poly-L-lysine for 10 min, air dried thoroughly and placed in 
individual wells of six-well plates. After overnight incubation, cells were treated 
with ITCs for 1 hr and induced with LPS for 0.5 h. Following treatment, the cells 
were washed with cold PBS, fixed with 4% paraformaldehyde in PBS for 10 min 
by gentle shaking, washed again with PBS for 5 min and stored at 4˚C for up to a 
week. For immunolabelling, fixed cells were permeabilized using 0.2% Triton X-
100 in PBS by gentle shaking for 10 min and washed with PBS-T (PBS with 0.05% 
Tween 20) 3X for 5 min each. Permeabilized cells were then blocked with 5% 
horse serum in PBS for 1 h to minimise non specific binding, incubated for 1 h 
with primary antibody for protein of interest (rabbit anti-p65 - 1:1000, mouse 





with Alexa Fluor 488-conjugated anti-rabbit IgG (1:1000) and washed finally with 
PBS-T 3X for 5 min each. The immunolabelled coverslips were mounted on glass 
sides using a drop of VECTASHIELD mounting medium with DAPI, observed 
under Nikon Eclipse Ti fluorescence microscope and images were captured at 60X 
or 100X.  
2.2.16 Phagocytosis assay 
 Human monocytes were suspended in serum free medium and added to 96-
well plate at a density of 7.5105cells in 200 μl/ well. The cells were treated with 
ITCs for 3 h. Alongside, fluorosphere polystyrene (Jeffrey et al.) beads in the stock 
solution were pelleted by centrifugation at 13,000 rpm for 10 min, washed with 
PBS-E + 0.1% bovine serum albumin(BSA) 2X for 7 min each and re-suspended in 
PBS-E + 0.1% BSA (4105beads/ μl). After ITC treatment, 20 μl of re-suspended 
fluorosphere PS beads were added to the wells (cells to beads ratio - 1:10) and the 
plate was incubated at 37˚C with gentle shaking for 20 min for phagocytosis to 
occur. Phagocytosis was terminated by placing plate on ice. Cells were collected in 
cold microtubes tubes, pelleted at 300g for 5 min, washed with PBS-E 2X for 5 
min and resuspended in buffer consisting of PBS-E and 2% BSA. Re-suspended 
cells were analyzed immediately using Beckman Coulter FC 500 MPL System and 
data was analyzed using the MXP Software. 
2.2.17 Chemotaxis assay 
 The migration assay was performed in transwell chambers with 
polycarbonate membrane insert (5.0 µm pore size). Human monocytes, suspended 
in serum free medium and pre-treated with ITCs for 3 h, were seeded on the upper 
layer of membrane (1106cells in 200 μl/ well) and 400 μl of serum free medium 
containing SDF-1α (200 ng/ml) was added to the lower chamber below the 
membrane. The transwell plate was incubated at 37˚C in CO2 incubator. After 1 h, 
the transwell inserts were removed from the plate, medium was aspirated and the 
cells on the upper side of the membrane were removed gently using a cotton swab. 
The transwell inserts were placed in crystal violet solution for 10 min to stain the 
cells on the lower side of the membrane and washed with water 4X. The 





The number of cells in five random fields was counted and mean was estimated as 
a representative measure.  
2.2.18 Transfection  
 For each well to be transfected, GeneJuice® and plasmid (2.7 μl : 1 μg)  
was mixed thoroughly in 100 μl serum-free medium by thorough pipetting and 
incubated at room temperature for 20 min for formation of liposome-DNA 
complexes. The mixture was added drop-wise and distributed across the entire 
surface of the well. The plate was then gently rocked to ensure even distribution. 
The plate with plasmid-transfected cells was incubated at 37˚C for 24-36 h to 
achieve 80-90% confluency of cells before ITC treatment for experiments.   
2.2.19 Immunoprecipitation  
  Lysates (in Triton-X-100 lysis buffer) were pre-cleared by 
centrifugation at 13000 rpm for 10 min at 4˚C to separate insoluble components 
and debris. The protein content was estimated by Bradford assay. For each sample, 
a volume of lysate containing 0.8-1 mg of protein was mixed with 25 μl of protein 
G-couple sepharose beads and 1.5 μl of antibody. The final volume of the mixture 
was adjusted to 1 ml using lysis buffer. The mixtures were incubated at 4˚C for 2-3 
h with gentle rocking. The beads were then washed 1X with ice-cold wash buffer 1 
(0.5 mM NaCl, 20 mM Tris-HCl, 1 mM EGTA, pH 7.4), 3X with ice-cold wash 
buffer 2 (0.4 mM NaCl, 20 mM Tris-HCl, 1 mM EGTA, pH 7.4) and finally 1X 
with ice-cold wash buffer 3 (50 mM Tris-HCl). During each wash, the protein-
bound beads were collected by centrifugation at 2000 rpm for 1 min. 50 μl of 2X 
Laemmili buffer containing 10% β-mercaptoethanol was added to the washed 
beads which were then boiled at 95˚C for 5-10 min to elute the protein bound to the 
beads. The boiled beads were centrifuged at 13000 rpm for 1 min to separate the 
beads from the eluate. The supernatant containing the immunoprecipitated and 
eluted proteins as well as their corresponding lysates (containing 30 μg of protein) 
were subjected to SDS-PAGE and immunoblotting. 
2.2.20 Luciferase gene reporter assay 
 HEK-293 cells were cultured in 24- well plates until they were 50% 
confluent. Cells were transfected with 0.1 μg of pGL3-ARE- dependent firefly 





transfection, cells were treated ITCs for 12 h. Firefly and renilla luciferase enzyme 
activities were determined using the Dual-Luciferase reporter assay kit (Promega) 
according to manufacturer’s protocol. Cell lysates were collected using lysis buffer 
(90 μl/ sample) in the kit. Firefly luciferase activity was estimated from  
luminescence measured from 20 μl lysates upon addition of 100 μl Luciferase 
assay reagent and Renilla luciferase activity was estimated from luminescence 
measured upon subsequent addition of 100 μl Stop and Glo reagent ( to quench 
firefly luciferase activity and initiate renilla luciferase reaction). Luminescence 
readings due to firely luciferase reaction were normalized to those from renilla 
luciferase reaction to correct for inherent variability due to difference in cell 














2.2.21 Treatment with test compounds and collection of cell lysate for analysis of proteins  
 
Protein of interest Cell line and cell culture  Drug treatment Lysate collection * 
Phospho-histone H3 HCT 116 cells (1106 cells/well) 
were seeded in 6-well plate and let 
to adhere to plate surface for 24 h. 
 
Cells were treated with ITCs for 
8 h. 
Floating cells in medium and adhered 
cells, which were dislodged by 
trypsinisation, were pooled, pelleted, 
washed with ice-cold PBS and added 
with of 180-200 μl of Triton-X-100 
lysis buffer to obtain lysates. 
 
Total tubulin HCT 116 cells (1106 cells/well) 
were seeded in 6-well plate and let 
to adhere to plate surface for 24 h. 
 
Cells were treated with ITCs for 
8 h. 
Floating cells in medium and adhered 
cells, which were dislodged by 
trypsinisation, were pooled, pelleted, 
washed with ice-cold PBS and added 
with of 150-175 μl of SDS lysis 
buffer. The whole cell lysates in SDS 
lysis buffer were sonicated 2X in 
pulses of 5 sec using probe sonicator. 
 











Protein of interest Cell line and cell culture  Drug treatment Lysate collection * 
Soluble and insoluble 
tubulin  
HCT 116 cells (1106 cells/well) 
were seeded in 6-well plate and let 
to adhere to plate surface for 24 h. 
 
Cells were treated with ITCs for 
8 h. 
Floating cells in medium and adhered 
cells, which were dislodged by 
trypsinisation, were pooled, pelleted, 
washed with ice-cold PBS and added 
with of 180-200 μl of Triton-X-100 
lysis buffer to obtain lysates. The 
lysates were centrifuged at 13000 
rpm, 4˚C for 10 min to obtain 
supernatants containing the soluble 
proteins and pellets containing the 
insoluble proteins and debris. The 
supernatants were separated as 
soluble fractions and for the 
insoluble fractions, the pellets were 
dispersed in SDS lysis buffer and 
sonicated 2X in pulses of 5 sec using 
probe sonicator. 
 
PARP and Caspase-3 HCT 116 cells (1106 cells/well) 
were seeded in 6-well plate and let 
to adhere to plate surface for 24 h. 
 
Cells were treated with ITCs for 
14 h. 
Floating cells in medium and adhered 
cells, which were dislodged by 
trypsinisation, were pooled, pelleted, 
washed with ice-cold PBS and added 
with of 180-200 μl of Triton-X-100 












Protein of interest Cell line and cell culture  Drug treatment Lysate collection * 
TrxR and Trx HCT 116 cells (1106 cells/well) 
were seeded in 6-well plate and let 
to adhere to plate surface for 24 h. 
 
Cells were treated with ITCs for 
14 h. 
Floating cells in medium and adhered 
cells, which were dislodged by 
trypsinisation, were pooled, pelleted, 
washed with ice-cold PBS and added 
with of 180-200 μl of Triton-X-100 




iNOS, COX-2 and 
MMP-9 
RAW 264.7 cells (1106 cells/well) 
were cultured in 6-well plate until 
they were 80 % confluent. 
 
Cells were serum starved for 12 
h prior to treatment with ITCs 
for 1 h and induction with LPS 
(500 ng/ml)  
for 20 h. 
Medium was aspirated, monolayer 
was washed with ice-cold PBS, 180-
200 μl of Triton-X-100 lysis buffer 
was added and mono layer was 




MMP-9 and TNF-α Human monocytes (2106 
cells/well) were seeded in 12-well 
plate. 
Cells were treated with ITCs for 
1 h and induced with LPS (100 
ng/ml) for 20 h. 
Floating cells in medium and adhered 
cells were pooled and pelleted. The 
pellet was washed in ice-cold PBS 
and followed by addition of 80μl of 














Protein of interest Cell line and cell culture  Drug treatment Lysate collection* 
(a) proteins of NF-κB 
and   MAPK pathway  
(b) proteins of PI3K 
pathway  
RAW 264.7 cells (1106 cells/well) 
were cultured in 6-well plate until 
they were 95-100 % confluent. 
 
Cells were serum starved for 12 
h prior to treatment with ITCs 
for 1 h and induction with LPS 
(500ng/ml) for 30 min (a) or 15 
min (b). 
Medium was aspirated, monolayer 
was washed with ice-cold PBS, 180-
200 μl of Triton-X-100 lysis buffer 
was added and mono layer was 
scraped using cell scraper to collect 
lysates. 
 
Human monocytes (2106 
cells/well) were seeded in 12-well 
plate. 
Cells were treated with ITCs for 
1 h and induced with LPS (100 
ng/ml) for 20 h. 
Floating cells in medium and adhered 
cells were pooled and pelleted. The 
pellet was washed in ice-cold PBS 
and followed by addition of 80μl of 
Triton-X-100 lysis buffer to obtain 
lysates. 
 







cells/well) were cultured in gelatin-
coated 6-well plates until 90% 
confluent. 
 
Cell culture medium was 
replaced 6 to 8 h before 
treatment with ITCs for (a) 16 h 
and (b)3 h. 
Medium was aspirated, monolayer 
was washed with ice-cold PBS, 150-
180 μl of Triton-X-100 lysis buffer 
was added and mono layer was 
scraped using cell scraper to collect 
lysates.  
phospho-H2AX 
(Analysis of protection 
against doxorubicin-
induced DNA damage) 
HEK-293 cells (1106 cells/well) 
were seeded in 6-well plate and 
grown until 85-90% confluent. 
Cells were treated with ITCs for 
12 h and challenged with 
Doxorubicin (2 μg/ml) for 12 h. 
Medium was aspirated, monolayer 
was washed with ice-cold PBS, 150-
180 μl of Triton-X-100 lysis buffer 
was added and mono layer was 
















HEK-293 cells (1106 cells/well) 
were seeded in 6-well plate grown 
until 50% confluent and 
transfected with 0.5 μg of 
pcDNA3.1 FLAG-IKK-β 
plasmid.  
Cell culture medium was 
replaced 6 to 8 h before 
treatment of cells with SF for  
16 h. 
Medium was aspirated, monolayer was 
washed with ice-cold PBS, 150-180 μl 
of Triton-X-100 lysis buffer was added 
and lysates were collected. 
IKK-β  
(analysis of 
degradation by (a) 
proteasome pathway 
and (b) lysosomal 
pathway) 
HEK-293 cells (1106 cells/well) 
were seeded in 6-well plate grown 
until 50% confluent and 
transfected with 0.5 μg of 
pcDNA3.1 FLAG-IKK-β 
plasmid.  
Cell culture medium was 
replaced 6 to 8 h before 
treatment with (a) MG132 (20 
μM) and SF or (b) Chloroquine 
sulphate (25 μM) and SF for  
16 h.  
Medium was aspirated, monolayer was 
washed with ice-cold PBS, 150-180 μl 
of Triton-X-100 lysis buffer was added 
and lysates were collected. 
 
phospho-IKK-α/β 
(investigation of role 








(1106 cells/well) were cultured 
in gelatin-coated 6-well plates 
until 95-100% confluent. 
 
Cells were treated with ITCs for 
1 h and induced with TNF-α 
(50ng/ml) for 30 min. 
Medium was aspirated, monolayer was 
washed with ice-cold PBS, 150-180 μl 
of Triton-X-100 lysis buffer was added 
and mono layer was scraped using cell 
scraper to collect lysates.  
Table 2.4 Drug treatments of cells and lysates collection methods for analysis of proteins 
* All lysates were collected in microtubes and stored at -20˚C until further analysis by sodium dodecyl sulfate-









2.2.22 Analysis of proteins in cell lysates 
 Frozen cell lysates were thawed at 4˚C and pre-cleared by centrifugation at 
13,000 rpm for 10 min at 4˚C to remove insoluble components and cell debris. 
Protein content of cell lysates in Triton-X-100 lysis buffer was determined by 
Bradford protein assay while that of lysates in SDS lysis buffer was estimated by 
Bicinchoninic acid protein assay.  
2.2.22.1 Bradford assay 
 Protein sample (standard or 1 to 2 μl of cell lysates) was dispersed in 1 ml 
of 1X Bradford reagent (diluted from 5X Bradford reagent) in a cuvette by 
vortexing and absorbance was measured at 595 nm using spectrophotometer. Mean 
of duplicate readings for each sample was estimated. Standard plot was obtained 
using BSA for a range of protein concentrations (0.5-4 μg/ml). Concentration of 
proteins in each sample was calculated based on the standard curve. 
2.2.22.2 Bicinchoninic acid protein assay 
 Working reagent for the assay was obtained by mixing 50 parts of Reagent 
A with 1 part of Reagent B. Protein sample (standard or 10 μl of cell lysates) was 
dispersed in 200 μl of working reagent in a well in 96-well plate. BSA solutions of 
concentrations in the range of 25 μg/ml to 2 mg/ml were used as standards. The 
plate was incubated at 37˚C for 30 min with continuous shaking for thorough 
mixing. Absorbance was then measured at 562 nm and protein concentrations were 
estimated based on the standard curve. 
2.2.22.3 SDS-PAGE 
 Resolving gels containing 10, 12 or 15 % w/v acrylamide and stacking gels 
containing 4% acrylamide were used to resolve the proteins in lysates samples 
using SDS-PAGE. The components of the resolving and stacking gel solutions are 










Resolving gel solution (8 ml) 
Stacking gel 
solution (5 ml) 
10% 12% 15% 4% 
40% acrylamide:bisacrylamide 
(37:1:1) (ml) 
2.5 3 3.75 0.5 
Resolving gel buffer (1.5 M 
Tris, 0.4% SDS, pH 8.8) (ml) 
2.5 2.5 2.5 - 
Stacking gel buffer (0.5 M Tris, 
0.4% w/v SDS, pH 6.8) (ml) 
- - - 1.25 
Distilled water (ml) 5 4.5 3.75 3.25 
10% APS (μl) 50 50 50 30 
TEMED (μl) 7.5 7.5 7.5 4 
Table 2.5 Components of resolving and stacking gel solutions 
 The resolving gel solution was freshly prepared and poured into a casting 
cassette with a layer of distilled water overlaid on surface of gel solution. The 
solution was left to polymerize for about 20-30 min. The layer of distilled water 
was discarded once the gel was made. Stacking gel solution was then freshly 
prepared and poured over the resolving gel in the casting cassette. A 10- or 15- 
well comb was inserted in the stacking gel solution to create wells in the gel and 
stacking gel solution was left to polymerize for 20-30 min. Upon complete 
formation of gel, comb was removed and the casting cassette with the gel was 
positioned in an electrophoresis tank containing gel running buffer (25 mM Tris-
HCl, 192 mM glycine and 0.1% SDS).    
 Cell lysates samples containing equal amounts of proteins (30-50 μg) were 
mixed with 2X Laemmli sample buffer (62.5 mM Tris-HCl, 25% glycerol, 2% SDS 
and 0.02% bromophenol blue, pH 6.8) containing β-mercaptoethanol (final 
concentration 5% v/v, added fresh to sample buffer for each use) and boiled at 
95˚C for 10 min. The boiled samples were let to cool to room temperature, quick 
spun for 5 sec and loaded into the wells of the casted gel. 5 μl of protein ladder was 
added to one well of the gel and gel was subjected to electrophoresis at a constant 
voltage of 100-120 V in running buffer until sufficient separation of proteins, as 
indicated by the separation of bands in the ladder.  The gel was gently removed 




from the casting cassette after electrophoresis for further analysis by Coomasie 
staining or immunoblotting.   
2.2.22.4 Coomasie staining 
 The gel with resolved proteins was stained with Coomasie stain solution 
(0.5% Coomasie Blue in 50% methanol and 10% acetic acid) for 1 h and destained 
(50% methanol, 10% acetic acid, 40% water) for 4 h-overnight (until the 
background is clear). 
2.2.22.5 Immunoblotting 
 Following the SDS-PAGE, a nitrocellulose membrane was overlaid onto 
the gel with the resolved proteins a nitrocellulose membrane and interceded 
between a top and bottom layer of filter paper and sponge. The stack was secured 
in a transfer cassette and subjected to electrophoresis overnight at a constant 
voltage of 25 V in ice-cold transfer buffer (25 mm Tris-HCl, 192 mM glycine and 
20% v/v methanol) for transfer of proteins onto the membrane. The electroblotted 
membrane was then incubated in 10% w/v non –fat dry milk in TBS-T (137 mM 
NaCl, 3 mM KCl, 25 mM Tris-HCl, pH 7.4 containing 0.05% v/v Tween 20) for 1 
h at room temperature to block non-specific protein binding. The blocked 
membrane was washed with TBS-T for 3X 5 min and incubated with primary 
antibody (at dilutions of 1: 2000 to 1: 7500 in TBS-T) for 2-3 h at room 
temperature or overnight at 4˚C with gentle shaking. Following incubation in 
primary antibody, membrane was washed again in TBS-T for 3X 5 min and 
incubated in HRP-conjugated secondary antibody (1: 10000 dilution in TBS-T 
containing 5% non-fat dry milk) for 1-2 h at room temperature. The membrane was 
once again washed with TBS-T for 3X 5 min to remove excess unbound secondary 
antibody and subjected to chemiluminescent detection of probes bound to protein 
of interest.  
 For chemiluminescent detection, equal volumes (300-400 μl) of reagent 1 
and 2 of the enhanced chemiluminescence system (ECL) were mixed and applied 
evenly to the membrane to generate chemiluminescent signals. The membrane was 
drained of excess mixture and placed between transparent sheets. In dark room, X-
ray films were exposed to the chemiluminescent signals on the membrane and 




2.2.23 Assay of BIAM labeling of IKK-β 
 HEK-293 cells were cultured in 6-well plate until 50 % confluent and 
transfected with 0.5 μg of pcDNA3.1 FLAG-IKK-β plasmid. 24 h after 
transfection, cells were treated with ITCs for 45 min and lysates were collected 
using Triton-X-100 lysis buffer. The protein content in clarified lysates was 
estimated using Bradford assay. 1 mg of protein in lysate was subjected 
immunoprecipitation for 4 h using FLAG-tagged agarose beads. After 
immunoprecitation, the beads were re-suspended in freshly prepared 30 μM BIAM 
solution in Tris-EDTA buffer (pH 6.5) in the dark for 15 min to biotinylate the 
immmunoprecipitated FLAG-IKK-β protein. The proteins were then eluted by 
boiling with 2X Laemmili sample buffer containing 5% β-mercaptoethanol. Eluted 
proteins were resolved using SDS-PAGE, transferred to membrane and membrane 
was probed using Streptavidin-HRP to detect biotinylated protein levels. Duplicate 
membrane was probed using FLAG antibody to ensure equal loading of protein.  
2.2.24 Assay of BIAM labeling of Keap1 
 HEK-293 cells were cultured in 6-well plate until 50 % confluent and 
transfected with 0.75 μg of pcDNA3.1 V5-Keap1 plasmid. 24 h after transfection, 
cells were treated with ITCs for 1.5 h and lysates were collected using Triton-X-
100 lysis buffer containing 100 μM BIAM (pH 6.5). The protein content in 
clarified lysates was estimated using Bradford assay. 1mg of protein in lysate was 
incubated with streptavidin tagged agarose beads for 4 h with gentle shaking to pull 
down all biotinylated proteins. The pulled-down-proteins were eluted by boiling 
with 2X Laemmili sample buffer containing 5% β-mercaptoethanol. Eluted 
proteins were resolved using SDS-PAGE, transferred to membrane which was 
probed using V5 antibody to detect Keap1 protein levels.  
2.2.25 Investigation of Keap1-IKK-β interaction 
 HEK-293 cells were cultured in 6-well plate until 50 % confluent and co-
transfected with 0.5 μg each of pcDNA3.1 ZeoV5-Keap1 and pcDNA3.1 FLAG-
IKK-β plasmid. 24 h after transfection, cells were treated with SF for 1.5 h and 
lysates were collected using Triton-X-100 lysis buffer (180-200 μl). Protein content 
of clarified lysates was estimated and 1 mg of protein in lysates was subjected to 
immunoprecipitation using FLAG antibody for 4 h. Immunoprecipitates were 




mercaptoethanol. Eluted proteins were resolved using SDS-PAGE, transferred to 
membrane and membrane was immunoblotted using V5 antibody to detect if 
Keap1 was pulled down along with IKK-β and FLAG antibody to ensure equal 
levels of IKK-β were pulled down. Lysates were also analyzed by SDS-PAGE and 
western blotting for expression levels of V5-Keap1 and FLAG-IKK-β. 
2.2.26 Statistical analysis 
 Numerical data points of quantitative assays were presented as mean of 
sample ± standard deviation of sample or experiment. One-way analysis of 
variance was performed. Samples treated with test compounds were compared 
against control using Dunnett’s test or Student’s t-test and p values less than 0.05 











Chapter 3  
Evaluation of anti-tumor properties of ITCs – disruption of cell 
cycle and induction of apoptosis 
 
3.1 Introduction 
 The natural ITCs AITC, SF, PEITC and BITC have been reported to 
possess anti-proliferative and cytotoxic properties in several cancer cell lines. The 
ITCs have been proposed to exhibit chemotherapeutic potential through their 
ability to induce cell cycle arrest, sensitize tumor cells to apoptosis and few other 
mechanisms yet to be understood in detail. ITCs are highly reactive with sulfhydryl 
groups and have been shown to bind to accessible cysteine residues of proteins and 
modulate their function. It has been reported that ITCs induce cell cycle arrest in 
different phases such as G2/M and G0/G1 phases in a cell-dependent manner, the 
exact molecular mechanisms underlying these differences are still mostly unknown 
(Nakamura, 2009).Interestingly, they have been found to bind directly to tubulin 
prior to causing a G2/M arrest (Mi & Chung, 2008b). ITCs induce apoptosis 
through multiple pathways in cancer cells. For instance, it has been demonstrated 
for BITC that apoptosis induction may be linked to cell cycle arrest at the G2/M 
phase (Miyoshi et al., 2004). Caspase-3, the executioner protease at the end of 
caspase-dependent apoptotic pathways, has been reported to be activated by several 
ITCs simultaneously or differentially through a caspase-9-dependent mitochondrial 
death pathway, caspase-8-dependent death receptor pathway and/or caspase-12-
dependent endoplasmic reticulum pathway (Nakamura et al., 2002). Generally, it 
has been suggested that the cell death pathway(s) involved is cell line-dependent 
(Nakamura, 2009).  
 In this chapter, as part of the initial attempts to search for ITCs that posses 
structural features that would give rise to more desirable anti-tumor activities, 
analogs of BITC, PEITC and SF that were synthesized previously in the laboratory 
were investigated for their anti-proliferative efficiencies. In addition, their effects 





3.2.1 Structure based properties and stability of ITC analogs  
  A number of physicochemical properties of aromatic and aliphatic 
ITC analogs were first studied using the online tool available at 
http://www.chemicalize.org and listed in Table 3.1. Based on the lower log P 
values the aliphatic ITC (SF, B7 and B8) were less lipohilic than the aromatic 
ITCs. Of note, replacement of the sulfinyl group in SF to a carbonyl group in B7 
and B8 increased the lipophilicity by a significant extent. For the aromatic ITCs, 
methoxy substitutions on the aromatic rings of BITC and PEITC generally 
decreased the lipophilicity while fluorine substitutions increased the lipophilicity. 
Polar surface area is a commonly used predictor for drug permeability. Of note, the 
polar surface area was almost doubled in aromatic ITC analogs (B9 and B10) with 
one methoxy substitution in the aromatic ring and almost tripled in aromatic ITC 
analog with two methoxy substitutions (B2) in the aromatic ring, suggesting that 
the passive transport of methoxylated aromatic ITCs B2, B9 and B10 into 

















*Calculations made for each parameter were based on online tool available at http://www.chemicalize.org 





Compound laboratory name, 
IUPAC name 
Chemical structure Molecular 
mass 






















167.203 2.94 17.53 214.84 12.36 















*Calculations made for each parameter were based on online tool available at http://www.chemicalize.org 
Compound laboratory name, 
IUPAC name 
Chemical structure Molecular 
mass 












PEITC, (2-isothiocyanatoethyl) benzene 
 





























*Calculations made for each parameter were based on online tool available at http://www.chemicalize.org 
 
Compound laboratory name, 
IUPAC name 

















177.288 0.22 19.27 267.30 29.43 
B7, 6-isothiocyanatohexan-2-one 
 
157.233 1.85 17.57 251.03 29.43 
B8, 5-isothiocyanatopentan-2-one 
 











 The stabilities of methoxylated aromatic ITCs and aliphatic ITCs over a 
duration of 72 h at 37˚C in phosphate buffer saline (pH 7.4, PBS) were next 
compared to those of their respective naturally-occurring parent analogs. Fig 3.1A-
C depicts the stability profiles of the ITC analogs obtained from stability analysis 
using HPLC (see Section 2.2.2). Considering the stability profiles of these ITCs for 
the first 48 h of incubation in PBS, their degradation appeared to follow a biphasic 
pattern with an inflection at 24 h. A semi-log plot of time versus concentration of 
drug exhibited linearity (See Appendix II). This suggested that the degradation of 
ITC analogs followed first order kinetics. The degradation rate constants and half 
lives for each ITC analog for the two degradation phases (0-24 h and 24-48 h) were 























Time of incubation in PBS (h) 
BITC 1 mM 
B10 1 mM 





















Time of incubation in PBS (h) 
PEITC 1 mM 
B9 1 mM 
B2 1 mM 


































































Figure 3.1 Stability profiles of ITC analogs in PBS (pH 7.4).  1 mM of indicated ITCs 
diluted in PBS were incubated at 37˚C and aliquots drawn at time points 0, 3, 6, 12, 36 
and 72 h were immediately analyzed by HPLC. Wavelength at 240 nm, which was 
within the detectable absorbance range of all ITCs, was chosen for evaluation. (A, B and 
C) Each data point represents relative percentage of peak area at time t h to peak area at 
time 0 h, giving rise to relative [peak area]t h % = ([peak area]t h/ [peak area]t h )×100. 
Each data point represents mean ± S.D of three independent experiments. (D) The data 
points represent relative [peak area] % taken at 24 and 48 h of ITC incubation in PBS. 
Each data point represents mean ± S.D of three independent experiments.  *, †, ‡, §, ¶ 
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Table 3.2Kinetics of degradation profiles of ITC analogs in PBS (pH 7.4) 
 
a 
First order rate constants were obtained from the slope (-k) of the graph obtained by plotting ln 
(relative percentage of peak area) versus time. The negativity of slope indicated loss of ITC.   
b 




 (linear regression coefficient) depicted the extent of linearity of the plot and closeness to 1 
suggested that the degradation of ITCs was first order. 
* Unable to determine rate constant and half-life as the gradient of the ln (relative percentage of 
peak area) versus time was too gentle 
 




 In the case of aromatic ITCs, there seem to be a rapid degradation phase for 
first 24 h followed by a gentle degradation phase beyond 24 h. While BITC had 
completely degraded during the first phase within 24 h, around 35 % of its methoxy 
analog B10 was undegraded at the end of 24 h. Similarly, while about 35 % of 
PEITC remained undegraded at 24 h, 52 % of its monomethoxy-substituted analog 
B9 and almost 99% of its dimethoxy-substituted analog B2 were detectable at 24 h. 
At the end of 48 h, while only 10 % of PEITC was detected to be stable, almost 
four-fold higher amounts (41 %) of B9 and around 99% of B2 were found to be 
undegraded. Of particular note, B2 (stable for first 24 h, second phase degradation 
half life >>7 days) was the most stable analog among the tested ITCs. The relative 
percent of B10 at 24h, 48 h, as well as its half lives for both first and second phase 
of degradation were greater than those of BITC. Similarly, these stability properties 
of B9 and B2 were also greater than those of PEITC (Figure 3.2D and Table 3.2). 
Based on these results, it could be concluded that methoxy substitutions on the 
benzene ring of aromatic ITCs had improved their stabilities. In addition, PEITC 
and B9 were found to be more stable than BITC and B10 respectively, which 
appeared to suggest that a longer methylene bridge between the benzene ring and 
ITC functional group enhanced stability.  
 The degraded product of the aromatic ITCs, however, could not be 
detected. There was no appearance of an extra peak in the HPLC profiles recorded 
at wavelengths 210, 240 and 270 nm for any of the aromatic ITCs that degraded in 
PBS. A possible reason was that the absorbance range of the degraded product was 
different from that of the ITCs. Subsequently, in order to detect the λmax of the 
degraded product, 1 mM of BITC was incubated in PBS for beyond 24 h to allow 
complete degradation and then subjected to an absorbance scan across wavelength 
range from 200 to 700 nm. However, the absorbance scan did not reveal a distinct 
peak. Therefore, it could also be possible that the concentrations of the degraded 
product(s) formed were not sufficient enough to reveal a detectable absorbance 
signal within the sensitivity range of the instruments employed. Experiments using 
higher ITC concentrations, which might overcome the sensitivity limit of the 
HPLC instrumentation, were not pursued due to the limited availability of 
synthesized ITCs. As such, further investigations using mass spectrometry could be 




  On the whole, aliphatic ITCs were more stable than aromatic ITCs. The 
aliphatic ITCs B7, B8 and SF exhibited a stable phase for the first 24 h of 
incubation, followed by a second phase of slow degradation beyond 24 h. The 
replacement of the sulfinyl moiety to carbonyl group as well as a change in 
aliphatic chain length appeared to have subtle effects on stability of ITCs beyond 
24 h. The second phase of degradation for aliphatic ITCs was found to be gradual 
as the estimated half lives of B7, B8 and SF were 3.9, 3.7 and > 7 days 
respectively. On the whole, aliphatic ITCs were more stable than the aromatic 
ITCs.  Biological investigations of all the ITCs analogs were pursued further. 
3.2.2 Anti-proliferative activities of ITC analogs against HCT 116 and A549 
cancer cells 
 The in vitro anti-proliferative activity of ITC analogs against human-
derived colorectal carcinoma HCT 116 and lung carcinoma A549 cells were 
evaluated by MTT assays (see Section 2.2.4). The MTT assays involved treatment 
of cancer cells with ITC analogs for 72 h. The calculated mean GI50 values 
(indicator of growth inhibitory activity) and LC50 values (indicator of cytotoxicity) 
are listed in Table 6.3. Among the naturally-derived ITCs, BITC with a single 
methylene bridge between the benzene ring and ITC functional group displayed 
marginally higher anti-proliferative activity and cancer-cell cytotoxicity than 
PEITC that has two methylene bridges. However, both BITC and PEITC possessed 
stronger anti-proliferative properties as compared to aliphatic ITC SF.  
 Among the aromatic ITC analogs, the anti-tumor activities of B14 and B15 
that possess a fluorine substituent at the meta- position on the aromatic ring were 
similar to their corresponding parent compounds BITC and PEITC. On the other 
hand, B10 and B9 that possess a methoxy substituent at the ortho position on the 
aromatic ring were marginally more anti-proliferative than BITC and PEITC 
respectively. Noticeably, the anti-tumor activities of B2 with methoxy groups 
substituted at both the meta and para positions on the aromatic ring was much 
higher than its parent analog PEITC and other PEITC analogs B14 and B9.  In 
addition, similar to higher potency of BITC than PEITC, the potencies of 
monomethoxylated and fluorinated BITC analogs B10 and B15 were higher than 




 Among the aliphatic ITC analogs, both B7 and B8 had exhibited stronger 
anti-proliferative activities than SF. Nonetheless, for both cell lines the aliphatic 
ITCs displayed relatively higher LC50 values than their counterparts. N-
methylphenethylamine (NMPEA), which is devoid of the ITC functional group, 
was used as negative control. It did not exhibit growth inhibition or toxicity in both 
cancer cell lines for concentrations up to of 100 μM, suggesting that the anti-
proliferative properties of the investigated ITC analogs could be attributed to the 
ITC functional group. 
 




Mean LC50 * 
(µM) 
 Mean GI50 * 
(µM) 
Mean LC50 * 
(µM) 
      Aromatic ITCs 
BITC 3.74 ± 2.2 26.81 ± 1.1  9.46 ± 1.2 55.82 ± 6.0 
B10 2.06 ± 0.5 21.03 ± 9.9  6.29 ± 0.9 35.97 ± 13.3 
B15 3.88 ± 1.7 25.98 ± 2.7  6.55 ± 1.0 35.19 ± 13.1 
PEITC 5.29 ± 0.8 27.07 ± 0.5  12.93 ± 3.0 49.9 ± 16 
B2 1.66 ±  0.2 9.29 ± 0.1  2.92 ± 0.1 25.12 ± 1.0 
B9 3.59 ± 1.9 26.51 ± 3.9  8.53 ± 0.2 36.19 ± 12.8 
B14 5.24 ± 3.4 26.51 ± 3.1  10.11 ± 1.2 28.66 ± 0.9 
    Aliphatic ITCs 
SF 17.42 ± 3.3 >100  24.86 ± 2.9 >100 
B7 4.43 ± 0.5 25.5 ± 1.4  6.68 ± 0.5 67.01 ± 9.2 
B8 5.86 ± 0.4 62.68 ± 32.3  10.75 ± 2.8 >100 
Table 3.3Anti-proliferative activities of ITC analogs against HCT 116 and A549 cells 
 
GI50 : The concentration of compound that causes 50% growth inhibition . 
LC50: The concentration of compound that causes 50% cell death. 
* Mean ± S.D of three independent experiments 




 Having observed that ITC analogs indeed possessed anti-tumor properties, 
mechanistic investigations were pursued further. In general, the GI50 and LC50 
values of the ITC analogs were relatively lower in HCT 116 cells than in A549 
cells, suggesting that HCT 116 cells were more susceptible to the anti-proliferative 
effects of the ITC analogs. The HCT 116 cell line was therefore used in subsequent 
experiments for investigation of their likely mechanism(s) of anti-tumor action. 
3.2.3 Induction of apoptosis by ITC analogs in HCT 116 cells 
 Having observed the cytotoxic effects of ITCs on HCT 116 cancer cells, we 
then investigated if the ITC analogs induced apoptosis in these cancer cells. Based 
on results obtained from the MTT assays, a dose of approximately 25 μM of 
aromatic ITCs was calculated to kill at least 50% of the cell population while 
higher concentrations of aliphatic ITCs were required for a similar effect. 
Microscopic observations revealed that cells treated with 20 and 30 μM of aromatic 
ITCs were found to be either rounded, stressed and loosely adhered to surface or 
shrunken and detached completely. These morphological changes were similar to 
those that usually appear during apoptosis. However, cells remained unaffected by 
treatment with aliphatic ITCs at these concentrations. To determine whether 
apoptosis occurred upon treatment with the ITCs, lysates of ITC-treated cells were 
analyzed by immunoblotting (see Sections 2.2.21 and 2.2.22) for apoptotic markers 
such as cleaved forms of poly (ADP-ribose) polymerase (PARP) and caspase-3.  
 PARP is a nuclear protein involved in DNA repair and programmed cell 
death. It is activated upon DNA so as to initiate DNA repair process. When DNA 
damage is extensive, apoptosis is triggered during which caspases are activated and 
PARP is inactivated. Activation of caspases involves their cleavage into subunits. 
Inactivate caspase-3 is activated through cleavage by upstream activated caspases 
into two subunits of 17 and 19 kDa, which form active heterotetramers required for 
execution of apoptosis (Salvesen, 2002). Cleaved caspase-3 inactivates PARP by 
cleaving it into fragments of 89 and 24 kDa, which separates the DNA binding 
domain from its kinase domain (Ivana Scovassi & Diederich, 2004). 
 As shown in Fig 3.2A, an appearance of cleaved PARP was observed upon 
treatment with 20 and 30 μM of aromatic ITCs. On the other hand, a conspicuous 




with 30 μM of aliphatic ITCs (Fig3.2B). A dose-dependent appearance of 
fragments of cleaved caspases-3 could not be detected for all aromatic ITCs (Fig 
3.2C). A possible reason could be that the ITC treatment had set in an intense 
apoptosis process much earlier than the time of lysates collection and the 
proteolysis occurring during apoptosis may have further broken down the cleaved 
domains into smaller fragments that were not detectable by the antibody. In support 
of this reason, a decrease in levels of caspase-3 was observed upon treatment with 


















Figure 3.2 Induction of levels of apoptotic markers by ITC analogs. HCT 116 cells were treated 
with indicated concentrations of (A and C) aromatic ITCs and (B) aliphatic ITCs for 14 h. Cell 
lysates were collected and levels of (A and B) PARP and cleaved PARP, as well as (C) 
caspase-3 and cleaved caspase-3 were analyzed by western blotting. β-actin levels were probed 
to verify protein loading. 
C 




3.2.4 Induction of cell cycle arrest at M phase by ITC analogs in HCT 116 cells 
 The effects of ITC analogs on cell cycle progression were investigated. 
HCT 116 cells treated with ITC analogs were investigated for their DNA content 
by flow cytometry (see Section 2.2.5). The DNA histograms representative of the 
percentage of cells in sub G1, G1, S and G2/M phase, as well as the relative fold 
increase in percentage of cells arrested in G2/M phase by each ITC analog to that of 
DMSO only-treated cells are presented in Fig 3.3A and B. It was observed that the 
aromatic ITCs (10 and 20 µM) produced a dose-dependent blockade of cells at the 
G2/M phase. In contrast, 10 μM of aliphatic ITCs SF, B7 and B8 had not caused an 
arrest of HCT 116 cells in G2/M phase. Accumulation of cells in G2/M phase only 
set in upon treatment at higher concentrations of 20 and 30 µM. 
 Given that cells in both G2 and M phase posses 4N DNA, the exact phase of 
cell cycle arrest by ITCs could not be revealed by the cytometric results. In order to 
investigate whether the ITCs inhibited mitotic entry by causing an arrest at the G2 
phase or inhibited mitotic exit by causing an arrest at the M phase, lysates of ITC-
treated cells were analyzed by immunoblotting for levels of phospho-histone H3. 
Histone H3 is specifically phosphorylated during mitosis, and its phosphorylated 
form is therefore a specific marker for mitosis (Hans & Dimitrov, 2001). Paclitaxel, 
a well-known mitotic inhibitor was used as positive control. As shown in Fig 3.4, 
the levels of phospho-histone H3 were significantly increased following treatment 
with 10 and 20 μM of aromatic ITCs and 5 μM of Paclitaxel. In addition, a 
marginal increase in levels of phospho-histone H3 was observed following 
treatment with 20 μM of aliphatic ITC analogs. Taken together, the results obtained 
indicated that the ITC analogs arrested cells in the M phase and prevented mitotic 

































































































































Figure 3.3 Effect of ITC analogs on cell cycle progression in HCT 116 cells. HCT 116 cells 
were treated with indicated concentrations of ITCs for 14 h. The DNA content in each cell 
sample was stained using propidium iodide and analyzed by flow cytometry. (A) 
Representative DNA histograms showing number of events plotted against DNA content per 
event. (B) For each sample, the relative fold increase in percentage of drug-treated cells in 
G2/M phase over the percentage of DMSO only-treated cells in G2/M phase was expressed. 








3.2.5 Induction of tubulin aggregation by aromatic ITC analogs in HCT 116 
cells 
 Following the observation that ITC analogs induced M phase arrest in HCT 
116 cells, the possible effects of ITC analogs on cellular tubulin were investigated. 
Immunocytochemical analysis (see Section 2.2.15) revealed that treatment with 
aromatic ITCs at 30µM caused disruption of the microtubule network and 
aggregation of tubulin (Fig 3.5A). However, treatment with similar concentration 
of aliphatic ITCs and NMPEA was not found to have any conspicuous effect on 
microtubule network. These findings were further supported by results from 
western blot analysis of soluble and insoluble fractions of lysates of HCT 116 cells 
treated with selected aromatic analogs (see Sections 2.2.21 and 2.2.22). Tubulin 
dimers are soluble and present in the soluble fraction of cell lysates, whereas 
microtubules and aggregated tubulin are not soluble and are present in the insoluble 
fraction of lysates. Cell treatment with aromatic ITC analogs had led to a dose-
dependent decline in the levels of soluble tubulin with an accompanying increase in 
levels of insoluble tubulin (Fig 3.5B). To investigate whether aromatic ITC analogs 
Figure 3.4 Induction of phospho-histone H3 by ITC analogs in HCT 116 cells. HCT 116 cells 
were treated with indicated concentrations of ITCs for 8 h. Whole cell lysates were collected and 
levels of phospho-histone H3 were analyzed by western blotting. β-actin levels were probed to 
verify protein loading.  
 




caused degradation of tubulin protein, the levels of total cellular tubulin (soluble 
and insoluble tubulin) in ITC treated-HCT 116 whole cell lysates were next 
analyzed (see Sections 2.2.21 and 2.2.22). As shown in Fig 3.5C, the analogs 
generally did not produce marked changes in total tubulin except for B9 at 30 µM. 
Taken together, the results had suggested that disruption of microtubules probably 
through aggregating tubulin that led to an accumulation of insoluble tubulin was an 
















Figure 3.5 Induction of tubulin aggregation by ITC analogs in HCT 116 cells 
 
 
Figure 3.5 Induction of tubulin aggregation by ITC analogs in HCT 116 cells. HCT 116 cells 
were treated with indicated concentrations of ITCs for 8 h. (A) Cells on coverslips were 
fixed and analyzed by immunocytochemistry. (B) Cell lysates were collected, segregated into 
soluble and insoluble fractions and β-tubulin levels were analyzed by western blotting. β-
actin levels were probed to verify protein loading. (C) Cell lysates were collected and levels 
of total β-tubulin (soluble and insoluble) were analyzed by western blotting. β-actin levels 







 Given that ITCs have been reported to bind to cysteines, the possible 
binding of ITC analogs to cysteine residues of tubulin was next investigated (see 
Section 2.2.6). Porcine tubulin protein was incubated with ITC analogs and finally 
reacted with DTNB. DTNB is reduced to TNB by free sulfhydryl groups to form a 
disulfide. The number of sulfyhydryls modified per tubulin dimer by the ITC 
analogs was calculated based on the assumption 20 sulfhydryls per tubulin dimer 
(corresponding to 20 cysteine residues present in a tubulin dimer) would have been 
available in untreated control for DTNB reduction (Table 3.4). The results obtained 
suggested that ITCs could bind to cysteine residues of tubulin. Interestingly among 
the aromatic ITCs, the better potent B10, B9 and B2 exhibited stronger interaction 
with cysteine residues of tubulin (Table 3.4). The aliphatic ITCs, which did not 
exhibit effective anti-tumor properties, also exhibited stronger interaction with 
cysteine residues of tubulin. However, it should be noted that this experimental 
setup was a cell-free system and binding of ITCs to tubulin intracellularly would 
depend on several other factors such as accessibility of cysteine residue and 
lipophilicity of ITC analog.  
 
Compound Number of sulfhydryl groups modified 
per tubulin dimer 
CONTROL 0.00 
BITC 1.37 ± 0.15 
B10 1.56 ± 0.02 
B15 1.41 ± 0.00 
PEITC 1.25 ± 0.01 
B2 1.76 ± 0.17 
B9 1.57 ± 0.12 
B14 1.22 ± 0.00 
SF 2.59 ± 0.23 
B7 1.78 ± 0.10 
NMPEA 0.00 
Table 3.4 Number of sulfhydryl groups modified per tubulin dimer upon ITC treatment 
 
 





 The polar surface area of drug compounds had been shown to correlate with 
passive transport of drug across membranes and is an established predictor for 
absorption (Palm et al., 1997). Preliminary structure-based estimation of 
physicochemical properties revealed that aliphatic ITCs SF, B7 and B8 possessed 
larger polar surface area than their naturally occurring aromatic counterparts BITC 
and PIETC. However, methoxy substitutions on the benzene ring of aromatic ITCs, 
which yielded B2, B9 and B10, elevated their polar surface areas to values similar 
to those of aliphatic ITCs. Therefore, the methoxy substitutions could improve 
passive transport of aromatic ITCs inside cells. The fluorine substitutions did not 
affect the polar surface area. 
 Stability studies revealed a biphasic trend of degradation with each phase 
spanning over 24 h. The results demonstrated that all three aliphatic ITCs SF, B7 
and B8 were relatively much stable than the aromatic ITCs in aqueous conditions. 
Interestingly, methoxy substitutions on the benzene ring also brought about 
improved stability of aromatic ITCs. While B9 and B10 had enhanced stability as 
compared to their parent ITCs BITC and PEITC, B2 bearing two methoxy 
substituents on the benzene ring displayed the strongest improvement; the stability 
profile of B2 had become comparable to those of the aliphatic ITCs. 
 Natural ITCs BITC, PEITC and SF have been reported to possess 
anticancer properties demonstrated on several cultured cancer cells that include 
lung, breast, prostate, colorectal and cervical cancer cells. However, limited studies 
have ventured into exploring the structural features that can influence the anti-
tumor properties of ITCs. In our study, chemical modifications on synthetic 
derivatives of BITC, PEITC and SF were investigated for their ability to influence 
anti-tumor properties.  
             Our studies revealed that BITC and PEITC displayed greater growth 
inhibitory and apoptosis inducing activities than SF. These observations were 
consistent with a study performed by Chung FL and coworkers (2009). The 
fluorine and methoxy substituted aromatic ITC analogs were found to exhibit 
enhanced anti-proliferative activities and cytotoxicities in HCT 116 and A549 




carbonyl-containing aliphatic ITCs were weaker than those of aromatic ITCs.
 Mechanistically, the ITCs were found to induce an M phase arrest in HCT 
116 cells. The aromatic ITCs outperformed the aliphatic ITCs in induction of M 
phase arrest in HCT 116 cells. BITC and PEITC have been reported to bind to 
cysteine residues of β-tubulin causing their aggregation and leading to M phase 
arrest of cell cycle and apoptosis of A549 cells (Mi et al., 2009). In our study, 
immunocytochemical analysis revealed that the aromatic ITC analogs brought 
about β-tubulin aggregation. Although the aliphatic ITCs employed at 
concentrations around 25 μM did not affect microtubules in HCT 116 cells to an 
extent similar to PEITC and BITC, it is possible that they could cause mitotic arrest 
through similar mechanisms at higher concentrations. Of note, SF has been 
reported to cause mitotic arrest in MCF7 breast cancer cells through microtubule 
stabilization (Azarenko et al., 2008). Representative aromatic analogs B9 and B10 
were subsequently found to induce dose-dependent decline in soluble β-tubulin 
coupled with accumulation of insoluble β-tubulin. Additionally, all the aromatic 
analogs were observed to interact with sulfhydryl groups of recombinant β-tubulin. 
The modification of tubulin cysteine residues have been demonstrated to affect 
tubulin structure and function in vitro and in vivo. Mutation of a single tubulin 
cysteine residue Cys354 had been found to affect microtubule dynamics (Gupta et 
al., 2001). It could therefore be postulated that tubulin cysteine modification by 
aromatic ITC analogs could lead to disruption of microtubule network and could 
contribute at least in part to their induction of M phase arrest. Notably, BITC had 
been found to covalently modify Cys347 of α-tubulin in a cell-based study (Xiao et 
al., 2012). Like their aromatic counterparts, the aliphatic analogs were also found 
to bind to cysteine residues of tubulin. Of note, AITC has been reported to bind to 
multiple cysteine residues of recombinant β-tubulin in vitro (Geng et al., 2011). 
However, it remained possible that aliphatic ITCs that are more hydrophilic could 
be less available for binding to protein targets such as tubulin inside the cell when 
employed at lower concentrations.  Interestingly, it had been previously 
demonstrated that PEITC bound to cellular proteins more extensively than SF (Mi 
& Chung, 2008b). This might explain the weaker anti-tumor properties of SF 
despite its high tubulin binding potential in a cell-free system. Notably, given that 
the lipophilicity of B7 and B8 is higher than SF, it would be reasonable to deduce 




indeed observed to exhibit stronger anti-proliferative properties than SF. It had 
been reported previously that treatment of HeLa with BITC and PEITC initiated 
proteasomal-dependent degradation of β-tubulin following their aggregation (Mi et 
al., 2009). However, in our study, no significant decrease in total tubulin levels 
were observed in HCT 116 cells treated with ITCs. It should be noted that the anti-
tumor mechanisms of ITCs have been reported to be cell-dependent. The apparent 
contradictions in the observations regarding effect of ITCs on tubulin degradation 
could possibly be attributed to the difference in cell lines employed to conduct the 
experiments.  
 Earlier studies on BITC, PEITC, AITC and SFN have reported cell cycle 
arrest followed by apoptosis induction through multiple pathways that include the 
mitochondrial death pathway, death receptor pathway and endoplasmic reticulum 
pathway. However, the exact sequence of events linking cell cycle arrest to 
apoptosis induction remains elusive. In this study, microscopic observations and 
the appearance of apoptosis marker, cleaved PARP and cleaved caspase-3 in ITC-
treated HCT 116 cells suggested that aromatic ITCs could induce apoptotic cell 
death following an M phase arrest. The cleavage of PARP has been reported to be 
mediated through caspase-3, as well as other caspases such as caspase-7 or 
caspase-3-like proteases. It should also be noted that PARP cleavage has been 
suggested to be associated with necrosis (Gobeil et al., 2001) and it is debatable if 
it is a unique hallmark of apoptosis. Although cleaved PARP fragments were 
observed upon treatment with the aromatic ITCs, cleaved caspase-3 fragments 
could not be detected, especially for potent ITCs such as B2. While one possible 
reason could be that proteolysis occurring during intense apoptosis may have 
degraded the cleaved caspases fragments (Tawa et al., 2004), other reasons that 
include involvement of other caspases such as caspase 7 or occurrence of necrosis 
could not be ruled out. Interestingly, in consistence with our previous suggestion 
on cytostatic potential of aliphatic ITCs, cleavage of PARP was not observed for 
aliphatic ITCs at concentrations exhibiting an M phase arrest.  
 Based on the results in this study, aromatic ITCs were found to exhibit 
stronger anti-proliferative activities than the aliphatic ITCs. A few structural 
features that could augment or attenuate the anti-proliferative efficacies of ITCs 




–N=C=S functional group was found to decrease anti-proliferative potencies of 
aromatic ITCs. While substitution of fluorine on benzene ring was found to 
marginally increase anti-proliferative potencies of aromatic ITCs, substitutions of 
methoxy groups at the ortho and/or para position were revealed to significantly 
enhance the anti-proliferative efficacies of aromatic ITCs. 
 In summary, the aromatic analogs were suggested to bind to the cysteines in 
tubulin protein, causing disruption of the microtubule network followed by M 
phase arrest and induction of apoptosis. Given that the methoxylated analogs of 
BITC and PEITC were found to possess stronger anti-proliferative properties, they 






Chapter 4  
Evaluation of anti-tumor properties of ITCs – inhibition of 
thioredoxin reductase and glutathione reductase  
4.1 Introduction 
 TrxR and GR are redox enzymes that play essential roles in the redox 
homeostasis of cells. They supply electrons for the functioning of a diverse range 
of enzymes and are involved in cell proliferation, cell cycle regulation, protection 
against oxidative stress and apoptosis. Over the past few years, overexpression of 
these enzymes has been associated with survival, growth and progression of tumor 
cells (Saydam et al., 1997) (Soini et al., 2001) (Lincoln et al., 2003). They have 
also been associated with development of resistance to anticancer treatment and 
poor patient prognosis (Cole et al., 1990) (Carmichael et al., 1988) (Koo et al., 
2013).  
 Natural ITCs have been shown to cause apoptosis in cancer cells likely to 
be mediated at least partly through modulation of the oxidative status of cancer 
cells. Interestingly, ITCs have been shown to cause irreversible inhibition of 
purified TrxR and GR in a time-dependent manner. The inhibitory potencies of 
natural ITCs was in the order BITC > AITC > PEITC > SF (Hu et al., 2007). 
Additionally, Chung FL and co-workers (Mi et al., 2011) had identified TrxR as 
one of the potential ITC targets in radiolabel-2-D gel electrophoresis.   
 Given that ITCs are multi-targeting, having found that ITC analogs 
displayed anti-tumor potential and likely to target tubulin (revealed in Chapter 3), 
we were interested to investigate their TrxR inhibitory potential. In this chapter, 
aromatic ITC analogs B2, B9 and B10, which were most potent in exhibiting anti-
tumor properties among the tested ITC analogs, were investigated for their 







4.2.1 Inhibition of purified recombinant TrxR enzyme activity by ITC analogs 
 The inhibitory effects of ITC analogs on purified recombinant ratTrxR at 
two time points, 30 and 60 min, were analyzed by the DTNB reduction assay (see 
Section 2.2.7). All aromatic analogs of BITC and PEITC were found to inhibit 
TrxR activity in a dose-dependent (Fig 4.1A and B). 
 At 30 min, BITC and B10 were more potent than PEITC and B9 
respectively (Table 4.1). Based on this observation, among the ITC analogs TrxR 
inhibitory potency was observed to decrease with an increase in alkyl chain length 
between the benzene ring and ITC functional group. 
 B10, the methoxylated ITC analog containing one methylene group 
separating the benzene ring and ITC functionality was found to inhibit TrxR more 
strongly than its parent BITC. In the case of methoxylated ITC analogs containing 
two methylene groups between the benzene ring and ITC functional group, B2 with 
dimethoxy substituents in the meta- and para-position was found to be more 
inhibitory than PEITC, whereas B9 with monomethoxy substituent inhibited TrxR 
to the same extent as PEITC. These observations suggested that methoxy 
substitutions on the benzene ring brought about enhancement of TrxR inhibitory 






Figure 4.1 In vitro Inhibitory effects of aromatic ITCs on mammalian TrxR activity 
 
 
Figure 4.1 In vitro Inhibitory effects of aromatic ITCs on mammalian TrxR activity.  TrxR 
activity was evaluated using DTNB reduction assay after (A) 30 min or (B) 60 min 
incubation of indicated concentration of ITCs with 100 nM recombinant ratTrxR. Each data 










IC50(30 min)  
(μM) 
IC50(60 min)  
(μM) 
   
BITC 13.88 15.6 
B10 8.349 11.63 
PEITC 25.26 32.98 
B9 19.16 28.08 
B2 16.03 26.07 
SF >75 >35 
B7 >75 >35 
B8 >75 >35 




 The concentrations to bring about 50% of TrxR inhibition for each 
compound were calculated and tabulated in Table 4.1. All tested analogs exhibited 
time-dependent enzyme inhibitory effect, where 60 min of incubation of ITCs with 
TrxR produced a lower IC50 value. In Addition, it was observed that the aliphatic 
ITCs SF, B7 and B8 produced significantly weaker TrxR inhibition than their 
aromatic counterparts (Table 4.1). 
4.2.2 Inhibition of TrxR but not Trx activity in HCT 116 cells by ITC analogs 
 Subsequently, the effect of ITC analogs on the components of the Trx 
system was investigated in HCT 116 cells by insulin end point assay (see Section 
2.2.7).  As illustrated in Fig 4.2A, significant inhibition of cellular TrxR activity 
was observed at lethal concentrations (30 μM) of all tested ITCs. In consistence 
with results obtained for their inhibitory effects on recombinant ratTrxR, BITC and 
B10 were found to inhibit cellular TrxR to a greater extent than PEITC and B9 
Table 4.1 In vitro Inhibitory activities of ITCs against recombinant ratTrxR  
 
IC50(30 min): Concentration of an inhibitor which brings about 50% inhibition of an enzyme in 
30 minutes. 








respectively. Dimethoxylated B2 also displayed strong TrxR inhibitory activity at 
lethal concentrations of 20 and 30 μM. On the other hand, at sublethal 
concentrations of 5 and 10 μM, the ITCs failed to produce a decrease in cellular 
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Figure 4.2 Effect of ITC analogs on the activity and protein levels of TrxR and Trx in HCT 116 cells 
 
 Cellular Trx activities in the collected lysates were also determined. The 
ITCs were found to exhibit negligible effect on cellular Trx activity (Fig 4.2B). To 
examine whether the TrxR inhibitory effects of ITCs were due to a decline in the 
levels of cellular TrxR, ITC-treated HCT 116 lysates were analyzed by western 
blotting (see Sections 2.2.21 and 2.2.22). It was observed that TrxR levels were 
either induced or had remained the same as compared to those in DMSO-treated 
cells. Additionally, levels of Trx protein were also observed to remain at the same 
levels (Fig 4.2C)  
4.2.3 Inhibition of GR enzyme activity by ITC analogs in HCT 116 cells 
 Following the observations that ITCs displayed inhibitory activities against 
TrxR in cancer cells, the inhibitory activities against GR in HCT 116 cells were 
investigated using glutathione reduction assay (see Section 2.2.8). Results 
presented in Fig 4.3 show that majority of the ITCs significantly inhibited GR 
activity at lethal concentrations of 20 and 30 μM. Interestingly, the GR inhibitory 
potencies exhibited by the tested ITC analogs were similar to that observed for 
Figure 4.2 Effect of ITC analogs on the activity and protein levels of TrxR and Trx in HCT 
116 cells. HCT-116 cells were incubated with indicated concentrations of ITCs for 14 h and 
cell lysates were collected. Cell lysates were used in the determination of TrxR (A) and Trx 
(B) activity. The activity was expressed as a percentage of that of DMSO control cells. * 
Significant difference (p < 0.05) versus control. Each column represents mean (extracted from 
two independent experiments) ± S.D (defined over all estimates of two independent 
experiments). (C) Lysates were analyzed by western blotting. β-actin levels were probed to 





their TrxR inhibitory potencies; methoxylated ITCs B10, B9 and B2 had exhibited 
greater cellular GR inhibition than their parent ITCs. At sublethal concentrations, 
the analogs were observed to cause a mild elevation of cellular GR activities.  
 
Figure 4.3 Effect of ITC analogs on GR activity in HCT 116 cells 
 
4.3 Discussion 
 ITCs have been reported to exhibit anticancer properties mediated through 
multiple mechanisms. Intriguingly, natural ITCs have been reported to inhibit 
activities of isolated TrxR and GR (Hu et al., 2007). Given that TrxR and GR are 
overexpressed in cancer cells, inhibition of TrxR and GR activities is a feasible 
strategy against cancer. Indeed inhibitors of TrxR and GR are widely being 
investigated as cancer therapeutics and adjuvants for chemotherapy (Chew et al., 
2008, Tonissen et al., 2009, Simons et al., 2009, Scarbrough et al., 2012, Gan et 
al., 2013). In Chapter 3, cell cycle disruption mediated through aggregation of 
tubulin and apoptosis induction by ITCs was investigated and analogs with potent 
anticancer properties were identified.  In this chapter, inhibitory activities of novel 
ITC analogs against TrxR and GR were investigated as a possible mechanism 































Figure 4.3 Effect of ITC analogs on GR activity in HCT 116 cells. HCT 116 cells were 
incubated with indicated concentration of the ITCs for 14 h and cell lysates were collected. 
Lysates were used in the determination of GR activity by glutathione reductase assay. The 
activity was expressed as a percentage of DMSO control cells. * Significant difference 
(p<0.05) versus control. Each column represents mean (extracted from two independent 




 The novel methoxylated aromatic analogs B10, B9 and B2 were first found 
to inhibit purified mammalian TrxR. They were subsequently found to possess 
TrxR inhibitory activities at lethal doses in cancer cells. In addition, they were also 
found to inhibit GR activities in cancer cells. These results suggested that inhibition 
of redox-related enzymes TrxR and GR, which led to dysregulation of redox 
homeostasis, could be a contributing mechanism underlying the cytotoxic activities 
of ITCs against cancer cells. A recent study by Fernandes and co-workers (Selenius 
et al., 2012) demonstrated that inhibition of TrxR caused disturbances of the 
mitotic process. This study has lent support to our observations that suggest on M 
phase arrest and TrxR inhibition as mechanisms underlying the cytotoxicities of 
aromatic ITCs. On the other hand, ITCs at sublethal concentrations were observed 
to cause an induction in TrxR and GR activities. This could be attributed to the 
increase in expression of TrxR and GR as part of the cellular defensive response 
against non-cytotoxic doses of electrophilic ITCs.  
 The structure-activity relationship revealed for the TrxR and GR inhibitory 
activities of ITCs were similar to that revealed for their anticancer properties 
mediated through tubulin binding and aggregation (Chapter 3);  monomethoxy 
substitution at the ortho- position and dimethoxy substitutions at the meta- and 
para- positions of the benzene ring enhanced TrxR and GR inhibitory potencies of 
ITCs. In contrast, aliphatic ITCs were found to display weaker TrxR inhibitory 
potencies than their aromatic counterparts. 
 ITCs have indeed been demonstrated to bind to cysteine residues of proteins 
and modify their biological functions. Interestingly, the three cellular proteins, 
namely tubulin, TrxR and GR, which had been revealed to be targeted by ITCs, 
possess nucleophilic cysteine or selenocysteine (Hu et al.) residues that are critical 
for their functions. Cys59, Cys64, Cys497 and Sec498 of TrxR and Cys58 and 
Cys63 of GR are important for the catalytic activity of the respective enzyme; 
electrophilic adduction at these residues could therefore hinder enzymatic activity. 
In the previous chapter, ITCs had been demonstrated to modify cysteine residues of 
tubulin. It is highly probable that ITCs could modify the nucleophilic 
selenocysteine and cysteine residues in TrxR and GR, leading to inhibition of their 
activities. Mass spectrometry investigations are recommended to reveal the exact 




relationship, it is possible that methoxy substituents at the aromatic ring could 
enhance binding of ITC analogs to protein targets. The weaker TrxR inhibitory 
potency of aliphatic ITCs could be attributed to their low hydrophobicity, small 
compound size and shape, which probably make them less accessible and 
accommodable in the active sites of TrxR.  
 In summary, aromatic analogs of BITC and PEITC were found to possess 
enhanced TrxR and GR inhibitory activities at cytotoxic concentrations. These 
observations suggested that inhibition of redox regulating enzymes TrxR and GR 
was one of the mechanisms underlying the anticancer activities of ITCs. Unlike 
aromatic ITCs, aliphatic ITCs that were found to possess weaker anticancer 















Chapter 5  
 
Investigation of anti-inflammatory activities 
of aliphatic ITC analogs  
 
5.1 Introduction 
  Inflammation is a defense-intended immune response. While acute 
inflammation occurs transiently and resolves timely, chronic inflammation is 
dysregulated and an unintended threat. It has been implicated in several auto-
immune, cardiovascular, metabolic and neurological disorders, as well as several 
cancers. Attempts to attenuate chronic inflammation in such disease states by 
employing conventional anti-inflammatory drugs that are usually inhibitors of 
specific targets such as iNOS and COX-2, have yielded either temporary benefits 
of symptomatic relief that may be used only in mildly dysregulated inflammatory 
states or significant side effects that may outweigh their medicinal benefits. In 
addition, there have been several reports on risks associated with long term use of 
these agents. As such, there is an increasing interest in alternatives. Given that 
inflammation is a myriad of simultaneous biological events at multiple anatomical 
levels, a feasible strategy would be to employ agents that can modulate multiple 
events of the chronic inflammatory phenomenon. Phytochemicals known to 
modulate multiple intracellular events are thus promising alternatives.  
  SF has been widely studied for its chemopreventive potential 
mediated through multiple mechanisms. Exploration of multiple mechanisms 
underlying its chemopreventive potential had revealed its anti-inflammatory 
potential as a contributing mechanism. It has been found to suppress the expression 
of inflammatory mediators such as iNOS, COX-2 and TNF-α through inhibition of 
NF-κB and MAPK pathways in mouse macrophages and neuronal cells 




indeed been reported to decrease infiltration of macrophages to blood vessel walls, 
hearts and kidneys of spontaneous hypertensive rats (Wu et al., 2004).  
  Based on the results obtained from the MTT cell viability assays as 
revealed in Chapter 3, aliphatic ITCs, namely SF and its analogs B7 and B8 were 
found to possess were found to possess weaker anti-proliferative potencies than the 
aromatic ITCs. On this basis, the aliphatic ITC analogs were selected for 
investigation of their possible anti-inflammatory properties.  
5.2 Results 
  Pro-inflammatory mediators secreted by activated leukocytes are the 
major players of an inflammatory response. In this chapter, investigation of the 
effects of aliphatic ITC analogs B7 and B8 on lipopolysacharide (LPS)-induced 
levels inflammatory response in RAW 264.7 mouse macrophage-like cells 
(henceforth referred to as mouse macrophages) and human CD14
+ 
monocytes 
(henceforth referred to as human monocytes). LPS is a bacterial endotoxin and a 
strong elicitor of inflammatory response. SF with known anti-inflammatory 
activities was used as positive control and NMPEA, a compound devoid of the ITC 
functional group, was used as the negative control.     
5.2.1 Cytotoxicity of ITC aliphatic analogs on RAW 264.7 cells and human 
monocytes 
 To rule out the possibility that any experimental observations made were 
due to the cytotoxic effects of ITCs, MTT cell viability assays were first performed 
to assess the cytotoxicity profiles of B7 and B8 on RAW 264.7 cells. As shown in 
Fig 5.1A, the analogs produced little toxicity for concentration up to 30 μM. 
Similar non-toxic range of concentrations, as determined by the trypan blue 
exclusion (see Section 2.2.10), was obtained with freshly isolated human CD14
+
 
monocytes (Fig 5.1B). Therefore, the concentrations in the range of 1 – 20 μM, 
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Figure 5.1 Cytotoxicity of ITC analogs B7, B8 and SF on RAW 264.7 cells and human CD14
+
 
monocytes. (A) RAW 264.7 cells were treated with indicated concentrations of ITCs for 24 h and 
subjected to MTT assay. Absorbance of dissolved formazan crystals (formed by viable cell-
mediated reduction of MTT) in ITC-treated sample is presented as percentage of DMSO control. 
(B) Human CD14
+
 monocytes were treated with indicated concentrations of ITCs for 24 h and 
subjected to trypan blue staining. Average number of monocytes/ microscopic field that did not take 
up the trypan blue stain in ITC-treated sample is presented as percentage of DMSO control. Each 
column represents mean ± S.D of at least three independent experiments. * Significant difference (p 
< 0.05) from DMSO control (cell viability =100%).   
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5.2.2 Inhibition of LPS-induced nitrite and PGE2 release with suppression of 
mRNA and protein levels of iNOS and COX-2 in RAW 264.7 cells by ITC 
analogs 
 The effect of ITC analogs on release of NO and PGE2 into cell culture 
medium was studied using the nitrite assay and ELISA respectively (see Sections 
2.2.11 and 2.2.12.1). B7 and B8 were found to exhibit dose-dependent inhibition of 
LPS-induced NO and PGE2 secretion (Fig 5.2A and B). While the IC50 values of 
B7 for NO and PGE2 secretion were calculated to be 1.64 ± 0.17 and 1.66 ± 0.36 
µM respectively, that of B8 were 2.23 ± 0.01 and 2.92 ±0.19 µM respectively. 
Notably, 10 µM of B7 and 20 μM of B8 had suppressed LPS-induced NO and 
PGE2 secretion levels comparable to those of 10 µM SF, where as NMPEA 
produced no inhibitory effects. The effect of ITC analogs on LPS-induced 
expression of iNOS and COX-2, the corresponding enzymes catalyzing the 
production of NO and PGE2, was next examined (see Sections 2.2.13 and 2.2.22). 
As shown in Fig 5.2C and D, both ITC analogs brought about a dose-dependent 
decrease in iNOS and COX-2 mRNA and protein levels. On the other hand, 



































































Figure 5.2 Inhibitory effects of ITC analogs B7 and B8 on NO and PGE2 release and expression 
of pro-inflammatory enzymes in LPS-stimulated RAW 264.7 cells. (A) and (B). RAW 264.7 
cells were treated with indicated concentrations of ITCs for 1 h, followed by induction with LPS 
(500 ng/ml) for 20 h. Spent cell culture media was collected and freshly analyzed for amounts of 
nitrite using the Griess reaction assay and amounts of PGE2 using ELISA. The estimated nitrite 
content (A) and PGE2 content (B) was expressed as a percentage of difference between LPS and 
DMSO control. Each column represents mean ± S.D of three independent experiments. * 
Significant difference (p < 0.05) from LPS. (C) RAW 264.7 cells were treated with indicated 
concentrations of ITCs for 1 h followed by induction with LPS for 5 h. Total mRNA was 
extracted, reverse transcribed, and amplified by PCR using gene specific primers. The PCR 
product was analyzed by agarose gel electrophoresis. GAPDH primers were used to verify levels 
of RNA reverse transcribed. (D) RAW 264.7 cells were treated with indicated concentrations of 
ITCs for 1 h and induced with LPS for 20 h. Cell lysates were collected and analyzed by 





Figure 5.2 Inhibitory effects of ITC analogs B7 and B8 on NO and PGE2 release and expression of pro-inflammatory 
enzymes in LPS-stimulated RAW 264.7 cells. 
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5.2.3 Suppression of LPS-induced MMP-9 levels and activity in RAW 264.7 
cells by ITC analogs 
 The inflammatory response involves activated immune cells migrating to 
the site of inflammation. To do so, immune cells secrete MMPs to breakdown the 
ECM. Therefore, the effect of the ITC analogs on the production and secretion of 
pro-inflammatory MMP-9 by LPS-induced RAW 264.7 cells was assessed (see 
Sections 2.2.21 and 2.2.22). As shown in Fig 5.3A and B, the ITC analogs B7 and 
B8 exhibited a dose-dependent suppression of LPS-induced intracellular levels of 
MMP-9 and corresponding release of MMP-9 into cell culture medium. 
Suppressive effects by 10-20 μM of B7 and B8 were comparable to those produced 
by 10 μM SF. Consistent with suppressed levels of MMP-9 secreted into medium, 
the corresponding MMP-9 gelatinolytic activities of ITC-treated medium samples 
were also found to be suppressed (Fig 5.3B) (see Section 2.2.14). Unlike B7, B8 
and SF, NMPEA did not affect the LPS-induced levels and gelatinolytic activity of 








Figure 5.3 Inhibitory effects of ITC analogs B7 and B8 on the expression, secretion and gelatinolytic activity of MMP-9 
in LPS-stimulated RAW 264.7 cells. 
Figure 5.3 Inhibitory effects of ITC analogs B7 and B8 on the expression, secretion and 
gelatinolytic activity of MMP-9 in LPS-stimulated RAW 264.7 cells. (A) and (B) RAW 264.7 
cells were treated with indicated concentrations of ITCs for 1 h followed by induction with 
LPS (500 ng/ml)  for 20 h. (A) Cell lysates were collected and analyzed by western blotting. 
β-actin levels were probed to verify protein loading. (B) Spent cell culture media was 




5.2.4 Inhibition of LPS-induced expression of pro-inflammatory cytokines in 
RAW 264.7 cells by ITC analogs 
 Following experimental observations made of inhibitory effects of ITC 
analogs on LPS-induced expression of pro-inflammatory enzymes, we were 
interested to examine effects of ITCs on LPS-induced expression of pro-
inflammatory cytokines such as IL-6, IL-1β and TNF-α (see Section 2.2.13). Each 
of these cytokines is involved in exacerbating the inflammatory response. As 
evident from the dose -dependent decline in the mRNA levels (Fig 5.4), B7 and B8 
were found to suppress expression of all three investigated cytokines at a 
transcriptional level, suppressive effects produced by 10-20 μM of B7 and B8 were 







 Having observed that the ITC analogs indeed displayed an inhibitory effect 
on LPS-induced expression of inflammatory mediators in mouse macrophage-like 
cells, the investigation was next extended to CD14
+ 
monocytes isolated from 
human blood (see Section 2.2.9). 
 
Figure 5.4 Inhibitory effects of ITC analogs B7 and B8 on expression of pro-inflammatory 
cytokines at a transcriptional level in LPS-stimulated RAW 264.7 cells. RAW 264.7 cells were 
treated with indicated concentrations of ITCs for 1 h and followed by induction with LPS (500 
ng/ml)  for 0.5 or 5 h. Total mRNA was extracted, reverse transcribed, and amplified by PCR 
using gene specific primers. The PCR product was analyzed by agarose gel electrophoresis. 
GAPDH primers were used to verify levels of RNA reverse transcribed. Gel images shown are 
representative of three independent experiments.  
 
Figure 5.4 Inhibitory effects of ITC analogs B7 and B8 on expression of pro-inflammatory cytokines at 




5.2.5 Suppression of LPS-induced MMP-9 levels and activity in isolated 
human CD14
+
 monocytes by ITC analogs 
 Similar to experimental observations made in RAW 264.7 cells, the ITC 
analogs B7 and B8 suppressed LPS-induced levels of MMP-9 in cell lysates and 
cell culture medium of human monocytes (Fig 5.5A and B). The corresponding 
gelatinolytic activity of MMP-9 in the ITC-treated medium samples was also 
reduced (Fig 5.5B). Of note, 10- 20 μM B7 and B8 produced suppressive effects 
comparable to that of positive control SF 10 μM, whereas negative control 






Figure 5.5 Inhibitory effects of ITC analogs B7 and B8 on expression, secretion and activity of 
MMP-9 in LPS-stimulated human monocytes. (A) and (B) Human monocytes were treated with 
indicated concentrations of ITCs for 1 h and followed by induction with LPS (100 ng/ml) for 20 
h. (A) Cell lysates were collected and analyzed by immunoblotting. β-actin levels were probed to 
verify protein loading. (B) Spent cell culture media was collected and analyzed by 




Figure 5.5 Inhibitory effects of ITC analogs B7 and B8 on expression, secretion and activity of MMP-9 in 




5.2.6 Inhibition of LPS-induced expression of pro-inflammatory cytokines in 
isolated human CD14
+ 
monocytes by ITC analogs  
 ELISA results obtained of the medium collected from LPS-stimulated 
human monocytes revealed that pre-treatment with B7 and B8 brought about a 
dose-dependent decrease in the amount of secreted IL-6, IL-1β and TNF-α (Fig 5.6 
A-C) (see Section 2.2.12.2). The medium samples were also subjected to western 
blot analysis of the levels of TNF-α using anti-TNF-α antibody. As shown in Fig 
5.6D, the TNF-α levels were found to have decreased by B7 and B8 in a dose-
dependent manner. Western blot analysis of the levels of the collected cell lysates 
also showed trend of ITC-mediated dose-dependent decrease in TNF-α levels. 
Taken together, results obtained from ELISA and western blot analysis of the 
medium and lysates samples of LPS-stimulated human monocytes corroborated 
with the findings obtained in RAW 264.7 cells. Therefore, it was surmised that ITC 
analogs B7 and B8 possessed anti-inflammatory activities that were comparable to 
those of prototypical SF. The negative control NMPEA had no effect on LPS-
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 Taken together, the findings obtained from human monocytes corroborated 
with the observations made in RAW 264.7 mouse macrophage-like cells; novel 
ITC analogs B7 and B8 were found to inhibit the release of pro-inflammatory 
mediators in LPS-stimulated macrophages and their precursor monocytes while 
NMPEA did not show any inhibitory effect. Such inhibition was coupled with 
consistent attenuation of expression of inflammatory mediators. It was noteworthy 
that the inhibitory activity of B7 was comparable to SF but that of B8 was 
relatively less. This therefore demonstrated that both B7 and B8 exhibited anti-
inflammatory activities.  
Figure 5.6 Inhibitory effects of ITC analogs B7 and B8 on the release and expression of pro-
inflammatory cytokines in LPS-stimulated human monocytes. Human monocytes were treated 
with indicated concentrations of ITCs for 1 h followed by induction with LPS (100 ng/ml) for 
20 h. Spent cell culture media was collected and freshly analyzed for amounts of cytokines 
using ELISA. The estimated contents of (A) IL-6, (B) IL-1β and (C) TNF-α are expressed as a 
percentage of difference between LPS and DMSO control. Each column represents mean ± S.D 
of three independent experiments. * Significant difference (p < 0.05) from LPS only treated 
group. (D) Spent cell culture media or cell lysates were collected and analyzed by 
immunoblotting. β-actin levels in lysates were probed to verify protein loading.  
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Figure 5.6 Inhibitory effects of ITC analogs B7 and B8 on the release and expression of pro-inflammatory 
cytokines in isolated and LPS-stimulated human monocytes. 
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5.2.7 Investigation of the effects of ITC analogs on the migratory AND 
phagocytic abilities of isolated human CD14
+
 monocytes 
 Having ascertained that ITC analogs displayed inhibitory effects on the 
inflammatory response through suppression of expression of pro-inflammatory 
mediators, we moved on to investigate whether the compounds possessed 
suppressive effects on certain immunological functions of monocytes.  
 During inflammation, leukocyte precursor monocytes perform functions 
such as chemotaxis to site of inflammation, phagocytosis and differentiation to 
mature inflammatory cells. Therefore, the chemotaxis assay was performed to 
assess the effect of ITCs on migration of human monocytes (see Section 2.2.17).  
Chemotaxis of monocytes pretreated with either ITCs or DMSO was induced by 
stromal cell derived factor-1 alpha (SDF-1α). SDF-1α is a chemokine usually 
sourced at the site of inflammation to attract leukocytes to the site of inflammation 
by driving their migration towards an increasing concentration gradient (Bleul et 
al., 1996). As evident from Fig 5.7A and B, the number of monocytes that migrated 
towards higher concentrations of SDF-1α was significantly decreased when pre-
treated with 10 μM B7, B8 or SF.  This had suggested that the ITCs could either 
hinder chemotactic stimulation of monocytes and or alter their motility. In addition, 
the ITCs were found to attenuate inflammatory stimulant-induced MMP-9 
gelatinolytic activity of monocytes (Fig 5.5). Given that the ECM-degrading ability 
of monocytes facilitates their migration during chemotaxis across ECM to the site 
of inflammation, the results, taken together, indicated that the ITC analogs could 
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Figure 5.7 Suppressive effects of ITC analogs SF, B7 and B8 on SDF-1α-induced migratory 
abilities of isolated human monocytes. Migration assay was performed in human monocytes 
treated with indicated concentrations of ITCs for 1 h following induction with SDF-1α (200 ng/ml) 
for 1 h. (A) The migrated cells were analyzed under microscope. (B) The average number of 
monocytes migrated across membrane across in ten random microscopic fields is presented in 
column. Each column represents mean ± S.D of three independent experiments. * Significant 






 The phagocytic ability of human monocytes was next assessed based on 
their ability to internalize polystyrene microspheres (PSM) (see Section 2.2.16). 
Human monocytes possessed inherent phagocytic ability. Phagocytosis assays were 
focused to examine the effects of ITCs on the abilities of human monocytes to 
internalize PSM. As shown in Fig 5.8A and B, treatment with 10 μM B7, B8 or SF 
suppressed the phagocytosis of PSM by isolated monocytes.  
 For the experiments conducted in human monocytes, microscopic 
observations revealed that LPS caused the clumping of monocytes, which was 
similar to a phenomenon known as leuko-agglutination reported in the blood 
samples of patients with acute and chronic inflammation-associated states (Grob & 
Angelillo-Scherrer, 2012). Interestingly, pretreatment with ITCs brought about a 
suppression of the LPS-triggered agglutination of human monocytes (Fig 5.9A). 
 The effect of ITCs on differentiation of monocytes to macrophages was 
preliminarily examined through microscopic observations. The differentiation of 
monocytes to macrophages was triggered using macrophage colony stimulating 
factor (M-CSF), a cytokine that acts as a growth factor for the proliferation, 
differentiation and survival of monocytes (Stanley et al., 1997). As depicted in Fig 
5.9B, upon stimulation with M-CSF, monocytes transformed into elongated, 
spindle-shaped macrophage-like cells and adhered well to the surface of the culture 
plate. However, the morphology of monocytes pre-treated with ITCs remained 
unchanged. Flow cytometric analysis for expression levels of macrophage specific 
CD markers CD40, CD68 and CD64 are recommended to obtain concrete evidence 






















































Figure 5.8 Suppressive effects of ITC analogs SF, B7 and B8 on the phagocytic ability of 
isolated human monocytes. Human monocytes were treated with indicated concentrations of 
ITCs for 3 h and subjected to phagocytosis assay. (B) The estimated number of monocytes that 
exhibited phagocytosis is presented in relative percentage of DMSO control. Each column 
represents mean ± S.D of three independent experiments. * Significant difference (p < 0.05) 








Figure 5.9 Suppressive effects of ITC analogs SF, B7 and B8 on LPS-induced agglutination and M-CSF-
induced morphological changes in isolated human monocytes 
 
Figure 5.9 Suppressive effects of ITC analogs SF, B7 and B8 on LPS-induced agglutination and 
M-CSF-induced morphological changes in isolated human monocytes. (A) Representative 
microscopic images of human monocytes pre-treated with indicated concentrations of ITCs for 1 
h and induced with LPS (100 ng/ml) for 20 h. (B) Human monocytes were treated with indicated 
concentrations of ITCs for 1 h followed by induction with M-CSF (100 ng/ml) for 5 days. 





  Together the above results demonstrated that SF and its analogs B7 
and B8 possessed repressive effects on inflammation associated functions of 
human monocytes contributing to their anti-inflammatory potential. In 
inflammation, several cellular signaling cascades span and fuel the events from 
activation of surface receptors of leukocytes to expression of an array of 
inflammatory mediators. Having established that B7 and B8 exhibit anti-
inflammatory activity, we sought to investigate the underlying molecular 
mechanisms.  
5.2.8 Evaluation of the possible effects of ITC analogs on the components of 
the TLR-4 signaling pathway in mouse macrophage   
 We first examined the effects of ITCs on molecular events involving the 
NF-ĸB pathway (see Sections 2.2.15, 2.2.21 and 2.2.22), a major signaling pathway 
that is involved in the transcriptional activation of pro-inflammatory proteins. The 
NF-κB signaling cascade has been reported to be targeted by SF (Heiss et al., 
2001) and we hypothesized that it would be a molecular target of ITC analogs B7 
and B8. In RAW 264.7 cells, both B7 and B8 were found to prevent LPS-induced 
nuclear translocation of p65 (Fig 5.10A). Consistently, they caused a dose-
dependent inhibition of LPS-stimulated p65 phosphorylation (Serine536) (Fig 
5.10B). Furthermore, they were found to attenuate LPS-stimulated IκB-α 
phosphorylation (Serine32) that was accompanied by an increase in total IκB-α, as 
well as block IKK-α/β phosphorylation (Serine176/180) (Fig 5.11B).  B7 and B8 
also exhibited similar inhibitory effects on LPS-stimulated p65 phosphorylation 
and IKK-α/β phosphorylation in human monocytes (Fig 5.10C). These results 
demonstrated that NF-κB signaling pathway was one molecular target contributing 



















 Among the several kinases acting upstream of the NF-κB pathway, the 
MAPKs have been widely explored as targets for anti-inflammatory therapy. We 
then probed for the effects of ITCs on three upstream MAPK signaling cascades, 
namely the p38, p44/42 and SAPK/JNK pathways (see Sections 2.2.21 and 2.2.22). 
Pretreatment of RAW 264.7 cells and human monocytes with B7 and B8 produced 
a dose-dependent decrease in LPS-induced levels of phosphorylated p38 
(Threonine180/Tyrosine182), p44/42 (Threonine202/Tyrosine204) and SAPK/JNK 
(Threonine182/Tyrosine185), whereas the levels of total p38, p44/42 and 
SAPK/JNK had maintained unchanged (Fig 5.11A and B). These results indicated 
that B7 and B8, like SF, could suppress inflammatory activation of MAPK/ERK 
pathway. It could therefore be deduced that the mode of action of ITCs originated 
further upstream of the NF-κB and MAPK signaling pathways. 
Figure 5.10 Inhibitory effects of ITC analogs B7 and B8 on LPS-induced activation of NF-κB 
signaling pathway. (A and B) RAW 264.7 cells were treated with indicated concentrations of 
ITCs for 1 h and followed by induction with LPS (500 ng/ml) for 0.5 h. (A) RAW 264.7 cells 
were fixed and analyzed by immunocytochemistry. Representative fluorescence microscopic 
images are presented. (B) Cell lysates were collected and levels of phosphorylated and total forms 
of NF-κB pathway proteins were analyzed by immunoblotting. β-actin levels were probed to 
verify protein loading. (C) Human monocytes were treated with indicated concentrations of ITCs 
for 1 h and followed by induction with LPS (100 ng/ml) for 0.5 h. Cell lysates were collected and 
levels of phosphorylated and total forms of NF-κB pathway proteins were analyzed by 
immunoblotting. β-actin levels were probed to verify protein loading. 
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Figure 5.11 Inhibitory effects of ITC analogs B7 and B8 on LPS-induced activation of p38, 
SAPK/JNK and p44/42 MAPK signaling pathways. (A) RAW 264.7 cells were treated with 
indicated concentrations of ITCs for 1 h followed by inductions with LPS (500 ng/ml) for 0.5 h. 
(B) Human monocytes were treated with indicated concentrations of ITCs for 1 h followed by 
inductions with LPS (100 ng/ml) for 0.5 h. (A and B) Cell lysates were collected and levels of 
phosphorylated and total forms of MAPK pathway proteins were analyzed by immunoblotting. 
β-actin levels were probed to verify protein loading.  
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Figure 5.11 Inhibitory effects of ITC analogs B7 and B8 on LPS-induced activation of p38, SAPK/JNK 




 We then examined the effect of B7 and B8 on LPS-stimulated activation 
(through phosphorylation) of PDK1 and Akt (see Sections 2.2.21 and 2.2.22), the 
kinases lying upstream of the NF-κB and MAPK pathways. As shown in Fig 5.12, 
the increase in phosphorylation of PDK1 upon LPS stimulation was dose-
dependently abrogated upon pretreatment of RAW 264.7 cells with the ITCs dose 
dependently. Of note, the increase in phosphorylation of Akt upon LPS stimulation 
was also abolished by B7 and B8 in a dose-dependent manner. Attempts to assess 
the effects of ITCs on phosphorylation of p85, the regulatory PI3K upstream of 
PDK1 and Akt were hindered due to insensitivity of commercial anti-p85 antibody 
(from Cell Signaling, Inc) used for western blot analysis. Nevertheless, the results 
obtained from analysis of levels of phosphorylated PDK1 and AKT indicated that 
both B7 and B8 were capable of blocking inflammatory signal-mediated activation 





  Overall, the results presented in Fig 5.10 to 5.12 had provided 
experimental evidence demonstrating the potential of ITCs to suppress the 
activation of several signaling pathways involved in mediating an inflammatory 
response.  
Figure 5.12 Inhibitory effects of ITC analogs B7 and B8 on LPS-induced activation of PI3K-
PDK1-Akt pathway. (A) RAW 264.7 cells and (B) human monocytes were treated with 
indicated concentrations of ITCs for 1 h followed by inductions with LPS (500 ng/ml) for 0.5 
h. Cell lysates were collected and levels of phosphorylated and total forms of PDK1 and Akt 
analyzed by immunoblotting. β-actin levels were probed to verify protein loading. 
 





5.2.9 Elucidation of ITCs binding to cysteine residues in IKK-β 
  Among the components of the signaling pathways investigated as potential 
targets of ITCs above, IKK-β of the NF-κB pathway is a known redox-sensitive 
kinase. IKK-β possesses a reactive cysteine residue at position 179 whose pKa is 
lower than that of a typical cysteine (pKa 8); allowing it to be ionized at 
physiological pH thereby susceptible to reaction with electrophiles.  We therefore 
investigated whether ITCs containing an electrophilic isothiocyanato functional 
group could possibly bind to redox-sensitive cysteine residue(s) in IKK-β. The 
BIAM labeling assay was carried out on lysates of ITC-treated or untreated HEK 
293-cells overexpressing IKK-β (see Section 2.2.23). To assess the extent of 
electrophile addition specifically to reactive cysteine residue(s), the labeling by 
BIAM was conducted at pH 6.5. An oxidized or chemically modified cysteine 
residue would not be labeled by BIAM and the amount of BIAM labeling as 
monitored by streptavidin blot analysis, would therefore show a reduced BIAM-
streptavidin signal band. As shown from Fig 5.13A, decreased intensities of HRP-
streptavidin in lanes corresponding to 10 μM SF and B7 treatment had suggested 
that covalent binding of ITCs to reactive cysteine residues of IKK-β could possibly 
have occurred.  
 To further elucidate the actual cysteine residues modified by ITCs, IKK-β 
protein expressed in transfected HEK-293 cells was pulled-down (Fig 5.13B), 
trypsin-digested and the fragments were subjected to electron spray ionization mass 
spectrometry. However, the peptide fragment containing reactive Cys179 was not 
detected. Possible reasons contributing to the failed attempt could be due to 
insufficient concentrations of pulled-down IKK-β protein or limited sensitivity of 
the instrument used.  
 An experimental attempt to assess the effect of ITC binding on kinase 
activity of cellular IKK-β had not been successful too. Reasons contributing to the 
unsuccessful attempt had been the difficulty to optimize conditions to harvest 
sufficient immunoprecipitated IKK-β from cell lysates, as well as the experimental 
conditions to set up the kinetic reaction between immunoprecipitated cellular IKK-
β and its substrate. Nonetheless, a reduction in IKK-β being BIAM-labeled in 




ITCs, and suggested that the reactive cysteine residues within IKK-β were involved 













Figure 5.13 Investigation of binding of SF and B7 to cysteine residues of IKK-β. Transfected 
HEK-293 cells overexpressing Flag-IKK-β were treated with 10 μM SF and B7 for 45 min. (A) 
Cell lysates were collected and subjected to immunoprecipitation using FLAG antibody. 
Immunoprecipitates were analyzed by western blotting with streptavidin HRP or anti-FLAG 
antibody. Cell lysates were directly analyzed by immunoblotting for expression levels of IKK-β. 
(B) Cell lysates were collected and subjected to immunoprecipitation using FLAG antibody. 
Immunoprecipitates were resolved using SDS-PAGE electrophoresis and analyzed by Coomasie 
staining. The FLAG-IKK-β bands were cut, trypsin digested and subjected to mass spectrometry 
analysis. 




  Natural and synthetically derived ITCs have been studied for 
multiple biological potential that include antibacterial, antifungal, antiprotozoal, 
anti-proliferative and chemopreventive activities.  While a few earlier studies have 
reported the contribution of side chains in ITCs to their biological activities and 
physicochemical properties, the effect of structural modifications made to chemical 
backbone of prototypical SF on its anti-inflammatory activity had largely been 
unexplored. In this chapter, the anti-inflammatory activities of B7 and B8 the 
structural analogs of SF, that carry a carbonyl group in place of a sulfinyl group in 
SF, were examined and compared with those of SF.  
 Inflammation involves infiltration of leukocytes to the site of inflammation 
followed by interplay of inflammatory mediators derived from leukocytes to 
perpetuate the inflammatory response. At the molecular level, a complex cascade 
of signaling pathways regulate expression and release of inflammatory mediators 
and drive inflammatory functions of leukocytes. Chemical-induced inflammation 
and chronic inflammation caused by infectious (bacteria and viruses) and non 
infectious agents (cigarette smoke, asbestos, silica and others) are known to 
increase risk of developing cancer.  During inflammation, the generation of 
oxidative stress and several pro-inflammatory mediators such as cytokines, 
chemokines, prostaglandins, NO and leukotrienes), growth and angiogenic factors 
as well as matrix degrading proteases is tumor-promoting; several steps in the 
process of tumorigenesis like tumor initiation, tumor growth and metastasis are 
activated under chronic inflammatory conditions. The mediators further increase 
recruitment of monocytes and their differentiation to macrophages at the site of 
tumor development. These tumor associated-macrophages (TAMs), conditioned by 
components of the tumor microenvironment, can further exacerbate metastasis.   
 Using LPS as the stimulus to induce the anti-inflammatory response, B7 
and B8 were found to inhibit release and expression of pro-inflammatory mediators 
NO, PGE2, iNOS, COX-2 and MMP-9 in RAW 264.7 cells and cytokines IL-6, IL-
1β, TNF-α and MMP-9 in human CD14+ monocytes. These results had 
demonstrated the anti-inflammatory potential of B7 and B8, and were in agreement 




expression of pro-inflammatory mediators. It was observed that the anti-
inflammatory activities of B7 were comparable to those of SF whereas B8 was 
relatively less efficacious. It was therefore concluded that replacement of the 
sulfinyl (S=O) group in SF to a carbonyl (C=O) group had not led to abolishment 
of activity. Negative control NMPEA, devoid of an ITC (-N=C=S) group, was 
found to lack anti-inflammatory activity. This had affirmed that the ITC 
functionality was essential for bioactivities of this class of compounds. In addition, 
the aliphatic chain length had appeared to influence the activities; a 4-carbon chain 
length between the methylsulfinyl (in SF) or methylcarbonyl (in B7) ITC 
functional group had yielded stronger anti-inflammatory activities than a 3-carbon 
chain length (in B8). Previous studies (Zhang et al., 1992; Posner et al., 1994) that 
aimed to investigate the anti-carcinogenic/cytoprotective potencies of structural 
analogs of ITCs had also found that a longer carbon chain length and a carbonyl 
group in place of sulfinyl, as in SF, had generated more potent or equipotent 
analogs respectively. These findings had lent support to our findings. Given that 
ITC analogs of a longer carbon chain length possessed stronger anti-inflammatory 
and cyto-protective activities, it could suggest that the mechanism underlying these 
bioactivities might converge to a similar molecular target. At this point, it was 
unclear why a butyl chain length was more favourable than a propyl chain length. 
Possible reasons include differences in physicochemical optimal chain length 
required for favourable docking of the ITC analog to the binding side of the 
molecular target(s).  
 Persistent chemotactic recruitment of precursor monocytes to the site of 
inflammation during chronic inflammation has been one key factor contributing to 
the pathogenesis of inflammation-related disorders including, in our context of 
interest, inflammation-driven carcinogenesis. The subsequent monocytes-to-
macrophage differentiation aggravates damage to tissue surrounding the site of 
inflammation, thus leading to disease states. B7 and B8, along with SF, were found 
to possess suppressive effects against SDF-1α-stimulated chemotactic migration of 
human monocytes.  
 In the phagocytosis assay it was found that B7 and B8 suppressed the 
phagocytic ability of human CD14
+
 monocytes. Given that phagocytosis of PSM 




it is possible that ITC analogs inhibited scavenger receptor-associated 
phagocytosis. Notably, scavenger receptor-mediated phagocytosis has been 
implicated in inflammatory disorders like atherosclerosis (El Khoury et al., 1996). 
Contrary to our observations on the inhibitory effect of ITCs on phagocytosis, few 
other studies had demonstrated that SF increased phagocytosis (Harvey et al., 
2011)  (Suganuma et al., 2011). These studies had investigated the effect of SF on 
the phagocytosis of IgG-coated PSM and bacteria, by macrophages. As such, the 
experimental conditions in these studies had simulated antibody-dependent or 
receptor mediated phagocytosis. Unlike in these studies, in the experiment carried 
out in this chapter, unopsonized PSM were employed in that might be related to 
non-specific antibody-independent phagocytosis. This difference in experimental 
approach could be attributable for contradictory observations made in the reported 
studies and our study.  On the whole, the immuno-modulatory effects of ITCs on 
chemotactic migratory and phagocytic activities of leukocytes had demonstrated 
their holistic anti-inflammatory effects. 
 Inflammatory response is perpetuated through multiple intracellular 
signaling pathways, majority of which converge at the activation of the NF-κB 
signaling with the transcriptional factor p65 regulating the expression of several 
pro-inflammatory mediators and activating immune cells. Similar to a number of 
phytochemicals including flavonoids, cinnamaldehydes and SF (Reddy et al., 2004; 
Gonzalez et al., 2011), B7 and B8 were found to attenuate activation of the NF-κB 
pathway, a well established molecular target for inflammatory diseases and cancer . 
B7 and B8 were also found to dampen activation of MAPKs. Furthermore, the 
ITCs were found to inhibit the activation of PI3K/Akt pathway. While an inhibitory 
effect on the PI3K/Akt pathway by SF had been reported earlier in platelets 
(Chuang et al., 2013), this study had revealed that a similar effect was exhibited by 
the ITCs in an LPS-induced inflammatory cell model. 
 SF has been shown to possess electrophilic propensity to bind to 
nucleophilic residues of certain protein targets which leads to biological outcomes 
such as inhibition of enzyme activity disruption of signal transduction. In this 
study, IKK-β of the NF-ĸB pathway was revealed to be a specific target of SF and 
its analog B7. Based on the results obtained from the BIAM labeling assay, SF and 




sensitive kinase that gets phosphorylated at two serine residues (Ser176 and 
Ser181). In addition, Cys179 has been shown to be critical for enzyme activation 
by promoting phosphorylation of the serines in activation loop (Byun et al., 2006). 
Compounds such as staurosporine and quercetin that have been found to bind to 
Cys179 of IKK-β and inhibit its kinase activity have also been shown to possess 
correlating anti-inflammatory activities (Avila et al., 2009). Based on the BIAM 
assay results and the established nucleophilic nature of Cys179, it was likely that 
the ITCs could bind to Cys179 of IKK-β. Results from the yet-to-be optimized 
mass spectrometry analysis and kinase assays, if successful, would have provided 
more concrete evidence.  
 In summary, the results obtained in this chapter showed that B7 and B8 
possessed anti-inflammatory potential. B7 possessing a 4-carbon chain length 
separating the methylcarbonyl group from the ITC functional group was found to 
possess comparable and stronger activities than prototypical SF and B8 
respectively. The biological mechanism underlying the anti-inflammatory activity 
of aliphatic ITCs was elucidated to be mediated at least in part through the 
components of TLR-4 signaling pathway. IKK-β was identified as a potential target 
of ITCs.  Given the determined anti-inflammatory activities of B7 and B8, they 
could serve as potential drug candidates against chronic inflammatory diseases.  








Chapter 6  
 
Evaluation of chemopreventive potential of aliphatic ITC analogs 
and exploration of novel underlying mechanisms  
6.1 Introduction 
From the time of discovery of natural ITCs until recent times, 
accumulating in vitro and in vivo evidence have demonstrated the anti-carcinogenic 
potential of natural and synthetic ITCs such as AITC, BITC, PEITC, SF and their 
analogs (IARC, 2004). Carcinogenesis is a multistage process involving initiation, 
promotion and progression of cancer lesions. Interestingly, the chemopreventive 
potential of ITCs has been attributed to multiple mechanisms mediating 
intervention at several stages of carcinogenesis. Among the several mechanisms 
postulated to underlie the chemopreventive potential of ITCs, the induction of 
phase II detoxification enzymes by natural ITCs has been widely explored and 
considered an important mechanism driving their chemopreventive activities; 
increased levels of phase II enzymes hinder activation of carcinogenic substances 
and or augment their removal and consequently protect cells from the damaging 
effects to carcinogenic substances. 
SF has been shown to possess chemopreventive properties in several in 
vivo and in vitro studies. It is therefore promising to investigate the 
chemopreventive potential of its analogs. Multiple biological mechanisms, which 
include inhibition of histone deacetylases, induction of cell cycle arrest, apoptosis, 
modulation of oxidative status and induction of phase II enzymes, have been found 
to contribute to its chemopreventive potential (Juge et al., 2007). Interestingly, 
being derived from broccoli, SF had been discovered for its high potency of 
inducing NQO1 activity in hepatoma cells (Zhang et al., 1992) and reported to be a 
monofunctional inducer which selectively increases phase II enzyme induction 
without affecting the phase I enzymes. Phase II enzymes such as HO-1, NQO1, 




regulation of Nrf2. Mechanistically, it has been suggested that SF brings about 
inhibition of the activity of Keap1-Cul3 ubiquitin E3 ligase complex, which results 
in the suppression of Nrf2 ubiquitination, leading to Nrf2 stabilization and elevated 
Nrf2 levels that therefore enhance ARE-dependent gene transcription (Zhang, 
2006). Additionally, mass spectrometric studies have revealed the binding of SF to 
Keap1 (Hong et al., 2005; Hu et al., 2011). Nevertheless, the implications of such 
adduct formation on its chemopreventive potential remain speculative. On the other 
hand, researchers are also exploring alternative mechanisms such as activation of 
the MAPKs and regulation of GSK3β for Nrf2-ARE-dependent gene expression by 
SF (Keum et al., 2006; Das et al., 2013).  
The mechanisms underlying phase II enzyme induction by SF involves 
its effect on the Keap1-Nrf2 pathway and the mechanisms underlying suppression 
of inflammation involves its effect on NF-κB pathway (Heiss et al., 2001). 
Strikingly, both these pathways are major players in the process of carcinogenesis 
and cross signaling between these pathways have been reported (Kim et al., 2010) 
(Lee et al., 2009). While several phytochemicals have been reported to possess 
dual properties of Nrf2 induction and NF-κB induction, mechanisms linking these 
two pathways and contributing to the holistic chemopreventive potential of these 
phytochemicals remain largely unexplored (Liu et al., 2008b). 
In this chapter, B7 and B8, the aliphatic analogs of SF found to possess 
weaker anti-proliferative properties than the aromatic ITC analogs (revealed in 
Chapter 3), were investigated for their chemopreventive potential. In addition, we 
attempted to explore the possible effects of SF on the molecular events linking the 
Keap1-Nrf2 and NF-κB pathway with the intention to elucidate the mechanisms 









Figure 6.1 Cytotoxicity of ITC analogs B7, B8 and SF on HEK-293 cells. 
6.2 Results 
6.2.1 Cytotoxicity of aliphatic ITC analogs on HEK-293 cells 
 MTT cell viability assays were first performed to assess the cytotoxicity 
profiles of B7 and B8 on non-cancerous HEK-293 cells. As shown in Fig 6.1, the 
analogs produced little toxicity for concentration up to 10 μM.  Therefore, 
concentrations in the range of 1-10 μM, found not to cause cytotoxicities, were 
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Figure 6.1 Cytotoxicity of ITC analogs B7, B8 and SF on HEK-293 cells. HEK-293 cells were 
treated with indicated concentrations of ITCs for 24 h and subjected to MTT assay. Absorbance 
of dissolved formazan crystals (formed by viable cell-mediated reduction of MTT) is presented 
as percentage of DMSO control. Each column represents mean ± S.D. * Significant difference 






















6.2.2 Induction of ARE-dependent transcriptional activity in HEK-293 cells by 
ITC analogs 
 The effect of B7, B8 and SF on ARE-dependent phase II enzyme activation 
was investigated by assessing their ability to induce ARE-dependent gene 
transcriptional activity. The ARE-dependent luciferase reporter assay was 
performed for this purpose (see Sections 2.2.18 and 2.2.20). Activation of the ARE 
promoter in cells transfected with a ARE luciferase reporter gene construct would 
lead to increased expression of firefly luciferase that can produce luminescence 
upon reaction with the substrate luciferin. The fold induction in luminescence, 
compared to DMSO control, was then determined. As shown in Fig 6.2, B7, B8 
and SF exhibited dose-dependent induction of ARE-driven luciferase activity. In 
general, between B7 and B8, B7 produced a stronger ARE induction that was 
comparable to induction brought about by SF. On the other hand, negative control 
NMPEA failed to induce ARE-dependent transcriptional activity.  
 









































Figure 6.2 Induction of ARE-dependent transcriptional activity. HEK-293 cells transfected with 
pGL3-ARE-luciferase reporter and pCMV renilla luciferase plasmids were treated with 
indicated concentrations of ITCs for 14 h. Firefly luciferase activity normalized to renilla 
luciferase activities was measured for each treatment group. Fold induction expressed as 
luciferase activity of a treatment group over that of DMSO control, was determined. Each 
column represents mean ± S.D of three independent experiments. * Significant difference (p < 
0.05) from DMSO control. 
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MEFs by ITC 
analogs 
 Having observed an induction of ARE-dependent transcriptional activity by 
B7 and B8, their ability to stabilize Nrf2, the transcription factor regulating ARE 
activity, was next investigated in Keap1
+/+
 MEFs. B7 and B8 caused a subtle dose 
dependent increase in the protein levels of Nrf2 in Keap1
+/+
 MEFs (Fig 6.3A) (see 
Sections 2.2.21 and 2.2.22). As SF has been shown to induce Nrf2 by targeting 
cysteine residues in Keap1 (Zhang, 2006), we were interested to explore the 
involvement of Keap1 in Nrf2 induction by B7 and B8. The effect of B7 and B8 on 
the protein levels of Nrf2 was therefore assessed in Keap1 
-/-
 MEFs. As shown in 
Fig 6.3B, compared to levels detected in DMSO control cells, B7 and B8 did not 
cause an increase in Nrf2 levels in the absence of Keap1. Taken together, the 
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 MEFs and (B) Keap1
-/- 
MEFs were treated with indicated concentrations of ITCs for 
14 h. Cell lysates were collected and Nrf2 levels were analyzed by western blotting. β-actin 
levels were probed to verify protein loading. (C) Densitometric analysis of band intensities 
obtained in western blots (A) and (B) was performed using ImageJ software. Fold induction in 




















MEFs by ITC analogs 
  The effect of B7 and B8 on the expression of Nrf2 target genes was 




MEFs (see Sections 2.2.21 and 
2.2.22). As depicted in Fig 6.4A and B, levels of HO-1, NQO1 and γ-GCL in 
Keap1
+/+
 MEFs were significantly increased from their basal levels in DMSO 
control cells following treatment with B7, B8 and SF. On the contrary, in Keap1
-/- 
MEFs, the levels of these phase II enzymes remained relatively unchanged upon 
ITC treatment. These results therefore suggested that Keap1 was involved in 
mediating the induction of phase II enzymes brought about by ITC treatment. 
 
 







 MEFs and (B) Keap1
-/-
 MEFs were treated with indicated concentrations of ITCs for 
14 h. Cell lysates were collected and HO-1, NQO1 and γ-GCL levels were analyzed by western 








6.2.5 Cytoprotective effects of ITC analogs against DNA damage 
 As a preliminary attempt to investigate the effectiveness of ITC analogs on 
providing cellular protection in response to pro-carcinogenic damage, their ability 
to confer protection against DNA damage was investigated. Doxorubicin, an 
anthracycline antibiotic capable of causing breaks in DNA double helix through 
intercalation between nucleotide base pairs (Ross et al., 1978) was used to induce 
DNA damage, which would correspond to increased levels of phosphorylated 
histone H2AX (γ-H2AX), an established marker for DNA double strand breaks 
(Modesti & Kanaar, 2001). In order to examine whether ITCs could alleviate 
doxorubicin-induced DNA damage that was mediated through the effects of 
induced phase II cytoprotective enzymes and not a result of direct interaction 
between ITCs and doxorubicin, the experiment was carried out with B7, B8 and SF 
added to HEK-293 cells 12 h before doxorubicin treatment for another 12 h (see 
Sections 2.2.21 and 2.2.22). A dose of 2 μg/ml doxorubicin that had been 
previously found in the laboratory to cause conspicuous induction of γ-H2AX 
without triggering cytotoxicity was used. As depicted in Fig 6.5, pretreatment with 
ITC analogs B7, B8 and SF prior to doxorubicin challenge suppressed doxorubicin-
induced levels of γ-H2AX. These results indicated the cytoprotective effects of B7 







Figure 6.5 Cytoprotection conferred by ITC analogs against doxorubicin-induced DNA damage. 
HEK-293 cells were treated with indicated concentrations of ITCs for 12 h followed by treatment 
with 2 μg/ml doxorubicin for another 12 h. Cell lysates were collected and analyzed by western 
blotting. β-actin levels were probed to verify protein loading.  
 
Figure 6.5 Cytoprotection conferred by ITC analogs against doxorubicin–induced DNA damage. 
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6.2.6 Elucidation of binding of ITC analogs to cysteine residues in Keap1  
 
 Ubiquitin ligase adaptor protein Keap1, the negative regulator of Nrf2, is 
rich in reactive cysteine residues that serve as intracellular redox sensors (Dinkova-
Kostova, 2002). Modification of the cysteine residues in Keap1 by SF has been 
reported in mass spectrometric studies, while loss-of-function mutagenesis studies 
have revealed that modifications made to critical cysteines in Keap1 lead to 
increased stabilization of Nrf2 and enhanced ARE-dependent gene transcription 
(Hong, 2005; Hong et al., 2005; Zhang, 2006; McMahon et al., 2010; Hu et al., 
2011). We were therefore interested to investigate the binding of the ITC analog 
B7 to reactive cysteine residues in Keap1. The BIAM labeling assay was carried 
out with BIAM added to the samples to label free cysteines at the end of the 
immunoprecipitation reaction (see Section 2.2.23). However, this attempt of BIAM 
labeling of the Keap1 protein in DMSO control samples was not successful. Non-
reducing SDS PAGE followed by immunoblotting had revealed that the 
immunoprecipitated Keap1 in lysates of DMSO control cells was resolved as 
oxidized bands (personal communication Mr. Sandeep Balu Shelar, Department of 
Pharmacy, National University of Singapore). This suggested that the cysteines in 
Keap1 could have been oxidized under the experimental conditions and were 
unavailable for biotinylation. Given these failed attempts, we employed the 
following modifications to the assay procedure; BIAM was incorporated into the 
lysis buffer (pH 6.5) that was used to lyse the treated or untreated HEK-293 cells 
overexpressing V5-Keap1. In this way, BIAM labeling of free cysteines in Keap1 
could take place. Biotinylated proteins in the lysates were then pulled-down using 
streptavidin-beads and the amount of pulled-down V5-keap1 was analyzed by 
western blotting using anti-V5 antibody. Proteins with oxidized or chemically 
labeled cysteine residues would not be biotinylated and pulled-down. As such, the 
intensity of a protein band upon immunoblotting would therefore correlate to the 
extent of biotinylation. As compared to DMSO control, a decreased intensity of the 
V5-Keap1 band in the lanes corresponding to treatment with 10 μM of SF and B7 
(lane 3 and 4 respectively) was observed. The obtained results had demonstrated 






6.2.7 Investigation of possible molecular link underlying ITCs cytoprotective 
and anti-inflammatory effects 
 SF has been found to regulate Keap1/Nrf2 pathway (Zhang, 2006) as well 
as suppress NF-κB signaling (Heiss et al., 2001). Studies exploring cross signaling 
between these two pathways have to date found Keap1 to down-regulate NF-κB 
signaling through its interaction with IKK-β followed by inhibition of 
phosphorylation and/or degradation of IKK-β (Lee et al., 2009; Kim et al., 2010). 
While the anti-inflammatory activity of SF, through inhibition of phosphorylation 
of IKK-β, is well established and also demonstrated in our experiments as 
discussed in Chapter 5, coincidently, we made a serendipitous observation that 
treatment with a non-toxic dose of SF for 16 h, a duration of ITC treatment that 
corresponds to induction of phase II enzymes, caused a decrease in IKK-β level 
(Fig 6.7) suggesting that enhanced IKK-β degradation had set in. It was therefore 
intriguing to investigate whether ITCs’ anti-inflammatory effects through 
suppression of IKK-β were dependent on Keap1. As such, we questioned if the 
observed degradation of IKK-β was mediated through Keap that was modified by 
SF. In such a case, we first hypothesized that SF could enhance the interaction 
between Keap1 and IKK-β, leading to decrease in the susceptibility of IKK-β to 
phosphorylation and ultimately promote Keap1-mediated degradation of IKK-β. To 
address this question, immunoprecipitation experiments were performed on lysates 
of SF-treated or untreated HEK-293 cells co-transfected and co-expressing V5-
Keap1 and FLAG-IKK-β (see Sections 2.2.18 and 2.2.19). Taking into 
consideration that any possible effect on the interaction between Keap1 and IKK-β 
Figure 6.6 Investigation of ITCs binding to cysteine residues in Keap1. Transfected HEK-293 
cells overexpressing V5-Keap1 were treated with indicated concentrations of ITCs for 1 h. Cell 
lysates were BIAM-labeled and pulled-down using streptavidin-beads. Eluted pulled down 
proteins and cell lysates were then analyzed by western blotting.  
 




would occur much earlier than the onset of degradation of IKK-β, a short duration 
of SF (10 μM) treatment of 1.5 h was employed.  However, immunoprecipitation 
experiments did not show an expected increase in interaction between Keap1 and 
IKK-β (Fig 6.8) (see Sections 2.2.18, 2.2.19, 2.2.21 and 2.2.22).  Considering the 
possibility that simultaneous degradation of IKK-β could have occurred throughout 
the duration of SF treatment, it was possible that any real-time increase in 
interaction between Keap1 and IKK-β would be masked. We then attempted to 
eliminate this possibility by stabilizing the Keap1-IKK-β complexes through 
inhibiting the IKK-β-degradation with the use of inhibitors of the protein 
degradation pathways. While Hung and co-workers had reported the proteasomal 
degradation of IKK-β by Keap1 (Lee et al., 2009), Hwang and coworkers had 
reported that Keap1 mediated autophagic degradation of IKK-β (Kim et al., 2010). 
Given these contradictory reports, we employed inhibitors of both proteasomal and 
lysosomal protein degradation pathways, namely, MG-132 and chloroquine 
diphosphate (CHQ) (Kwong et al., 2011). As shown in Fig 6.9A and B (see 
Sections 2.2.18, 2.2.21 and 2.2.22), tested concentrations of neither inhibitor could 
block the decrease in levels of IKK-β. It could be that the concentration of MG-132 
and CHQ used was insufficient to inhibit IKK-β degradation entirely, or IKK-β was 
degraded by both the protein degradation pathways. In the case of latter, co-
administration of MG-132 and CHQ would be required to bring about a complete 
blockade of IKK-β degradation. Optimization of the experimental setup, taking into 





Figure 6.7 Effect of SF on level of FLAG-IKK-β. Transfected HEK-293 cells overexpressing 
FLAG-IKK-β were treated with 10 μM SF for 16 h. Cell lysates were analyzed by western 
blotting. β-actin levels were probed to verify protein loading. 










Figure 6.9 Effect of co-treatment of SF and inhibitors of proteasomal and lysosomal 
degradation pathways on level of expression of FLAG-IKK-β. Transfected HEK-293 cells 
overexpressing FLAG-IKK-β were treated with indicated concentrations of SF and /or MG-
132 or CHQ for 16 h. Collected cell lysates were then analyzed by western blotting. 
B 
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Figure 6.8 Effect of SF on the interaction between Keap1 and IKK-β. Transfected HEK-293 
cells co-expressing FLAG-IKK-β and V5-Keap1 were treated with 5 and 10 μM SF for 1.5 h. 
Collected cell lysates were subjected to immunoprecipitation using anti-FLAG antibody. 
Immunoprecipitates and lysates were then analyzed by western blotting. 
Figure 6.8 Effect of SF on the interaction between Keap1 and IKK-β. 
Figure 6.9 Effect of co-treatment of SF and inhibitors of proteasomal and lysosomal degradation 




 In an alternative hypothesis, it was proposed that SF’s inhibitory effect on 
phosphorylation of IKK-β induced by a pro-inflammatory stimulus was dependent 




  MEFs pre-treated with SF 
were subsequently stimulated by the addition of TNF-α, an endogenous 
inflammatory stimulus. Cell lysates were then collected for western blot analysis of 
levels of phospho-IKK-β (see Sections 2.2.21 and 2.2.22). Unexpectedly, under the 
experimental conditions employed, inhibition of TNF-α-induced phosphorylation 
of IKK-β by SF could not be consistently achieved in repeated experiments (Fig 
6.10). To the time this thesis was prepared and submitted, experimental conditions 




6.3 Discussion  
A study by Talalay and co-workers (2008) had exposed that 
phytochemicals such as SF not only possessed Nrf2 inducing activities, but also 
displayed correlating anti-inflammatory activities. Having observed the anti-
inflammatory potential of B7 and B8 as reported in Chapter 5, we investigated the 
chemopreventive potential of these ITC analogs. Structural analogs of SF had been 
Figure 6.10 Effect of SF on level of phospho-IKK-β in TNF-α-stimulated Keap1+/+ and 
Keap1
-/-
 MEFs. WT and Keap1-/- MEFs were treated with indicated concentration of test 
compounds for 1 h and induced with TNF-α (50 ng/ml) for 30 min. Cell lysates were then 
analyzed by western blotting. 




investigated for their anti-carcinogenic abilities based on their potency to induce 
NQO1 activity (Zhang et al., 1992; Posner et al., 1994). Here, the cytoprotective 
activities of SF and its analogs, B7 and B8, were assessed based on their abilities to 
induce ARE-dependent gene transcription. It was revealed that B7 and B8 
stimulated Nrf2-mediated induction of ARE-driven phase II response and conferred 
protection against DNA-damaging pro-carcinogens. In addition, ssimilar to the 
anti-inflammatory potencies observed in Chapter 5, B7, the SF analog bearing a 4-
carbon chain length and with the methylsulfinyl group replaced by methylcarbonyl 
group, was found to be as potent as SF in inducing phase II response, whereas B8, 
the SF analog bearing a shorter 3-carbon chain length and with the methylsulfinyl 
group replaced by methylcarbonyl group, was found to be possess weaker 
activities. These observations further underpinned the possible influence the 
aliphatic chain length could have on the biological activities of ITCs. 
 Keap1 had been established as a molecular target of SF for its Nrf2-
mediated effects. We thus hypothesized that B7 and B8 could stimulate an Nrf2-
mediated phase II response through similar mechanism(s) as SF. It was indeed 
observed that the phase II response induced by B7 and B8 was subdued in the 
absence of Keap1, thereby suggesting that the cytoprotective abilities of B7 and B8 
were mediated through Keap1. In addition, results from the BIAM assay had 
demonstrated the direct binding of B7 to reactive cysteine residues in Keap1. It is 
noteworthy that a number of reactive cysteine residues in Keap1 have been shown 
to be critical for Keap1’s function as a negative regulator of Nrf2 and they have 
also been found to be modified by electrophilic inducers (Dinkova-Kostova, 2002) 
(Zhang & Hannink, 2003; Holland & Fishbein, 2010). On this basis, we proposed 
that the binding of B7 to cysteine residues in Keap1 probably modified Keap1 such 
that its substrate adaptor activity was antagonized, which in turn led to a failure to 
repress Nrf2. Additional site-directed mutagenesis and mass spectrometric studies, 
which could shed light on the specific cysteine residues involved in the interaction 
between B7 and Keap1 could be performed in the future.  
  The experimental investigations focused on exploring the role of Keap1 in 
mediating the anti-inflammatory effects of SF had remained unsettled due to 
technical limitations. Despite the failed attempts, the finding regarding IKK-β 




pave way for new perspectives towards understanding common mechanisms 
underlying the dual chemopreventive and anti-inflammatory properties of 
phytochemicals. Interestingly, elevated expression levels of IKK-β are reported to 
be associated with malignancy and carcinogenesis (Jiang et al., 2010) and IKK-β 
has been reported as a key player in inflammation driven tumorigenesis (Greten et 
al., 2004). In addition, Keap1-mediated negative regulation of IKK-β has been 
reported to be altered in human cancers (Lee et al., 2009). It was therefore possible 
that the degradation of IKK-β induced by SF could partly contribute towards its 
anticarcinogenic activities. 
 In summary, B7 and B8 were found to possess cytoprotective properties. As 
similar to their anti-inflammatory potential, the chemopreventive potential of B7 
was found to be comparable to SF and stronger than B8. The Keap1/Nrf2 pathway 




Chapter 7  
 
General discussion, conclusion and future directions 
7.1 General discussion and conclusion 
 A library of novel ITC analogs were synthesized previously in the 
laboratory based on structural modifications of naturally-occurring ITCs. The 
library broadly consisted of aromatic ITCs that include BITC, PEITC and their 
analogs, as well as aliphatic ITCs that include SF and its analogs. The goal of this 
PhD project was to investigate the anticancer, anti-inflammatory and 
chemopreventive properties of the novel ITCs and elucidate the underlying 
mechanisms.   
 In general, the more lipophilic aromatic ITCs were found to possess potent 
anticancer properties while the less lipophilic aliphatic ITCs exhibited potent anti-
inflammatory and cytoprotective properties. The intracellular events underlying the 
effects of ITCs are depicted in Fig 7.1.  
 As discussed in Chapter 3 and 4, the aromatic ITCs disrupted the growth of 
cancer cells by arresting cell cycle at the M phase, leading to apoptosis induction. 
These effects were mediated at least in part through modification and aggregation 
of tubulin and inhibition of redox enzymes TrxR and GR. Anti-proliferative 
activities were found to decrease with an increase in alkyl chain length between the 
benzene ring and the ITC functional group. Analogs with ortho-monomethoxy 
substituent and meta-, para-dimethoxy substituents on the benzene ring exhibited 
the greatest anti-proliferative potencies against cancer cells. On the other hand, 
analogs bearing meta-fluorine substituents only exhibited marginal enhancement of 









Figure 7.1 Cellular effects of (A) aromatic ITCs and (B) aliphatic ITCs. 
Figure 7.1.Cellular effects of (A) aromatic ITCs and (B) aliphatic ITCs. Solid arrows represent 
effects demonstrated by findings obtained from experiments conducted in this PhD study. 





 The anti-inflammatory properties of aliphatic ITCs were revealed to involve 
inhibition of expression of pro-inflammatory mediators and associated functions of 
leukocytes. Attenuation of PI3k-Akt, MAPK and NF-κB signaling pathways by 
aliphatic ITCs was found to be a possible mechanism underlying their anti-
inflammatory properties. In addition, IKK-β was shown to be a possible target. 
Subsequently, aliphatic ITCs were demonstrated to exhibit chemopreventive 
properties based on their inductive abilities on Nrf2-mediated expression of phase 
II enzymes. Similar to SF, its carbonyl-containing analogs were also found to target 
Keap1. The anti-inflammatory activities of aliphatic analogs could also contribute 
to chemopreventive abilities. Additionally, the mechanism of their anti-
inflammatory action through suppression of the NF-ĸB activation pathway, a 
signaling cascade currently known to be a major link between inflammation and 
cancer, further strengthens their chemopreventive potential. An exploratory attempt 
to investigate Keap1 as molecular link between the Nrf2-Keap1 and NF-κB 
pathways brought to light a novel cellular effect of ITCs, the degradation of IKK-β 
upon treatment with SF over 16 h. Future investigations based on this discovery 
could unravel novel molecular cross signaling.  
 ITCs had been shown to readily react with thiol groups in small molecules 
(mainly GSH) and cysteine residues in cellular proteins. It had been reported that 
SFN exhibits better binding to GSH while PEITC exhibits preference for proteins. 
The difference in binding had been suggested to be attributed to the greater 
solubility of SF and higher hydrophobicity of PEITC (Mi & Chung, 2008a). In line 
with this report, in our study, results indicated plausible modification of cysteine or 
selenocysteine residues in tubulin, TrxR and GR by aromatic ITCs leading to 
tubulin aggregation and enzyme inhibition respectively. On the other hand, 
aliphatic ITCs were less efficacious in tubulin aggregation or inhibition of TrxR 
enzyme. It is possible that the aliphatic ITCs were preferentially conjugated to 
GSH, such that the GSH-ITC conjugates were readily metabolized instead of acting 
as intermediates for protein thiocarbamoylation. Thus they might be less available 
to produce cytotoxic effects. It should be noted that, the aliphatic ITCs were shown 
to bind to cysteines residues of IKK-β and Keap1. This was feasible likely due to 




readily ionized and accessible cysteine residues. These results are suggestive of the 
possibility that a wider range of protein targets are modified by aromatic ITCs 
while aliphatic ITCs are selective towards a more narrow range of protein targets. 
 Cancer and inflammation are complex abnormalities that involve 
dysregulation of multiple signaling pathways. Taken together, the results reported 
in this study had demonstrated the multi-targeting nature of ITCs. The ITCs may 
therefore be effective against these complex diseases that involve multiple 
signaling pathways. Cancer is also a rapidly evolving disease and cancer cells 
possess a dynamic unstable genome. A major problem with current target-specific 
chemotherapeutics is cancer drug resistance developed by highly adaptable cancer 
cells.  Multi-targeting drugs such as ITCs are therefore feasible alternatives to 
address the emerging problem of cancer drug resistance.  
 Overall, the aromatic ITCs could serve as potential drug candidates for 
treatment of cancer while the aliphatic ITCs could be potentially exploited for 
prevention of chronic inflammation, carcinogenesis and associated disorders. The 
effective concentrations of ITCs to display anti-proliferative, anti-inflammatory 
and cytoprotective effects in cultured cells were in the micromolar range, which 
might limit their advancement as clinical candidates as higher concentration would 
be required to attain systemic levels in a living subject. Although it may seem 
logical to anticipate problems of toxicity with administration of high doses, 
assessment of pharmacokinetic and pharmacodynamic parameters and in vivo 
investigations are warranted for a holistic judgement regarding the therapeutic 
potential of ITC analogs. In summary, this PhD study has verified the 
concentration and structure-dependent anticancer and chemopreventive properties 
of ITCs. The findings in this study have provided insight into the diverse 
mechanisms underlying the biological effects of ITCs. Novel analogs were 
demonstrated to exhibit superior activities and structural features that augment or 






7.2 Future directions 
7.2.1 Novel compound design 
  Based on the structural features identified to augment the anticancer 
potential of ITCs (see Sections 3.3 and 4.3), a meta-, para-dimethoxy substituted 
analog of BITC is proposed to possess superior anti-tumor activities. This analog 
shall be synthesized and examined in biological assays. In the case of desirable 
anti-inflammatory and chemopreventive activities, aliphatic analogs with methyl 
carbonyl or methyl sulfinyl group separated by a 5-carbon alkyl chain from the ITC 
functional group are worthy for future investigation and development.  
7.2.2 Characterization of target binding 
 Tubulin is an established target for PEITC and BITC, and Cys347 had been 
reported to be modified by BITC (Xiao et al., 2012). Results obtained and 
presented in Chapter 4 were suggestive of ITCs’ propensity to bind to TrxR and 
GR. As such, similar to experiments conducted to investigate possible binding of 
ITC to IKK-β, TrxR and GR can be pulled down from lysates of aromatic ITC-
treated cells and subjected to BIAM assay and mass spectrometry analysis so as to 
identify specific residues targeted by aromatic ITCs. 
 The results in Chapter 5 revealed the modification of cysteine residues of 
IKK-β by SF. Experiments aimed to clarify the exact consequences of ITC binding 
to IKK-β are warranted. These experiments shall be focussed in investigating 
possible consequences of ITC adduction on IKK-β that may involve loss of enzyme 
activity due to inhibition of phosphorylation of IKK-β, phosphorylation of IκB-α or 
disruption of binding between IKK-β and IκB-α. 
7.2.3 In vivo investigation of lead analogs  
 Investigation of metabolic stability and pharmacokinetic profiles of ITC 
analogs in mouse or rat model can allow preliminary determination of optimal 
dosing regimens required for in vivo studies. Aromatic ITC B2, which exhibited 
good stability in PBS and strongest anticancer properties among the test analogs, is 
a suitable candidate. B10, which closely followed B2 in its stability and anticancer 
potency, would be another potential analog to be evaluated in vivo. Careful dose 
optimization is required especially in the case of aromatic analogs in order to 




concentrations.  Subsequently, the effects of the compounds on the growth of 
established tumors in nude mice can be investigated. Aliphatic ITC B7 and SF at 
non-toxic concentrations can be evaluated for their anti-inflammatory and 
chemopreventive efficacies in animal models for chronic inflammatory disorders 
and multistep inflammation-induced carcinogenesis.  
7.2.4 Anti-metastatic potential of ITC analogs  
 The aliphatic ITCs displayed inhibitory effects on expression and secretion 
of MMP-9 in leukocytes (see Sections 5.2.3 and 5.2.5 in Chapter 5). Interestingly, 
SF, PEITC and BITC have been reported to inhibit metastasis potential cancer cells 
(Thejass & Kuttan, 2006; Lai et al., 2010; Wu et al., 2010; Gupta et al., 2013) .It is 
likely that the aromatic ITC analogs could exhibit similar effects in cancer cells. 
Therefore, investigation of inhibitory effects of aromatic ITC analogs on 
expression and secretion of MMP-9 enzyme in cancer cells could be pursued. 
Further studies can be focused to investigate the effects of ITC analogs on 
migration of cancer cells. These investigations could collectively reveal the anti-
metastatic properties of aromatic ITC analogs and additional mechanisms 
underlying their antitumor potential.  
7.2.5 Use as adjuvants to enhance efficacy of chemotherapy  
 ITCs have been shown to exhibit chemotherapeutic potential at non-toxic 
doses in the micro-molar range in vivo. In recent years, ITCs are being explored for 
potential use in combination with anti-cancer agents to improve antitumor 
potencies possibly considering the implications of their efficacies in the micro 
molar range. Interestingly, ITCs are suggested to affect the signaling pathways 
involved in pharmacokinetics and pharmacodynamics of anti-cancer drugs 
(Minarini et al., 2014). Of mention, ITCs have been shown to increase 
accumulation of daunomycin and vinblastine in resistant cancer cells in which 
efflux proteins are overexpressed (Tseng et al., 2002). PEITC has been shown to 
sensitize cancer cells to the apoptotic effects of cisplatin (Wang et al., 2011). The 
aromatic analogs with methoxy substitutions which were shown to exhibit 
improved antitumor efficacies could be explored for their potential to enhance the 
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Appendix I: Mobile phase composition for stability analysis of ITC analogs 
using HPLC 
 
ITC Compound Mobile phase composition 
(Acetonitrile : Water) (%) 
Retention time 
(in Eclipse XDB-C18 
reverse phase column) 
(Min) 
BITC 67 : 33 6.54 
B10 67:33 7.58 
PEITC 67:33 7.00 
B9 67:33 8.38 
B2 55:45 8.25 
SF 25:75 6.0 
B7 40:60 11.0 










Appendix II: Stability profiles of ITC analogs in semi-log plot 
 The semi-log plots of time versus concentration of ITC analogs were 
analyzed for linearity to confirm first-order kinetics of time-dependent degradation 









y = -0.089x + 4.6093 
R² = 0.9998 
y = -0.0414x + 4.4972 






















Time of incubation in PBS (h) 
 
BITC 1 mM 
B 10 1 mM 
y = -0.0447x + 4.527 
R² = 0.9848 
y = -0.0263x + 4.5761 
















Time of incubation in PBS (h) 
PEITC 1 mM 
B9 1 mM 







y = -0.0111x + 3.8634 



















Time of incubation in PBS (h) 
B10 1mM 
y = -0.0398x + 4.3637 
R² = 0.8058 
y = -0.009x + 4.1705 
R² = 0.91 
y = -0.0011x + 4.6141 


















Time of incubation in PBS (h) 
PEITC 1 mM 
B9 1 mM 
B2 1 mM 
y = -0.0074x + 4.769 
R² = 0.9608 
y = -0.0078x + 4.7533 
R² = 0.9915 
y = -0.0038x + 4.701 


















Time of incubation in PBS (h) 
B7 1 mM 
B8 1 mM 
SF 1 mM 
24 – 48 h  
 170 
 
 
 
 
 
 
 
